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Abstract 
 
Dysregulation of the phosphotidylinositol-3-kinase (PI3-kinase)/AKT signalling pathway is 
one of the most frequent mutational events in various human malignancies, including ovarian 
cancer. Increased PI3K/AKT activity in malignant cells is associated with resistance to 
chemotherapeutic agents.  
 
GSK2141795 is a potent pan-AKT kinase inhibitor, being developed for ovarian and other 
cancers. The aim of the present study was to evaluate the ability of GSK2141795 to restore 
platinum sensitivity to platinum-resistant ovarian cancer cell lines. Effective 
pharmacodynamic (PD) biomarkers are critical for the implementation and assessment of 
targeted therapeutics. The second aim of this study was to explore the utility of using fluoro-
deoxy-glucose positron emission tomography (FDG-PET) imaging as a PD marker by 
correlating changes in glucose metabolism (as measured by changes in FDG uptake) with 
changes in AKT pathway biomarkers, as an alternative to invasive tumour biopsies. The third 
aim of this study was to assess the role of DNA-PK mediated activation of AKT, compared to 
PI3K, in mediating drug resistance.  
 
The results demonstrate that GSK2141795 synergistically enhances cisplatin induced 
apoptosis in platinum-resistant ovarian cancer cells, grown as either 2-dimensional 
monolayers or 3-dimensional multi-cellular tumour spheroids (MTS). Similar results were 
achieved when cisplatin was combined with the DNA-PK inhibitor NU7441, but not in 
combination with the selective PI3K inhibitor GSK2126458 in vitro. In vivo, combination of 
GSK2141795 or NU7441 with cisplatin led to superior tumour growth inhibition in murine 
xenografts, compared to either agent alone. In all three model systems (2D monolayers 3D 
MTS and in vivo xenografts), GSK2141795 decreased levels of phospho-PRAS40 and FDG 
uptake. FDG uptake and pPRAS40 expression were strongly correlated. In addition, reverse 
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phase protein arrays (RPPA) was used to study the effects of GSK2141795 on cell signalling 
pathways in vitro, in vivo and using tumour biopsies from a phase I clinical trial of 
GSK2141795 in ovarian cancer. This identified a signature of AKT-pathway inhibition that 
includes consistent changes in phosphorylation of S6, 4E-BP1 and AKT itself.  
 
Taken together, this report shows that GSK2141795 inhibits AKT signalling in platinum-
resistant ovarian cancer cells, and can reverse platinum resistance in pre-clinical systems, 
and merits clinical exploration. In addition, the results demonstrate significant differences in 
the role of DNA-PK and PI3K mediated AKT activation in modulating the response to 
platinum chemotherapy, and support further clinical development of AKT or DNA-PK 
inhibitors in combination with cisplatin to overcome platinum resistance in ovarian cancer. 
FDG uptake was also found to be potential non-invasive PD biomarker, subject to clinical 
validation, for guiding dose selection in ovarian cancer patients. RPPA also identified a 
proteomic PD signature that could be used for pre-clinical development and applied to 
clinical tumour biopsies. 
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1.1 Ovarian Cancer 
 
Ovarian cancer is the most lethal gynaecological malignancy and the fifth most common 
cancer in women in developed countries. In 2010, 7,011 new cases of ovarian cancer were 
diagnosed in the UK. The cause of ovarian cancer is unknown; however, risk factors for 
developing ovarian cancer include older age, low parity, and a family history of breast and 
ovarian cancer. Ovarian cancer is a heterogeneous disease, with a 5-year overall survival of 
only 35-40%. This is due to the presence of advanced disease in most patients at initial 
presentation, and the development of drug resistance. Novel standards for reversal of drug 
resistance are urgently required to improve the outlook for this disease.  
 
1.2 Classification of Ovarian Cancer 
Ovarian cancer is classified according to the histology of the tumour into three main groups: 
epithelial ovarian cancer (EOC); sex cord-stromal tumours and germ cell tumours (Cho and 
Shih Ie 2009). More than 90% of ovarian cancers are epithelial, and historically were thought 
to be derived from the mesothelial cells that cover the ovarian surface or that line sub-
surface inclusion cysts (Dubeau 2008). Recent histopathological studies, however, suggest 
that the majority of high-grade, serous carcinomas arise from high-grade intraepithelial 
serous carcinomas in the fallopian tube, which then spread to the ovary (Lee, Miron et al. 
2007). 
 
Ovarian tumours of epithelial origin are classified as benign, borderline / low malignant 
potential (LMP) or malignant, depending on the extent of cellular atypia and invasion of the 
basement membrane. Tumours are further sub-classified into four main histotypes: serous 
(60-70%), endometrioid (10-20%), mucinous (5%) and clear cell (5%). These histotypes 
differ with regard to the frequency of different genetic alterations, gene expression profiles, 
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immuno-histochemical markers, clinical response to chemotherapy and prognosis (Kaku, 
Ogawa et al. 2003, Carlson, Roh et al. 2008)  
 
More recently, these ovarian tumours have been divided into type I and type II tumours. 
Type I tumours are composed of low grade serous, low grade endometrioid, clear cell, 
mucinous and transitional carcinomas. Type II tumours include conventional high grade 
serous carcinoma, high grade endometrioid, undifferentiated carcinoma and malignant 
mixed mesodermal tumours. Type I and type II tumours have distinct molecular and clinical 
features. Type I tumours are generally slow growing, lack TP53 and BRCA1/2 mutations, 
have a high frequency of RAS pathway activation, and are chromosomally stable. In contrast 
Type II tumours have a high frequency of TP53 mutation, rarely have RAS pathway 
mutations, usually have dysfunctional BRCA1/2 and are genomically unstable with 
widespread DNA copy number changes (Shih Ie and Kurman 2004, Kobel, Kalloger et al. 
2008, Vang, Shih Ie et al. 2009, Bowtell 2010).  
 
1.3 Diagnosis 
 
Most patients with EOC present, initially, with non-specific symptoms of bloating, early 
satiety and alteration of bowel or bladder function. Clinical examination, complemented by 
transvaginal ultrasound (US), usually shows evidence of ovarian masses with increased 
vascularity (van Nagell, Higgins et al. 1990). The tumour marker CA125 is often raised and 
is used, in combination with imaging, to make a provisional clinical diagnosis of ovarian 
cancer, using pre-operative algorithms such as the RMI (Risk of Malignancy Index). 
Subsequent pre-operative tumour staging is performed using computed tomography (CT) of 
the chest abdomen and pelvis. In addition, magnetic resonance imaging (MRI) and positron 
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emission tomographic imaging (PET) are sometimes used (Das and Bast 2008, Su, Graybill 
et al. 2013).  
 
1.4 Staging 
 
In EOC, the tumour stage is one of the most important prognostic factors and definitive 
staging is performed at debulking surgery. EOC is classified into four stages. Stage 1 EOC is 
defined as a tumour confined to the ovaries, and is further sub-divided into: stage 1a, 1b and 
1c disease. In Stage 1a disease, only one ovary is involved. In stage 1b, both ovaries are 
involved and in stage 1c, there is evidence of cancer cells in peritoneal washing and/or 
presence of cancer cells on the surface of the ovary or of the tumour cyst rupture. Stage 2 
EOC refers to spread of the cancer to other pelvis organs, such as the uterus or bowel 
surface. Stage 3 disease is defined as spread of the cancer beyond the pelvis with 
involvement of the omentum and/or upper abdominal cavity, usually. Finally, stage 4 disease 
refers to spread beyond the peritoneal cavity, most commonly due to the presence of pleural 
effusions, and/or with intra-parenchymal visceral liver/spleen metastases such as liver and 
spleen (Cannistra 2004, Cho and Shih Ie 2009). 
 
1.5 Treatment 
 
The standard management of EOC comprises a combination of debulking surgery and 
combination chemotherapy (Coleman, Monk et al. 2013) 
 
1.5.1 Surgery  
 
EOC is unique in oncology in that debulking surgery is performed even in the context of 
metastatic peritoneal disease (Ie Stage 1-3 disease). The three goals of initial debulking  
surgery for patients with suspected ovarian cancer are: establishing a histological diagnosis, 
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staging and achieving complete macroscopic cytoreduction (Coleman, Monk et al. 2013) as 
the extent of residual disease after debulking surgery is the most significant prognostic factor 
in EOC.  
 
One of the first reports on debulking surgery in EOC indicated that patients with post- 
surgery residual tumours greater than 1.5cm in size, compared to patients with residual 
tumours of 1.5cm or less, had a median overall survival of 12 months versus 26 months, 
respectively (Griffiths 1975). Since then, the definition of optimal debulking has varied 
between less than 2cm of residual disease to no gross residual disease (Fader and Rose 
2007). Currently, cytoreductive surgery, resulting in less than 1cm maximum diameter of 
residual disease, is classified as ‘optimal debulking’, whereas those resulting in any larger 
residual tumours are defined as ‘suboptimal’ (Hoskins, McGuire et al. 1994, Bristow, 
Tomacruz et al. 2002). However, the best outcomes are achieved in patients who have a 
complete macroscopic debulk and should be the primary goal of surgery (du Bois, Reuss et 
al. 2009, Coleman, Monk et al. 2013). Debulking is thought to impact prognosis by removing 
hypoxic chemo-resistant tumour cells, as well as increasing drug penetration into residual 
disease by reducing tumour bulk (Harter, Hilpert et al. 2009).  
 
Historically, patients have undergone primary debulking surgery followed by adjuvant 
chemotherapy. An alternative strategy to primary cytoreduction is neo-adjuvant 
chemotherapy with interval debulking. The rationale of neo-adjuvant therapy is to achieve 
‘chemical’ cytoreduction, to increase the likelihood of optimal debulking at interval surgery. 
However, there have been concerns that if the benefit from cytoreductive surgery is related 
to increased drug penetration, then this would be compromised in the pre-surgical cycles of 
chemotherapy with a neo-adjuvant approach. Other concerns have included the difficulty of 
surgery post-chemotherapy and potential increase in the risk of infective complications 
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(Vergote, De Wever et al. 2000, Schwartz 2002, Ivanov, Ivanov et al. 2004, Le, Faught et al. 
2005, Inciura, Simavicius et al. 2006, Lee, Kim et al. 2006). 
 
The largest study to date, to address this issue, was performed by Vergote et al through the 
EORTC. In this study stage, IIIC-IV EOC patients were randomised between primary surgery 
followed by adjuvant combination platinum-taxane chemotherapy versus 3 cycles of neo-
adjuvant chemotherapy using the same drugs, followed by interval debulking surgery (IDS), 
and at least a further 3 cycles of completion chemotherapy. The study showed that 41% of 
patients achieved optimal debulking after primary surgery, compared to 80% at IDS. 
Duration of surgery was also shorter during IDS, required fewer blood transfusions and was 
associated with less surgical mortality. Patients who have been treated with neoadjuvant 
chemotherapy also had non-inferior disease-free and overall survival, compared to primary 
surgery (Vergote, Trope et al. 2010). Extent of residual disease, whether performed after 
neoadjuvant chemotherapy or as primary treatment, was the strongest independence 
variable in predicting overall survival, and complete cytoreduction remains the main goal of 
surgery. The results of this study have led to a greater use of neoadjuvant chemotherapy 
and IDS, compared to primary surgery in EOC. 
 
1.5.2 Chemotherapy 
 
First-line chemotherapy for ovarian cancer has evolved in the past three decades. The 
platinum compounds, cisplatin and carboplatin, are the most active single agents in ovarian 
cancer and form the backbone of current therapy. Since the publication of GOG 111, which 
compared cisplatin in combination with cyclophosphamide versus paclitaxel, with an 
apparent survival advantage of the platinum-taxane arm, this has become standard first-line 
chemotherapy (McGuire, Hoskins et al. 1996). Carboplatin was introduced into the clinic in 
the 1980s and has been shown, in three randomised trials in combination with paclitaxel, to 
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be as effective as cisplatin-paclitaxel, but with significantly less toxicity, and since then it 
replaced cisplatin in most centres (Neijt, Engelholm et al. 2000, du Bois, Luck et al. 2003, 
Ozols, Bundy et al. 2003). First line chemotherapy with paclitaxel (175 mg/m2) and 
carboplatin (AUC 5-6) is usually given every three weeks, for 6 cycles. Although the initial 
response to this treatment is excellent, with a response rate of more than 80% with 40-60% 
complete responses, the majority of patients relapse with a median progression free survival 
of only 18 months (Greenlee, Hill-Harmon et al. 2001, Agarwal and Kaye 2003).  
 
In an interesting clinical trial in the early 1990s, patients with disease progression, after initial 
platinum-based chemotherapy, were re-challenged with carboplatin. This study uniquely 
showed that, in EOC, the response rate to carboplatin re-challenge was inversely 
proportional to the platinum free interval (PFI; time from last dose of carboplatin) (Gore, 
Fryatt et al. 1990). Tumours which relapse with a PFI greater than 12 months are classified 
as platinum sensitive and have response rates to platinum re-challenge of greater than 40%. 
Tumours which relapse between 6 and 12 months are classified as partially sensitive 
(response rates of 20-30%) and those which relapse with a PFI less than 6 months are 
classified as platinum-resistant (response rate 10%) (Harries and Kaye 2001, Agarwal and 
Kaye 2003). In the case of patients with first platinum sensitive relapse (PFI >6months), the 
current standard of care is to use a platinum-based doublet chemotherapy regimen. This is 
based on the results of several trials that have shown a survival benefit of combination over 
single agent carboplatin chemotherapy, in this setting, using paclitaxel, gemcitabine, and 
liposomal doxorubicin (Pfisterer, Plante et al. 2006, Sufliarsky, Chovanec et al. 2009, 
Wagner, Marth et al. 2012, Lawrie, Bryant et al. 2013). Subsequent relapse after second line 
therapy is similarly managed, based on PFI. With subsequent relapse, response rates to 
platinum chemotherapy falls with, ultimately, all patients developing platinum resistance 
(Agarwal and Kaye 2003). 
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In patients with platinum-resistant disease, liposomal doxorubicin and weekly paclitaxel are 
most commonly used. Other agents used include topoisomerase inhibitors such as 
topotecan. However, only small numbers of platinum-resistant tumours respond to these 
agents, with relatively short response durations (ten Bokkel Huinink, Gore et al. 1997, Rose, 
Blessing et al. 2003, Gordon, Tonda et al. 2004 , Naumann and Coleman 2011). 
 
Two recent strategies for improving outcomes following first-line therapy have shown benefit. 
First, a study led by the Japanese Gynecologic Oncology Group (JGOG) has shown that 
administration of 3-weekly carboplatin, in combination with weekly paclitaxel, results in 
improvement in progression-free and overall survival compared to the current standard of 3- 
weekly dose scheduling (Katsumata, Yasuda et al. 2009). Currently, these results are being 
tested in the international ICON8 study (www.clinicaltrials.gov). Second, the addition of 
bevacizumab, in combination with carboplatin-paclitaxel chemotherapy, followed by 
maintenance bevacizumab in two phase III trials (GOG218 and ICON7) has also 
demonstrated improved PFS in comparison to standard carboplatin-paclitaxel, However, the 
benefit appears to be most marked for patients with sub-optimally debulked stage III, and 
stage IV EOC (Burger, Brady et al. 2011, Perren, Swart et al. 2011). 
 
1.6 Survival 
 
Patients diagnosed with Stage 1 EOC have a greater than 90% 5-year overall survival. The 
5-year overall survival following surgery and adjuvant chemotherapy for Stage 2 disease is 
approximately 55-65%. At the time of diagnosis, most patients are in the advanced stage of 
the disease (Stage 3 and 4) in which the 5-year survival rate decreases dramatically to less 
than 30% (Agarwal and Kaye 2003, Cannistra 2004, Jemal, Siegel et al. 2008). 
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1.7 Drug Resistance in Ovarian Cancer 
 
Most patients with EOC are initially chemo-sensitive but eventually develop chemo-resistant 
disease. Understanding the mechanism of resistance and development of novel therapeutic 
strategies for overcoming drug resistance are, therefore, vital to improving outcomes in this 
disease. 
 
Chemo-resistance in ovarian cancer is very poorly understood. Drug resistance can arise 
due to cancer cell-specific genetic and/or cellular abnormalities, as well as pharmacokinetic 
and tumour micro-environment-derived effects (Agarwal and Kaye 2003). For example, 
alterations in drug influx and efflux, due to changes in cell membrane transport proteins, can 
affect intracellular drug concentration and has been shown to correlate with chemo-
resistance in vitro (Borst, Evers et al. 2000). Tumour cell capacity for drug-induced damage 
repair can also result in resistance (Dijt, Fichtinger-Schepman et al. 1988). Drug inactivation 
within the cell and changes in the concentration of the intracellular drug target, as well as 
alteration in binding affinity of the drug to target proteins, are other potential mechanisms of 
drug resistance (Giannakakou, Sackett et al. 1997, Kavallaris, Kuo et al. 1997, Sale, Sung et 
al. 2002). In addition, increased DNA-damage repair mechanism, or prevention of apoptosis, 
may result in increased viability and therefore resistance to platinum (Dijt, Fichtinger-
Schepman et al. 1988, Dabholkar, Bostick-Bruton et al. 1992, Dabholkar, Vionnet et al. 
1994, Brown, Hirst et al. 1997). Recently, the role of the microenvironment and specific 
extracellular matrix (ECM) proteins, has been explored as potential new targets for reversal 
of drug resistance (Tredan, Galmarini et al. 2007) 
 
It is also important to consider that cytotoxic agents are often more effective against 
proliferating cells. However, even in rapidly proliferating tumours, there is always a 
proportion of cells in a quiescent state and these cells show a degree of resistance to 
cytotoxic agents, compared to proliferating cells (Shah and Schwartz 2001). In 2010, Cooke 
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et al provided evidence by genomic analysis of cell line series, derived from high-grade 
serous carcinomas before and after platinum resistance, in support of the model for 
resistance in ovarian cancer in which pre-existing intra-tumour genetic heterogeneity is a 
major factor in determining relapse with resistance disease (Cooke, Ng et al. 2010).  
 
1.8 Strategies for Reversing Platinum Resistance 
 
Chemical modifications of DNA bases (adducts) are common types of DNA damage 
introduced by reactive cytotoxic drugs that covalently bind DNA and interfere with replication 
fork. These DNA-damaging agents are grouped into two groups; bifunctional agents and 
monofunctional agents. Monofunctional agents have one active site and modify single bases 
(Hsiang, Lihou et al. 1989, Helleday, Petermann et al. 2008).  
 
 Bifunctional agents such as platinum base agents cisplatin and carboplatin, have two 
reactive sites and crosslink two DNA bases within the same strand (intra-strand crosslinks) 
or on opposite DNA strand (inter-strand crosslinks). Inter-strand crosslinks cause more 
severe damage by blocking the replication fork.  
 
Carboplatin, cisplatin and oxaliplatin are three most commonly used DNA damaging 
chemotherapeutic drugs used in clinic to treat solid cancers (Rosenberg, VanCamp et al. 
1969). The active species of these platinum-containing anti-cancer drugs including is formed 
by aqueous hydrolysis as these compounds enter the cells. This active form of the drug 
interacts with DNA, RNA and protein but the cytotoxic effect of the compound is mediated 
via the formation of DNA intrastrands and interstrands (Lawley and Phillips 1996, Noll, 
Mason et al. 2006). The major problem associated with using these drugs is the emergence 
of platinum resistance in patients. This resistance can be either intrinsic or occur during 
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cyclical treatment (Helleday, Petermann et al. 2008). Many researches are currently focused 
on finding additional agents to be added to the treatment, to overcome platinum resistance in 
patients.  
 
1.8.1 Targeting the tumour microenvironment 
 
Interaction between tumour cells and the stroma (ECM) may result in resistance to 
chemotherapy-induced apoptosis (Elliott and Sethi 2002). Production of collagen VI by 
tumour cells results in resistance to chemo-therapy (Sherman-Baust, Weeraratna et al. 
2003). In addition, many genes up-regulated in resistant cells are related to ECM. For 
example, COL6A3 encoding for collagen alpha-3(VI) chain, one of the alpha chains of type 
VI collagen, is one of the most expressed genes in chemo-resistant cells. Moreover, growing 
platinum-sensitive cells in rich collagen VI condition promotes resistance to platinum-based 
chemotherapy. Staining of tumours with collagen VI antibody indicates expression of 
collagen VI in tumour cells and also reorganisation of ECM around tumour cells (Sherman-
Baust, Weeraratna et al. 2003). Remodelling of ECM may promote resistance in tumours 
when exposed to chemotherapy reagents, therefore a component of ECM may represent 
novel targets for overcoming chemo-resistance in cancer therapy (Shahzad, Lopez-
Berestein et al. 2009).  
 
1.8.2 Targeting Pharmacokinetic Factor 
 
1.8.2.1 Dose of Chemotherapy 
 
Chemotherapy is usually given to patients at close to the maximal tolerated dose (MTD) to 
achieve maximum tumour cell death. There is some correlation between dose and survival in 
advanced ovarian cancer (Kaye, Paul et al. 1996) In this clinical trial, patients with advanced 
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ovarian cancer received 6 cycles of cyclophosphamide-cisplatin at a dose of 50 mg/cm2 and 
75 mg/cm2. The higher dose of cisplatin resulted in a significant increase in median survival 
initially (Kaye, Paul et al. 1996). However, the survival benefit decreased over time (Vasey 
2005).  
 
Alternatively, intraperitoneal (IP) administration of chemotherapy can increase the local 
concentration of the cytotoxic agent without increasing total dose by direct delivery,  into the 
intraperitoneal cavity, which is the predominant site of tumour in ovarian cancer (Pinato, 
Graham et al. 2013). However, patients with IP administration of cisplatin and taxane 
experienced higher rates of grade III/IV gastro-intestinal toxicity in trials and poorer quality of 
life, compared with patients who received IV (Armstrong, Bundy et al. 2006). Despite this 
there is a consistent increase in survival in patients treated with IP chemotherapy. These 
trials were limited by differences in dose and schedule between treated arms. Hence, a 
phase III trial PETROC is ongoing to determine the relative benefits of IP versus IV 
chemotherapy in EOC (www.clinicaltrials.gov). 
 
1.8.2.2 Improving drug delivery 
 
Poor drug delivery to the tumour may result in low or no response to chemotherapy in cancer 
patients. Low bioavailability of drug, high plasma protein binding, high first-pass metabolism 
and low tissue binding are some of the factors that can result in a drug concentration lower 
than its effective concentration in the tumour. To date, some novel delivery systems have 
been introduced to improve the delivery of chemotherapeutic agents to tumour cells such as 
liposomes and polymer-drug carriers (Duncan 2003, Harris and Chess 2003). Liposomes 
achieve increased tumour-cell delivery by exploiting the increased permeability of tumour 
vasculature relative to normal capillaries. Gene-directed enzyme prodrug therapy and 
antibody-directed enzyme prodrug therapy are other approaches developed to increase 
tumour cell-specific drug exposure (McNeish, Green et al. 1998, Houba, Boven et al. 2001).  
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1.8.3 Targeting Cancer Pathways 
 
To date, many small-molecule inhibitors and monoclonal antibodies, targeting key molecules 
of signalling pathways involved in cell growth, cell survival, metastases, angiogenesis and 
other cancer hallmarks have been developed and entered clinical trials. This includes small 
molecule inhibitors of MEK, PARP, VEGF, mTOR, AKT and PI3K (Hainaut and Plymoth).  
 
1.8.3.1 DNA repair pathways and their components 
 
Many DNA-damaging agents currently used in treatment of cancer trigger apoptosis by 
causing DNA double-strand breaks. The toxicity of DNA-damaging drugs can be reduced by 
the activity of several DNA-repair pathways. Different DNA-damage agents trigger different 
mechanisms of DNA repair (Helleday, Petermann et al. 2008). 
 
Mismatch repair (MMR) 
 
The base substitution mismatches and insertion-deletion mismatches generated during DNA 
replication, are corrected by MMR pathway. Activation of the MMR pathway by platinum-
induced DNA damage normally triggers apoptosis (Blommaert, Floot et al. 1998, Perez 
1998).  One of the causes of drug resistance is Mismatch repair (MMR) deficiency within the 
cancer cell. Defects in MMR genes which code for hMLH1 and hMSH2 result in the failure of 
tumour cells to recognise DNA damage. MMR deficiency may result in the resistance of 
ovarian cancer cells to a wide range of DNA-damaging agents, including doxorubicin and 
cisplatin (Brown, Hirst et al. 1997). However, sensitivity to oxaliplatin, a platinum analogue, is 
independent of the MMR status of tumour cells and it has been hypothesised that oxaliplatin 
can be effective in platinum-resistant patients with MMR deficiency (Fink, Nebel et al. 1996). 
Results of a Phase II clinical study in platinum-resistant ovarian cancer patients indicated 
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that oxaliplatin can be comparable with paclitaxel, in terms of efficiency and safety, if given 
to patients every three weeks (Piccart, Green et al. 2000).  In addition, MLH1 promoter 
methylation has been associated with drug resistance. In a clinical study, plasma DNAs of 
patients with epithelial ovarian cancer, enrolled in the SCOTROC1 Phase III clinical trial, 
were examined for methylation of hMLH1 CpG island before carboplatin/taxol chemotherapy 
and at relapse. It was shown that methylation of hMLH1 is increased in relapsed tumours 
and 34 of 138 relapse samples had hMLH1 methylation which was not detected before 
chemotherapy. Those patients had a worse outcome, following further chemotherapy, 
compared with the patients in whom methylation did not occur (Gifford, Paul et al. 2004). 
Moreover, demethylating agent DAD sensitised MMR-deficient, drug resistant ovarian and 
colon tumour xenografts ,that were MLH1 negative because of gene promoter 
hypermethylation, to temozolomide, carboplatin, cisplatin and epirubicin. However, DAD 
alone had no effect on tumour growth rate. DAD treatment did not sensitise the same 
xenografts to taxol and also did not increase chemo-sensitivity in tumour xenografts which 
had deficient MMR because of hMLH1 mutation (Plumb, Strathdee et al. 2000). 
 
Nucleotide Excision Repair (NER) 
 
NER pathway is responsible for removal of DNA lesions that distorts the DNA double helix or 
block DNA replication and transcription. NER plays an important role in mediating resistance 
to platinum-based agents (Rabik and Dolan 2007). The excision repair cross-
complementation group 1 (ERCC1) is one of the proteins playing a major role in mediating 
this pathway (Bergstralh and Sekelsky 2008). In vitro association between increased 
expression of ERCC1 and resistance to cisplatin has been demonstrated in ovarian cancer 
cells (Ferry, Hamilton et al. 2000). Also, silencing ERCC1 expression using RNA 
interference resulted in sensitivity to platinum agents in platinum-resistant ovarian cancer 
cells (Selvakumaran, Pisarcik et al. 2003). Also, the level of ERCC1 is significantly high in 
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clear cell ovarian cancer tumours which are known to be relatively platinum-resistant and 
having poor prognosis (Reed, Yu et al. 2003).  
 
Homologous recombination (HR) 
 
Replication associated DSBs are repaired by homologous recombination (HR) and other 
replication-associated repair pathways. In the homologous recombination process, a DNA 
sequence from an intact DNA molecule, often the newly-synthesised sister chromatid, is 
used to repair replication lesions (Arnaudeau, Lundin et al. 2001). BRCA plays an important 
role in this process. Cancer cells that are deficient in BRCA1 and BRCA2 function show a 
high degree of chromosome instability.  There is a correlation between the BRCA deficiency 
and platinum sensitivity in EOC (Dann, DeLoia et al. 2012). Ovarian cancer patients with 
BRCA1/2 mutations who are treated with platinum-based chemotherapy show better 
response rate and survival compared with ovarian cancer patients with functional BRCA1/2 
treated with the same treatment (Ben David, Chetrit et al. 2002, Tan, Rothermundt et al. 
2008).  Cells lacking wild-type BRCA1 and BRCA2 are highly sensitive to inhibitors of PARP, 
a nuclear enzyme that facilitates the repair of single stranded DNA breaks. Inhibition of 
PARP leads to formation of double strand breaks that require functional BRCA1 and BRCA2 
for DNA repair. Inhibition of PARP is a promising strategy in treatment of BRCA mutation-
associated ovarian cancer (Banerjee and Kaye 2011). 
 
Non-homologous end joining (NHEJ) 
 
Ionising radiation and radiomimetic drugs induce double-strand breaks (DSB) that are mainly 
repaired by non-homologous end joining (NHEJ). In this process, the two ends of DNA 
strand break are connected and resealed without the need for sequence homology between 
the ends. In this process (NHEJ), each broken DNA end is first bound by one Ku 70/80 
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heterodimer and two heterodimer must come together to bridge matching ends to ensure 
efficient ligation. This complex is bound by the DNA-dependent protein kinase catalytic sub-
unit (DNA-PKcs) which stabilises the protein/DNA binding, therefore enabling the NHEJ DNA-
repair process to carry on (Cary, Peterson et al. 1997, Hammarsten and Chu 1998, Gell and 
Jackson 1999, Singleton, Torres-Arzayus et al. 1999, Yoo and Dynan 1999, DeFazio, 
Stansel et al. 2002). In addition to the DNA-PKcs and Ku molecules bound to DNA, remaining 
molecules forming the NHEJ apparatus consist of the DNA ligase IV/XRCC4 (X-ray cross 
complementation group 4 proteins) complex (Hsu, Yannone et al. 2002). 
 
1.8.3.1.1 DNA-dependent protein kinase (DNA-PK) 
 
DNA-dependant protein kinase (DNA-PK) is a nuclear serine/threonine kinase and a 
member of the PI3K like kinases (PI3KK), mainly involved in the non-homologous end-
joining DNA repair process. Other members of this family include the DNA-repair protein 
kinases, ataxia telangiectasia mutated (ATM) and ataxia telangiectasia and Rad3-related 
protein (ATR). These three protein kinases (DNA-PK, ATM,ATR) show sequence homology 
with other members of the phosphatidylinositol-3-kinae (PI3K) family. However, they do not 
phosphorylate lipids, therefore they are not true PI3K kinases (Hartley, Gell et al. 1995, 
Smith, Divecha et al. 1999) (Bosotti, Isacchi et al. 2000). Lack of DNA-PKcs in cells causes 
radio-sensitivity, due to defective DSB repair (Jung and Alt 2004). In addition to the role of 
DNA-PKcs in DNA DSB repair, DNA-PKcs is critical for telomere capping and protection of 
chromosomes’ ends. (Bailey, Meyne et al. 1999, Gilley, Tanaka et al. 2001, Goytisolo, 
Samper et al. 2001)  . 
 
Autophosphorylation of DNA-PK results in kinase inactivation and dissociation of DNA-PKcs 
from the heterodimer Ku (Chan and Lees-Miller 1996, Douglas, Moorhead et al. 2001). DNA-
PK has two main autophosphorylation clusters ranging from residues 2031-2056 and 2609-
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2647. The most conserved site among eukaryotes is thr-2609 which is autophosphorylated 
following irradiation and has been found to co-localise at sites of DNA damage (Anderson 
and Lees-Miller 1992, Chan, Chen et al. 2002, Reddy, Ding et al. 2004). Only minutes after 
exposure to irradiation, phosphorylated kinase is detectable at the site of DNA damage. This 
suggests that post-translational modification of DNA-PK is necessary for the initiation of the 
cellular response to DSBs (Ding, Reddy et al. 2003).  
 
Moreover, Involvement of DNA-PK in transcriptional control has been indicated in a number 
of studies. This includes the involvement of DNA-PK in regulation of RNA polymerase I. 
DNA-PK inhibits transcription initiation by Pol I. This inhibitory process requires 
phosphorylation of Pol I (Kuhn, Gottlieb et al. 1995).  
 
Inhibition of components of the NHEJ pathway, particularly DNA-PK is an attractive 
approach to modulate resistance to DNA DSBs induced by therapeutic agents. The most 
successful approach to inhibit DNA-PK is targeting the ATP binding site of the kinase 
domain by small molecules (Allen, Halbrook et al. 2003). Screening of compounds libraries 
has revealed several small molecules that are able to inhibit DNA-PK efficiently but 
unfortunately, most of those molecules have poor pharmacokinetic properties.  
 
1.8.3.1.1.1.1 Inhibitors of DNA-PK  
 
Wortmannin was one of the first molecules that was revealed to inhibit DNA-PK. This 
compound is a non-competitive general inhibitor of PI3 kinases (Stein 2001). Wortmannin 
inhibits DNA-PK by irreversible alkylation of lysine 802 in the active site of DNA-PKcs. Lysine 
802 is required for phosphate transfer (Wymann, Bulgarelli-Leva et al. 1996).  Wortmannin is 
also an effective radio-sensitiser in vitro (Sarkaria, Tibbetts et al. 1998, Hashimoto, Rao et 
36 
 
al. 2003), but despite the efficiency of wortmannin in vitro, it’s in vivo toxicity, poor solubility 
in aqueous solution and lack of specificity limit the application of this DNA-PK inhibitor in the 
clinic (Collis, DeWeese et al. 2005).  
 
LY294002 is another non-specific DNA-PK inhibitor used in many studies as a PI3K inhibitor. 
LY294002 binds reversibly to the kinase domain of DNA-PK. Lack of specificity, in vivo 
toxicity and rapid metabolic clearance are some of factors that limit clinical utility of this 
compound (Collis, DeWeese et al. 2005).  
 
NU7026 is a more specific DNA-PK inhibitor which has a modified structure of LY29002 and 
is 70-fold more selective for DNA-PK than other PI3Ks, and five-fold more selective for DNA-
PK than for ATR and ATM (Hollick, Golding et al. 2003). This compound has been shown to 
potentiate the growth inhibitory effect of a variety of chemotherapeutic agents including 
doxorubicin, idarubicin, etoposide and mitoxantrone in vitro (Willmore, de Caux et al. 2004). 
However, poor solubility of NU7026 remains problematic for clinical application of this 
compound.  
 
NU7441 is a small molecule DNA-PK inhibitor based on the LY294002 backbone with 
improved potency compared to NU7026 (Willmore, de Caux et al. 2004). NU7441 increased 
the cytotoxicity of IR and etoposide in colon cancer cells (Zhao, Thomas et al. 2006). In 
addition, this compound delayed the repair of IR and etoposide-induced DSBs and increased 
G2/M accumulation associated with IR and etoposide in colon cancer cells (Zhao, Thomas et 
al. 2006). Although pharmacokinetic properties of NU7441 need to be improved, the ability of 
this compound to enhance the effect of IR and chemotherapy in vitro and in vivo has made it 
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a promising candidate for further development. The effect of NU7441 on platinum resistance 
has not been reported. 
 
IC86621, IC87102 and IC87361 are other compounds, based on the LY294002 structure, 
that have been tested in vitro as DNA-PK inhibitors. IC86621 caused decreased repair of IR 
DSBs and increased sensitisation to IR in vitro (Kashishian, Douangpanya et al. 2003). In 
addition, IC87361 showed significant radio-sensitisation and growth delay in xenograft 
models (Shinohara, Geng et al. 2005). All these three compounds are non-toxic and have 
therapeutic potential to increase the effects of DNA-damaging agents on cancer cells.  
 
Recently a topoisomerase II alpha inhibitor, NK314, was shown to induce the degradation of 
DNA-PK. This compound appears to be a dual inhibitor of TII-alpha and DNA-PK (Hisatomi, 
Sueoka-Aragane et al. 2011). The mechanism by which this compound inhibits DNA-PK is 
still unknown. NK314 is currently in clinical trial for the treatment of adult T-cell leukaemia-
lymphoma (www.clinicaltrials.gov).  
 
1.8.3.1.2 Poly ADP ribose polymerases (PARPs) 
 
Poly ADP ribose polymerases (PARPs) form a large, multifunctional family of enzymes 
which play an important role in repairing DNA single strand breaks. They are present in the 
nucleus and facilitate the repair of single strand DNA breaks by signalling the DNA damage 
presence to the DNA repair machinery. This signalling is performed via addition of ADP – 
ribose polymers to the DNA. PARP1 is the most abundant enzyme in this group which 
repairs base excisions. Inhibition of PARP1 results in the accumulation of single strand DNA 
breaks, eventually leading to double strand breaks (Dantzer, Ame et al. 2006). 
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BRCA1 and BRCA2 play major roles in double strand break repair process (Powell and 
Kachnic 2003, Ashworth 2008). Germline BRCA1/2 mutations have been found in about 10-
15% of ovarian cancer tumours (Pal, Permuth-Wey et al. 2005). Genetic or epigenetic 
inactivation of BRCA1/2 genes is frequently found in high grade serous ovarian cancer 
tumours (Press, De Luca et al. 2008). In addition, recent analysis of ovarian cancer tumours 
published by the Cancer Genomic Atlas (TCGA) indicates the presence of BRCA1/2 
mutations or BRCA1 silencing in 33% of high-grade ovarian cancer tumours (Cancer 
Genome Atlas Research 2011). Deficiency in BRACA1/2 function are associated with a 
better response to platinum-based agents in ovarian cancer (Tan, Rothermundt et al. 2008). 
 
PARP inhibition may be beneficial to increasing the efficacy of platinum in patients with 
BRCA1/2 mutations. To date, several ongoing or completed studies have evaluated the 
effect of the combination of PARP inhibitors and different chemotherapeutic reagents on the 
reversal of chemo-resistance. In a phase I clinical trial, Fong et al assessed the anti-tumour 
activity of the PARP inhibitor olaparib in platinum-sensitive, resistant and refractory ovarian 
cancer patients with BRCA1/2 deficiency and found a association between  clinical benefit 
rate across the platinum sensitive and resistant subgroups (69% and 45% respectively)  
(Fong, Yap et al. 2010).  
 
1.8.3.2 Apoptosis pathway 
 
A failed attempt to repair DNA damage, induced by cytotoxic agents, may result in the trigger 
of programmed cell death (apoptosis). Apoptosis is initiated by various stimuli such as DNA 
damage, growth factor deprivation, heat shock leading to the activation of apoptotic genes 
and eventually activation of caspase cascades. Initiation of apoptosis can occur either by the 
extrinsic or intrinsic pathways (Elmore 2007, Ouyang, Shi et al. 2012).  
39 
 
Intrinsic pathway 
 
The intrinsic pathway is mediated primarily by mitochondrial dysfunction (Khosravi-Far and 
Esposti 2004, Fulda and Debatin 2006). Signals triggered from mitochondria, activate the 
initiator caspases, caspase 9 (Villa, Kaufmann et al. 1997). Formation of a large protein 
complex called the apoptosome is required for activation of caspase 9 (Salvesen and 
Renatus 2002, Shi 2002, Hill, Adrain et al. 2003). The key components of apoptosome are 
cytochrome c, which is released from mitochondria and a co-factor known as the apoptotic 
protease activating factor-1 (APAF-1) (Adams and Cory 2002, Cain, Bratton et al. 2002). 
Once activated, initiator caspases activate downstream effector caspases through cleavage 
at asparate residues which leads to separation of the large and small subunits. Activated 
effector caspases are responsible for cleavage of several downstream protein targets which 
are involved in vital cellular functions such as DNA repair, replication and transcription 
(Earnshaw, Martins et al. 1999). The enzymatic function of caspases is inhibited by the 
inhibitor of apoptosis proteins (IAP) (Bergmann, Yang et al. 2003, Vaux and Silke 2003).  
 
The intrinsic pathway is regulated by B-cell lymphoma 2 (Bcl-2) proteins. Bcl-2 proteins form 
a large family of polypeptides which contain at least one Bcl-2 homology (BH) domain that 
mediates protein- protein interaction (Youle and Strasser 2008). The most well-known 
members of this family are Bcl-2 and Bcl2-assosiated X (BAX) proteins. Bcl-2 is an 
oncogene that can protect cells from apoptotic response to DNA-damage agents 
(Hockenbery 1992). BAX on the other hand, is a pro-apoptotic protein and acts as a 
dominant inhibitor of Bcl-2. Following stimulation of apoptosis, BAX undergoes a 
conformational shift and integrates into the outer mitochondrial membrane (Korsmeyer, 
Shutter et al. 1993, Yang and Korsmeyer 1996, Soriano and Scorrano 2011). BAX 
oligomeric complexes act as channels through which proapoptotic proteins, such as 
cytochrome c, can be released. The ratio of Bcl-2 to BAX determines whether a cell enters 
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apoptosis (Gross, McDonnell et al. 1999). Sensitivity to cytotoxic agents can be increased by 
the inhibition of anti-apototic proteins and introduction of pro-apoptotic genes. 
 
 Extrinsic pathway 
 
Induction of apoptosis by the extrinsic pathway occurs when death receptors located on the 
cell surface, such as FAS, Apo2L and other members of the tumour necrosis factor (TNF) 
receptor family, are activated by extra cellular ligands. FAS ligand binds to the FAS receptor 
cause dimerisation of the receptor followed by the binding of adaptor proteins such as the 
FAS-associated death domain (FADD) protein to the death domains of the both the adaptor 
and the receptor protein. In addition, procaspase 8 binds to the death-effector domain of 
FADD. This complex consists of FAS, FASL, FADD and procaspase 8 and is known as the 
death-inducing signalling complex or DISC. Formation of this complex results in self-
activation of procaspase 8 molecule. Activated caspase 8 then activates downstream 
effector caspase including caspase 3 (Elmore 2007).  
 
Caspase 3 
 
Both intrinsic and extrinsic pathways lead to activation of the effector caspase, caspase 3. 
Caspase 3 has a vital role in several key events during apoptosis, such as DNA 
fragmentation and nuclear fragmentation. Caspase 3 has a central role in the regulation of 
essential apoptotic pathways. For instance, cisplatin-induced cytochrome c release and 
caspase 8 mediated procaspase-9 process are dependent on caspase 3 in MCF-7 breast 
cancer cells (Blanc, Deveraux et al. 2000). It has also been indicated that apoptosis in MCF-
7 caspase 3 deficient cells is defective in response to cisplatin. Stable transfection of those 
cells with caspase 3 cDNA restored the deficiency (Blanc, Deveraux et al. 2000).  
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Tumour suppressor protein P53  
 
TP53 which encodes for the tumour suppressor protein P53, is one of the most frequently 
mutated genes in human cancers, including ovarian cancer. P53 plays an important role in 
apoptosis. Following DNA damage, p53 becomes activated either directly or indirectly and 
up-regulates expression of mitochondrial pro-apoptotic proteins such as BAX, p53 up-
regulated modulator of apoptosis (PUMA) and p53-regulated apoptosis-inducing protein 1 
(p53AIP1), as well as proteins like TRAIL-R1, TRIAL-R2, involved in cell death receptor 
pathways (Hengartner 2000). Lack of functional p53 in cancer cells can, therefore, result in 
chemo-resistance as these cells are unable to undergo apoptosis in response to DNA 
damage (Gasco and Crook 2003).   
 
Several attempts have been made to overcome resistance to cisplatin in tumour cells having 
dysfunctional p53. This includes the development of a triplatinum analogue BBR3464. This 
compound is 20-fold more potent than cisplatin in vitro with a different pattern of activity in 
cancer cells. It forms DNA intrastrand cross-links that are not removed by nucleotide 
excision repair and therefore may persist longer in tumour cells (Kasparkova, Zehnulova et 
al. 2002). This drug induces apoptosis independent of the p53 status of cells in vitro and has 
also shown good activity in p53 mutant xenografts (Manzotti, Pratesi et al. 2000). Clinical 
assessment of BBR3464 indicated that some response was demonstrated in platinum-
sensitive patients but unfortunately, little activity was seen in platinum-resistant tumours 
(Sessa, Capri et al. 2000).  
 
1.8.3.3 Angiogenesis  
 
Angiogenesis, the formation of new blood vessels  is one of the key factors in tumour growth 
and metastasis (Verheul and Pinedo 2000). Vascular Endothelial Growth Factor (VEGF) and 
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its receptors play a crucial role in this process. The VEGF protein family consists of at least 
five structurally-related family members which transmit their signal via three VEGF receptor 
tyrosine kinases (VEGFR1, VEGFR2 and VEGFR3). VEGFA (also known as VEGF) is the 
best known member of the VEGF family and is secreted by a range of tumour cells  Binding 
of VEGF to its receptor leads to dimerisation and auto-phosphorylation of the receptor which 
causes activation of RAS-RAF-MAP kinase cascade and also PI3K/AKT pathway (Olsson, 
Dimberg et al. 2006). Activation of these two pathways in endothelial cells leads to 
angiogenesis and in tumour cells lead to eventually cell invasion, migration, survival and 
proliferation. In keeping with this, ovarian cancer cells express both VEGF and VEGFR2. It 
has been suggested that VEGF–mediated signalling acts through the PI3K/AKT pathway 
and activation of AKT is required for VEGF-mediated endothelial cell survival (Gerber, 
McMurtrey et al. 1998, Fujio and Walsh 1999). Angionenesis, induced by VEGF, can be 
inhibited either by targeting the VEGF molecule itself or via its receptor.  
 
Inhibition of angiogenesis pathway in ovarian cancer  
 
Evidence from phase II and III clinical trials using the angiogenesis inhibitor, bevacizumab, 
indicate that inhibition of angiogenesis is a promising strategy in treating recurrent ovarian 
cancer (Perren, Swart et al. , Burger, Sill et al. 2007, Cannistra, Matulonis et al. 2007).To 
date, bevacizumab is the most developed and promising angiogenesis inhibitor in the 
treatment of ovarian cancer. Bevacizumab is a humanised monoclonal antibody directed 
against VEGFA (Folkman 1971, Jain 2005, Ellis and Hicklin 2008).  
 
Small molecule inhibitors of tyrosine kinase inhibitors can also inhibit VEGF signalling by 
inhibiting the activity of VEGF receptors. However, tyrosine kinase inhibitors usually have 
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multi-targeting activity and have additional activity against other tyrosine kinases. (Morabito, 
De Maio et al. 2006).  
 
Several VEGFR inhibitors are under evaluation regarding their use in ovarian cancer 
patients, either as monotherapy or in combination therapy with cytotoxic agents. For 
example, sorafenib is a VEGFR-2 and VEGFR-3 inhibitor which also inhibits Raf-1, therefore 
it potentially inhibits tumour proliferation via RAS-ERK pathway as well as angiogenesis. 
However, activity of sorafenib, in Phase II clinical trials with patients with recurrent ovarian 
cancer, has been reported to be low (Biagi, Oza et al. 2011). In contrast, cediranib, also an 
inhibitor of VEGFR, has showed encouraging results in a Phase II clinical trial of ovarian 
cancer patients, resulting in a clinical response rate of 30% and median progression-free 
survival of 5.2 months (Matulonis, Berlin et al. 2009). Pazopanib and vandetanib are other 
TKI of VEGFR under clinical and non-clinical evaluation (Annunziata, Walker et al. 2010, 
Friedlander, Hancock et al. 2010). 
 
1.8.3.4 Epithelial growth factor receptor pathway 
 
Epithelial growth factor receptor (EGFR) is widely expressed on the surface of mammalian 
epithelial cells (Miettinen, Berger et al. 1995). EGFR belongs to the human epithelial 
receptor family (HER), which consists of 4 members: HER1/EGFR, HER2/neu, HER3 and 
HER4. These 4 receptors share a similar structure consisting of an intracellular tyrosine 
kinase domain, an extracellular ligand binding domain and a transmembrane lipophilic 
domain (Yarden and Sliwkowski 2001).  
EGFR becomes activated by ligand binding, followed by heterodimerasation or 
homodimerasation. To date, several molecules have been found to bind to EGFR, including 
epidermal growth factor (EGF), amphiregulin (AR), transforming growth factor α (TGF-α), 
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epiregulin (ER) and neuroregulin (Lemmon and Schlessinger 1994). The main pathways 
activated by EGFR dimerization are the RAS-RAF-mitogen-activated protein kinase 
(RAS/RAF/MAPK) and PI3K/AKT pathways (Buettner, Mora et al. 2002, Arteaga 2003, Citri 
and Yarden 2006). 
 
EGFR plays a crucial role in tumourigenesis and its expression has been associated with the 
outcome of cancer treatment (Sibilia, Kroismayr et al. 2007). Overexpression of EGFR has 
been detected in 30-98% of epithelial ovarian cancers (Moscatello, Holgado-Madruga et al. 
1995, Bartlett, Langdon et al. 1996, Fischer-Colbrie, Witt et al. 1997, Alper, Bergmann-
Leitner et al. 2001). Dysregulation of EGFR can contribute to the malignancy of ovarian or 
other tumours via activation of cell proliferation, migration, angiogenesis or promotion of 
resistance to apoptosis (Ciardiello and Tortora 2001, Nicholson, Gee et al. 2001, Arteaga 
2002, Tsujioka, Yotsumoto et al. 2010). Increased expression of EGFR has been correlated 
with reduced recurrence-free or overall survival rate in head and neck, ovarian, cervical, 
bladder and oesophageal cancers (Ciardiello and Tortora 2001, Nicholson, Gee et al. 2001, 
Arteaga 2002, Tsujioka, Yotsumoto et al. 2010).  
 
 EGFR dysregulation in cancer cells is due to three main reasons; mutation in the gene, 
receptor amplification/overexpression and autocrine/paracrine loop formation. EGFR 
pathway can be inhibited by either extracellular, in which the ligand binding motif of the 
EGFR is blocked by monoclonal antibodies, or by using the tyrosine kinase inhibitors which 
inactivate downstream signalling cascades (Gui and Shen 2012).  
To date, two MAbs (panitumumab and cetuximab) and two tyrosine kinase inhibitors 
(erlotinib and gefitinib) have been approved by the food and drug administration (FDA) for 
different cancers, although neither have been licenced yet for use in epithelial ovarian 
cancer (Gui and Shen 2012). Preclinical studies have demonstrated that cetuximab can re-
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sensitise various human cancer cell lines and xenograft models (including epithelial ovarian 
cancer models) to chemotherapy and radiotherapy (Bull Phelps, Schorge et al. 2008). In a 
phase II clinical study of single agent cetuximab in patients with persistent or recurrent EOC, 
25 patients were recruited, all of whom were EGFR positive. Single agent cetuximab showed 
minimal activity in recurrent epithelial ovarian cancer patients in this phase II clinical study 
(Schilder, Pathak et al. 2009).  
 
Erlotinib and gefitinib are the most advanced tyrosine kinase inhibitors in clinical 
development. Erlotinib has been approved for the treatment of pancreatic cancer and non-
small cell lung cancer but it has shown minimal response in cell proliferations assays in 
ovarian cancer cell lines (Bull Phelps, Schorge et al. 2008). Results of a phase II 
combination therapy study of an unselected population with ovarian cancer has indicated 
that erlotinib plus carboplatin-paclitaxel does not improve pathological complete response 
compared with carboplatin-paclitaxel alone (Blank, Christos et al. 2010).  
 
1.8.3.5 RAS/RAF MEK Pathway 
 
Aberrant regulation of the RAS/RAF/MEK cascade has been found in various types of 
cancer including ovarian cancer. Mutation in BRAF and KRAS characterise the development 
of low-grade serous ovarian cancer (Singer, Oldt et al. 2003). Therefore, inhibition of 
RAS/RAF/MEK pathway may be a good target to treat the low-grade invasive disease. 
Mitogen-activated protein kinase (MAPK) signalling pathway has an important role in the 
regulation of cell proliferation, differentiation and survival. (Sebolt-Leopold and Herrera 
2004).  
RAS, which is a small GTPase, becomes activated by the exchange of GDP with GTP. RAS-
GTP then contributes to the activation of the serine/threonine kinase RAF by binding to this 
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protein. The recruitment of RAF to the cell membrane is essential for its activation by RAS-
GTP. Activated RAF then activates mitogen-activated protein kinase kinase (MAPKK;MEK) 
by phosphorylation (Mitin, Rossman et al. 2005). MEK is a dual tyrosine and 
serine/threonine kinase and once activated, it phosphorylates the mitogen-activated protein 
kinases (MAPKs), also known as extracellular signal regulated kinase (ERKs) (Gardner, 
Vaillancourt et al. 1994). MAPKs are a family of serine/threonine kinases. Activated MAPKs 
enters the nucleus and regulates the activity of many transcription factors involved in cell 
proliferation, survival and differentiation. There are three distinct but parallel MAPK 
pathways: MAPK, JNK and p38 (Johnson and Lapadat 2002). MAPK becomes activated by 
growth factors while JNK and p38 are activated by various environmental stress signals, 
such as ionising radiation. The JNK and p38 pathways usually trigger apoptosis (Behrens, 
Sibilia et al. 1999, Kralova, Dvorak et al. 2008).  
 
Cross-talk between the RAS/RAF/MEK and the PI3K/AKT pathways has been shown in 
several studies (Aksamitiene, Kiyatkin et al.). The PI3K/AKT pathway can interact with the 
RAS/RAF/MEK signalling pathway. AKT can phosphorylate and inactivate BRAF 
(Zimmermann and Moelling 1999, Guan, Figueroa et al. 2000). In addition, AKT has been 
shown to activate RAF1 through a protein kinase C dependent but RAS-independent 
mechanism leading to inhibition of apoptosis (Majewski, Nieborowska-Skorska et al. 1999). 
Both AKT and ERK can prevent apoptosis by phosphorylating the BH3-only domain protein, 
BIM. This phosphorylation causes BIM to become targeted for degradation in proteasome 
(Gelinas and White 2005). In addition, both pathways can prevent the apoptotic effect of the 
pro-apoptotic Bcl-2 Homologous domain-3 (BH-3) only domain protein BAD by 
phosphorylation (Datta, Dudek et al. 1997, Bonni, Brunet et al. 1999, Harada, Becknell et al. 
1999). 
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To date, several small molecule inhibitors of RAS/RAF MEK pathway have been developed 
(McCubrey, Steelman et al. 2012). Selumetinib (AZD6244) is a MEK inhibitor which is under 
clinical development. Selumetinib significantly suppressed tumour growth in a clear cell 
carcinoma (CCC) xenograft model (Bartholomeusz, Oishi et al. 2012). A phase II clinical 
study in patients with low-grade ovarian cancer carcinoma indicated that selumetinib 
controlled the disease in 81% of patients. From the fifty-one women who were recruited for 
the study, 8 patients had complete or partial response to treatment and 34 patients had 
stable disease. Sixty percent of patients had progression-free survival longer than six 
months. In addition, selumetinib was well tolerated. DNA analysis of patients showed that 
RAF/RAS mutation had no effect on clinical response in this study (Farley, Brady et al. 
2013). Moreover, a phase II trial studying the side effects of selumetinib in recurrent low-
grade ovarian cancer patients is currently ongoing (www.clinicaltrials.gov). 
 
1.8.3.6 PI3K/AKT pathway 
 
The phosphatidylinositol-3-kinase (PI3K) pathway is an important regulator of mammalian 
cell proliferation, growth, glucose metabolism and survival. These cellular processes are 
responsible for all aspects of tumourigenesis, so the PI3K pathway and downstream 
signalling components, such as AKT, are attractive targets for the development of 
therapeutic strategies for human cancers (Cantley 2002).  
 
The PI3K pathway is activated by direct or indirect binding of receptor tyrosine kinases to 
adaptor proteins. The PI3Ks are grouped into three classes; class I, class II and class III 
according to their structure, regulation and lipid substrate specificity. The class I PI3Ks are 
divided into two classes; class IA and class IB. Class IA catalytic subunits are divided into 
three isoforms; p110α, p110β and p110δ encoded by PIK3CA, PIK3CB and PIC3CD 
respectively. The regulatory subunits of class IA PI3Ks are divided into three groups; p85α, 
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p85β and p85γ, encoded by PIK3R1, PIK3R2 and PIK3R3, respectively. The class IB p110 
catalytic subunit is encoded by PIK3CG and binds the p101 regulatory subunit encoded by 
PIK3R5 upon activation by G protein-coupled receptors (GPCR) and RAS (Engelman, Luo et 
al. 2006).  
 
The functions of PI3K class IA subunits are better understood than those of the class IB and 
class II and class III PI3K proteins. Only class I PI3Ks have been heavily implicated in 
oncogenesis (Samuels and Ericson 2006). In this chapter, class IA PI3K proteins and their 
down-stream signalling are discussed.  
 
The class IA regulatory subunits, p85 recruit the p110 catalytic subunit to phosphotyrosine 
residues in the receptor or adaptor proteins. This leads to localisation of the p110 catalytic 
subunits of PI3K in the plasma membrane, where they phosphorylate their lipid substrate. 
Upon activation, the class I PI3K phosphorylates membrane bound phosphatidylinositol-4, 5-
bisphosphate (PIP2) to produce phosphatidylinositol-3, 4, 5-triphosphate (PIP3), a second 
messenger that binds to the pleckstrin-homology (PH) domain of AKT, recruiting AKT to the 
plasma membrane.  
 
 AKT, also known as protein kinase B, is a crucial signalling component down-stream of 
PI3K, and is therefore a very attractive therapeutic target (Manning and Cantley 2007). 
There are three members of the AKT family: AKT1, AKT2 and AKT3. All three isoforms are 
very similar in structure and consist of a central catalytic domain, an amino-terminal 
pleckstrin-homology (PH) domain and a short C-terminal carboxyl domain (Datta, Brunet et 
al. 1999).  
 
Following the PI3K mediated recruitment to the plasma membrane, AKT is phosphorylated 
by phosphoinositide-dependent kinase 1 (PDK1) on a T regulatory residue (Figure. 1.1) 
(Bellacosa, Chan et al. 1998). Dependent on the AKT isoform, PDK1 can phosphorylate AKT 
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on T308/309/305. This phosphorylation is sufficient for stabilising the activation loop of AKT 
whereas phosphorylation on an S regulatory residue (S473/474/472, dependent on the AKT 
isoform) by a second kinase is necessary for full activation of the kinase (Alessi, Andjelkovic 
et al. 1996). Several different kinases have been identified which phosphorylate AKT at 
Ser473, including the mTOR-Rictor complex 2, integrin-linked kinase (ILK), DNA-dependent 
protein kinase (DNA-PK) and even AKT itself. Phosphorylated AKT, in turn, regulates a wide 
range of target proteins that control cell growth, proliferation, survival, and glucose 
metabolism. These include glycogen synthase kinase 3 (GSK3), proline-rich AKT substrate 
of 40 kDa (PRAS40), Bcl-2-associated death promoter (BAD) and the Forkhead box O 
(FOXO) transcription factors (Diehl, Cheng et al. 1998, Brunet, Bonni et al. 1999, Noshita, 
Lewen et al. 2001, Wang, Harris et al. 2008). 
 
PI3K activity is negatively regulated by the tumour suppressor protein phosphatase and 
tensin homolog (PTEN). PTEN removes phosphate from phosphatidylinositol-3, 4, 5-
triphosphate (PIP3), converting it back to phosphatidylinositol-4, 5-bisphosphate (PIP2).  
 
1.8.3.6.1 Aberrations in the PI3K/AKT/mTOR pathway in cancer 
 
Dysregulation and mutation of several components of the PI3K-AKT pathway have been 
reported in various types of human malignancies, including ovarian cancer, and have been 
shown to lead to neoplastic transformation in model systems (Vivanco and Sawyers 2002). 
Genomic and epigenetic alternations of genes encoding AKT and the tumour suppressor 
protein phosphatase and tensin homolog (PTEN), including loss of heterozygosity and 
methylation, have been frequently reported in various types of human malignancies, 
including ovarian, breast and lung cancers (Ali, Schriml et al. 1999, Hanahan and Weinberg 
2000, Hanahan and Weinberg 2011).  
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Moreover, somatic missense mutations in PIK3CA, the gene encoding the p110α catalytic 
subunit of PI3K, are commonly detected genetic aberrations in breast cancer (Campbell, 
Russell et al. 2004, Samuels, Wang et al. 2004). Over-expression of p110 has also been 
observed in ovarian cancer (Shayesteh, Lu et al. 1999). A frequent mutation in PIK3CA  
(E545K) has been shown to activate AKT signalling and induce cellular transformation 
(Meyer, Koren et al. 2013). The regulatory subunit of PI3K, p85, has also been shown to be 
mutated in ovarian and colon cancers, along with the PIK3R1 gene, which encodes the p85a 
regulatory subunit and is found to be mutated in 10% of human gliomas (Philp, Campbell et 
al. 2001). Genetic abnormalities also commonly occur in PI3K related pathways. For 
example, mutations in the oncogene, RAS, which activates PI3K, is frequently detected in 
pancreatic cancer (Janku, Lee et al. 2011, Lau and Leung 2011). PIK3CA amplification is 
commonly seen in head and neck, cervical and NSCLC squamous cancers (Janku, 
Tsimberidou et al.). Consequently, efforts to develop specific and efficient inhibitors against 
the key components of the PI3K pathway will potentially result in new therapeutics to treat 
human malignancies. 
 
Overexpression and hyper-activation of AKT has been found in a number of human 
malignancies. Increased AKT1 activity has been observed in 50% of prostate carcinomas 
and also in 40% of ovarian and breast tumours (Bellacosa, Chan et al. 1998, Cheng, 
Lindsley et al. 2005). In addition, overexpression of AKT2 has been found in pancreatic and 
ovarian cancers, while AKT3 is overexpressed in hormone-insensitive prostate and breast 
cancers (Altomare and Testa 2005, Bellacosa, Kumar et al. 2005). Moreover, an activating 
mutation of AKT1 (E17K) has been reported in breast, ovarian and colorectal cancers. This 
transforming single mutation was found in the PH domain of the AKT1 gene and results in 
growth-factor independent membrane translocation of AKT and increased AKT 
phosphorylation levels (Carpten, Faber et al. 2007). The same mutation has also been 
detected in AKT3 in melanoma cells (Davies, Stemke-Hale et al. 2008). Constant 
overexpression of AKT leads to cell survival and malignant transformation, and in contrast, 
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inhibition of AKT activity stimulates apoptosis in a range of mammalian cells. There is also 
evidence suggesting an association between activation of AKT and tumour chemo-
resistance (Kim, Dan et al. 2005). 
 
 
 
 
Figure 1-1 PI3K signalling pathway 
 PI3 kinases are activated downstream of ligand-bound receptor tyrosine kinases. Activated 
PI3K produces PIP3 which recruits PKB/AKT to the cell membrane where it is activated 
through dual phosphorylation by PDK1 and the mTOR complex. Activated AKT, in turn, 
phosphorylates a wide range of downstream target proteins that control cell growth, 
proliferation, survival and glucose metabolism (Workman, Clarke et al. 2006). 
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1.8.3.6.2 Cellular functions of AKT 
 
1.8.3.6.2.1 Cellular survival  
 
Activated AKT plays an important role in the regulation of cell survival. AKT phosphorylates 
the pro-apoptotic Bcl-2 family member BAD on its inhibitory Ser136 site. This 
phosphorylation decreases the binding of BAD to Bcl-XL which leads to the inhibition of the 
release of mitochondrial death proteins (Datta, Dudek et al. 1997, Datta, Brunet et al. 1999). 
AKT also phosphorylates GSK3 isoforms on a highly conserved N terminal regulatory site 
which leads to inactivation of the kinase (Cross, Alessi et al. 1995). The pro-survival Bcl-2 
family member, MCL-1, is one of the direct targets inhibited by GSK3 (Maurer, Charvet et al. 
2006). This causes inhibition of the release of cytochrome c from mitochondria and 
therefore, inhibition of formation of caspase-9 from its pro-caspase form and prevention of 
apoptosis. In addition, AKT inhibits caspase-9 activity directly through phosphorylation of 
Ser196 (Cardone, Roy et al. 1998). AKT also inhibits the forkhead transcription factor 1 
(FOXO-1) through phosphorylation of Thr32 and Ser253. These phosphorylations facilitate 
binding of FOXO-1 to 14-3-3 proteins which leads to cytoplasmic sequestration and 
therefore decreases expression of FOXO1 targets (Tran, Brunet et al. 2003). Two of the 
most important targets of FOXO-1 in apoptosis pathway, in which their expression is 
decreased by this process, are the BH3-only protein BIM and the pro-apoptotic cytokine Fas 
ligand (Dijkers, Birkenkamp et al. 2002). AKT also phosphorylates Mouse double minute 2 
homolog (MDM2) on Ser166 and Ser186 leading to translocation of MDM2 to the nucleus. 
Activated MDM2 then negatively regulates p53 function in the nucleus leading cell survival 
(Mayo and Donner 2001). Moreover, AKT can promote cell survival through crosstalk with 
other pathways. For example, it has been reported that PI3K-AKT pathway can inhibit 
JNK/p38 apoptotic signalling (Ozes, Mayo et al. 1999, Kim, Khursigara et al. 2001). 
 
53 
 
1.8.3.6.2.2 Cellular Metabolism 
 
AKT stimulates glucose uptake in response to insulin. AKT-2 is the primary isoform of AKT in 
insulin-responsive tissues. In response to insulin, AKT-2 binds to the glucose transporter-4 
(GLUT4) -containing vesicles and phosphorylate their component proteins (Calera, Martinez 
et al. 1998). AKT activation, in response to insulin, results in translocation of the glucose 
transporter 4 (GLUT4) into the plasma membrane (Kohn, Summers et al. 1996). 
Translocation of GLUT4 to the plasma membrane is dependent on phosphorylation of Rab-
Gap TBC1 domain family member 4, also known as AS160. In response to insulin, AKT 
phosphorylates AS160, leading to inhibition of its GAP activity. This leads to allowing a Rab-
family GTPase to become GTP loaded and stimulate GLUT4 vesicle translocation (Sano, 
Kane et al. 2003, Eguez, Lee et al. 2005). There are five phosphorylation sites on AS160, 
known to be phosphorylated by AKT, of which S588 and T642 are the most crucial. 
Mutations on these two sites block insulin-stimulated GLUT4 translocation (Sano, Kane et al. 
2003). AKT phosphorylates combination of these five phosphorylation sites in response to 
insulin (Bai, Wang et al. 2007). However, recent studies suggest an AS160-independent 
mechanism of regulation of AKT-mediated translocation of GLUT4 to plasma membrane and 
other candidates. AKT substrates have been identified to be involved in this process, 
including PIKfyve (Berwick, Dell et al. 2004). 
 
GLUT1 is the main glucose transporter in most cell types. GLUT1 is regulated through 
alternation in expression level. AKT phosphorylates TSC2 and PRAS40 leading to the 
activation of mTORC1. Activation of mTORC1 is required for both HIFα-dependent 
transcription of the GLUT1 gene and cap-dependent translation of GLUT1-mRNA. AKT 
activation can also alter glucose metabolism within cells (Zelzer, Levy et al. 1998, Taha, Liu 
et al. 1999). Once glucose enters the cell, it is converted to its active form; glucose 6-
phosphate. Glucose phosphorylation and conversion to its active form is mediated by 
hexokinases in mitochondria. AKT has been found to stimulate the association of 
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hexokinase isoforms with mitochondria (Robey and Hay 2006). Glucose 6-phosphate can be 
either catabolised through glycolysis or be stored by conversion to glycogen. AKT can 
regulate both of these processes. AKT activation can enhance glycolysis by promoting the 
expression of glycolytic enzymes through HIFα (Lum, Bui et al. 2007). On the other hand, 
AKT can also stimulate glycogen synthesis by mediating the phosphorylation and inhibition 
of GSK3. Inhibition of GSK3 prevents GSK3 from phosphorylating its substrate glycogen 
synthesis (Elstrom, Bauer et al. 2004). In addition, AKT contributes to glucose homeostasis 
through phosphorylation and inhibition of FOXO1 (Accili and Arden 2004).  
 
1.8.3.6.2.3 Cell proliferation 
 
AKT can stimulate proliferation through affecting various downstream targets which are 
involved in cell cycle regulation. AKT phosphorylates the p27 cyclin-dependent kinase 
inhibitor on T157 and prevents its localisation to the nucleus. Phosphorylation of p27 on 
T157 leads to cytosolic sequestration of the kinase inhibitor via 14-3-3 (Liang, Zubovitz et al. 
2002, Shin, Yakes et al. 2002). AKT also inhibits expression of p27 through phosphorylation 
and inhibition of the FOXO1 transcription factor (Medema, Kops et al. 2000). AKT has also 
been shown to phosphorylate the cyclin-dependent kinase inhibitor p21 on T145. This 
phosphorylation leads to p21 cytosolic localisation (Zhou, Liao et al. 2001).  
 
AKT also regulates proliferation through phosphorylation of downstream targets which are 
involved in cell cycle entry. For example, GSK3 mediated phosphorylation of the G1 cyclin D 
and cyclin E and the transcription factors c-myc and c-jun leads to proteasomal degradation 
of these proteins which play an important role in the G1 to S phase cell cycle transition 
(Diehl, Cheng et al. 1998, Welcker, Singer et al. 2003, Yeh, Cunningham et al. 2004, Wei, 
Jin et al. 2005). Phosphorylation and inhibition of GSK3 by AKT increases the stability of 
these proteins and therefore, the transition of cells from G1 to S phase. AKT activation is 
increased during the G2/M phase of cell cycle and this activation promotes cell progression 
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through mitosis (Shtivelman, Sussman et al. 2002). Even in the presence of DNA damage, 
activated AKT overcomes the cell cycle checkpoint and progresses the cell through mitosis 
(Kandel, Skeen et al. 2002). AKT directly phosphorylates the DNA damage checkpoint 
kinase ChK1 on S280, which leads to translocation of ChK1 to the cytosol, therefore 
blocking its checkpoint function (Puc, Keniry et al. 2005). In addition, activity of mTOR1, 
which is a key regulator of cell proliferation, is controlled by AKT through phosphorylation of 
TSC2 and PRAS40. AKT mediated cell proliferation and oncogenic transformation is 
dependent on mTORC1 activation (Skeen, Bhaskar et al. 2006).  
 
1.8.3.6.2.4 Cell Growth 
 
One of the important roles of AKT is promoting cell growth. This regulation is mostly through 
the activation of mTOR complex 1 (mTORC1) in response to both growth factor and 
nutrients and signalling. MTORC1 has an evolutionary conserved role in cell growth control. 
It controls a wide range of growth-related processes including protein and lipid synthesis and 
ribosome biogenesis (Wullschleger, Loewith et al. 2006). The two best characterised targets 
of mTORC1 are the eukaryotic initiation factor 4E binding protein (4E-BP1) and the 
ribosomal protein S6 kinase (P70S6K). Phosphorylation of 4E-BP1 by mTORC1 leads to its 
dissociation from the translation repressor eIF4E, allowing the interaction of eIF4G to elF4E 
which initiate protein translation (Gingras, Gygi et al. 1999, Rhoads 2009). AKT was believed 
to directly phosphorylate mTOR on S2448, which is often associated with mTOR1 activation, 
but recent studies suggest S6K1 rather than AKT to be responsible for phosphorylation of 
this site (Chiang and Abraham 2005). AKT activates mTORC1 indirectly through 
phosphorylation and inhibition of the tuberous sclerosis complex 2 (TSC2) which is a critical 
negative regulator of mTORC1 signalling (Gao and Pan 2001, Goncharova, Goncharov et al. 
2002). AKT phosphorylates two sites on TSC2 directly (S939 and T1462). TSC2 with its 
binding partner TSC1 form a complex which acts as a GTPase-activating protein (GAP) for 
the Ras-related small G protein Rheb. Rheb activates mTORC1 when in its GTP-bound 
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active form (Manning and Cantley 2003). More recently, another substrate of AKT has been 
identified to be a regulator of mTOR1 complex. The proline-rich AKT substrate of 40 kDa 
(PRAS40) was initially identified for its ability to bind to 14-3-3 protein in a growth factor 
regulated manner (Harthill, Pozuelo Rubio et al. 2002). AKT was demonstrated to directly 
phosphorylate PRAS40 on T246. Phosphorylation of PRAS40 on T246 was later found to be 
important for 14-3-3 binding (Kovacina, Park et al. 2003, Vander Haar, Lee et al. 2007). 
PRAS40 is a negative regulator of mTORC1 (Sancak, Thoreen et al. 2007) and inhibits the 
activity of mTORC1 by preventing its binding to S6K1 and 4E-BP1. Phosphorylation of 
PRAS40 at T246 by AKT leads to the release of PRAS40 from the complex, therefore 
stimulation of mTORC1 signalling (Wang, Harris et al. 2007, Wang, Harris et al. 2008). 
Furthermore, it has been suggested that the phosphorylated P70S6K protein downstream of 
mTORC1 exerts negative feedback on insulin and insulin-like growth factor signalling 
through proteasomal degradation of Insulin receptor substrate 1(IRS-1) and IRS-2, resulting 
in down-regulation of PI3K/AKT signalling (Tremblay and Marette 2001).  
 
1.8.3.6.3 PI3K/AKT pathway and chemo-resistance 
 
Increased activation of PI3K/AKT pathway can lead to drug resistance in cancer. Resistance 
can arise from extended cell survival or AKT dependent blockage of the pro-apoptotic 
signalling cascades. In addition, increased activation of PI3K/AKT pathway can lead to 
overexpression of multidrug resistance associated protein-1, a transmembrane drug reporter 
that functions as a drug efflux pump. Overexpression of this protein leads to chemo-
resistance in cancer (Tazzari, Cappellini et al. 2007).  
 
The role of PI3K/AKT pathway in development of drug resistance to conventional anti-cancer 
therapies such as tyrosine kinase inhibitors, monoclonal antibodies against RTKs, radiation 
57 
 
therapy, hormone therapy and chemotherapy has been suggested in several studies (Burris 
2013).  
 
For example, increased activation of PI3K/AKT pathway has been associated with 
resistance to the anti-HER2 antibody, trastuzumab, in patients with breast cancer. Clinical 
studies have indicated that activation of PI3K/AKT pathway due to genetic alteration is linked 
with significantly shorter progression-free survival and was found to be a significant 
independent risk factor for disease progression in breast cancer patients receiving 
trastuzumab therapy (Berns, Horlings et al. 2007). Experiments in trasuzumab-resistant 
breast cancer cells has shown that inhibition of the PI3K/AKT pathway with pan PI3K 
inhibitors GDC-0941 and LY294002 and the dual PI3K/mTOR inhibitor BEZ235 significantly 
inhibited cell proliferation in a dose-dependent manner (Burris 2013). In addition, a 
combination of the PI3K inhibitor LY294002 with trastuzumab significantly decreased cell 
viability in trastuzumab-resistant breast cancer cell lines (Nagata, Lan et al. 2004). 
Moreover, activation of the PI3K/AKT pathway has been associated with a poorer response 
to treatment with lapatinib, a duel HER2/EGFR TKI in breast cancer patients, compared to 
those patients without oncogenic activation of the PI3K/AKT pathway (Wang, Zhang et al. 
2011). Inhibition of the PI3K/AKT signalling with BEZ235 reversed lapatinib resistance in 
PIK3CA activated of PTEN-deficient breast cancer cells (Eichhorn, Gili et al. 2008).  
 
The potential for PI3K/AKT pathway inhibitors to restore sensitivity to EGFR inhibitors has 
been assessed in several pre-clinical studies (Kim, Kim et al. 2010, Donev, Wang et al. 
2011, Burris 2013). Inhibition of PI3K/AKT pathway reversed resistance to cetuximab in non-
small cell lung cancer (NSCLC) cells (Kim, Kim et al. 2010). Moreover, inhibition of the PI3K 
signalling by PI-103, a pan PI3K inhibitor, resulted in the reversal of resistance to gefitinib in 
EGFR-mutant NSCLC cell lines (Donev, Wang et al. 2011).  
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RAS can activate both RAF/MEK and PI3K/AKT pathways and extensive cross-talks have 
been seen between the RAS/RAF/MEK and PI3K/AKT pathways. Increased activation of 
PI3K due to activating mutations in PIK3CA or loss of PTEN function has been shown to 
significantly reduce the response to MEK inhibitors in colorectal cancer cell lines (Wee, 
Jagani et al. 2009).  
 
Activation of PI3K/AKT pathway can lead to resistance to ionising radiation, due to 
promotion of cell survival even after radiation-induced DNA damage. Inhibition of PI3K/AKT 
signalling has been evaluated as a potential to increase sensitivity to radiation therapy. For 
example, inhibition of PI3K activity with LY294002 has been shown to sensitise glioblastoma 
cells to radiation therapy (Kao, Jiang et al. 2007). In addition, inhibition of the p110α isoform 
of PI3K was efficient to sensitise glioblastoma cancer cells to radiation, both in vitro and in 
vivo models (Chen, Zhou et al. 2008).  
 
Several studies have linked the PI3K/AKT pathway to platinum and taxol resistance in 
ovarian cancer and it has been demonstrated that constitutively active AKT2 leads to 
cisplatin resistance in previously sensitive A2780S ovarian cancer cells, whereas PI3K 
inhibition by LY294002 restored the sensitivity in this cell line. In addition, in the cisplatin-
resistant A2780CP ovarian cancer cell line, expression of the dominant negative AKT2 or 
treatment with the PI3K inhibitor LY294002 reversed resistance resulting in cisplatin-induced 
apoptosis  through regulation of the ASK1/JNK/p38 pathway (Yuan, Feldman et al. 2003). 
Furthermore, expression of a constitutively active PI3K catalytic subunit induced taxol 
resistance in ovarian cancer xenograft models. This effect could also be reversed with 
LY294002 (Hu, Hofmann et al. 2002). Similarly, resistance to paclitaxel can be reversed in 
both in vitro and in vivo ovarian cancer models by inhibition of PI3K (Hu, Hofmann et al. 
2002).  
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It has been shown, in chemo-sensitive ovarian cancer cells, that treatment with cisplatin 
induces apoptosis by reducing intracellular levels of X-linked inhibitor of apoptosis protein 
(XIAP), an inhibitor of apoptosis, and inducing AKT cleavage. Conversely, it has been shown 
that XIAP overexpression blocks cleavage of caspase-3 and caspase-7 and increases 
phosphorylation of AKT. This effect is associated with a decrease in cisplatin sensitivity, and 
has also been shown to be reversed by treatment with LY294002 (Fraser, Leung et al. 
2003). These findings suggest an involvement of the PI3K/AKT pathway in XIAP-mediated 
chemo-resistance of ovarian cancer cells.  
 
PTEN is overexpressed in chemo-sensitive ovarian cancer cell lines compared to chemo-
resistant cells, and reductions in levels of PTEN expression by shRNA in sensitive cells 
resulted in an up-regulation of phospho-AKT and a resistance of the cells to cisplatin (Yan, 
Fraser et al. 2006). Furthermore, it has been hypothesised that decreased AKT activity could 
increase cisplatin-induced apoptosis in transfected cells.  
 
PIK3CA genomic alternations are more frequent in ovarian cancer patients who relapsed 
with platinum resistance disease within 6 months (platinum resistant) than in those with more 
than 6 months of progression-free survival (platinum sensitive), or in patients with complete 
response to platinum. For examples, ovarian clear cell carcinoma (CCC) which is one of the 
most lethal types of ovarian cancer and often resistant to platinum based chemotherapy is 
characterised by frequent activating mutations of PIK3CA (35 – 45 %) (Kuo, Mao et al. 2009) 
 
In 2010, Wallin et al. explored the use of a potent PI3K inhibitor in combination with the 
DNA-damage agent doxorubicin (Wallin, Guan et al. 2010). They found that PI3K inhibition 
increased apoptosis and enhanced the anti-tumour effects of doxorubicin in a subset of 
ovarian and breast cancer cell lines. They reported that in most cell lines where combination 
synergy was observed, there was an increase in the expression of nuclear p-AKT S473 in 
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response doxorubicin treatment alone, suggesting that inhibition of AKT pathway in 
combination with cytotoxic agents is mostly effective in the set of tumour cells that rely on 
the PI3K/AKT pathway for survival (Wallin, Guan et al. 2010). 
 
Altogether, inhibition of the PI3K/AKT/mTOR signalling pathway is an attractive strategy to 
overcome resistance to standard treatments in cancer therapy.  
 
1.8.3.6.4 Inhibition of the PI3K/AKT pathway 
 
The AKT pathway can be inhibited either by targeting AKT itself, by blocking upstream 
activators such as PI3K or RTKs or by inhibiting downstream effectors of AKT activity, such 
as mTOR. AKT pathway inhibition holds great promise for a variety of tumour types and 
hence much of the progress to date is not specific to ovarian cancer. As the area continues 
to develop, the successful compounds will be tested more broadly, including in ovarian 
cancer. 
 
1.8.3.6.4.1 AKT inhibitors 
 
 AKT inhibitors can be categorised into four main groups based on their mechanism of action 
and chemical composition; ATP competitive inhibitors, allosteric inhibitors, peptide-based 
inhibitors and lipid-based inhibitors (Stronach, Cheraghchi-Bashi et al. 2011). 
 
1.8.3.6.4.1.1 Perifosine 
 
The lipid-based AKT inhibitor, perifosine, is one of the first generation of AKT inhibitors and 
the most advanced, with respect to clinical studies. Perifosine prevents AKT translocation 
into cell membrane (Kondapaka, Singh et al. 2003). The safety and efficacy of periposin as a 
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single agent, or in combination with other anti-cancer agents, has been evaluated in a 
number of phase I, II and III clinical trials in several types of cancer. The first phase I clinical 
study with prifosine was carried out, in 2002, in patients with advanced solid tumours. This 
study was incomplete due to the gastrointestinal toxicity caused by high daily doses of the 
drug (Crul, Rosing et al. 2002). Applying a different loading dose/maintenance dose 
schedule in a following phase I study, minimised the toxicity and improved the efficacy, 
resulting in reduced gastrointestinal toxicity and rapid achievement of steady plasma 
concentration (Van Ummersen, Binger et al. 2004). Single agent perifosine has been 
evaluated in several phase II studies in different types of cancer including prostate cancer, 
head and neck cancer, breast cancer and melanoma. Only a few objective responses were 
reported in these trials and gastrointestinal toxicities were seen (Ernst, Eisenhauer et al. 
2005, Posadas, Gulley et al. 2005, Argiris, Cohen et al. 2006, Bailey, Mahoney et al. 2006, 
Knowling, Blackstein et al. 2006, Marsh Rde, Rocha Lima et al. 2007, Leighl, Dent et al. 
2008). In these trials, using single agent perifosine showed poor results and gastrointestinal 
and constitutional toxicities were reported. In addition, perifosine has been used in 
combination with radiation, chemotherapy and other targeted agents in several clinical trials. 
The safety of daily perifosine in combination with fractionated radiotherapy has been 
demonstrated in a phase I clinical trial in patients with different types of advanced cancers 
including colon, bladder and prostate cancers (Vink, Schellens et al. 2006). Moreover, 
combination of perifosine with a number of traditional cytotoxic agents, such as taxanes and 
gemcitabine, has been shown to be safe in a phase I clinical (Bailey, Mahoney et al. 2006). 
However, in 2013 the discontinuing of phase III clinical studies of perifosine was announced 
(www.clinicaltrials.gov).  
 
1.8.3.6.4.1.2 MK2206 
 
MK2206 (Merck) is an orally active small molecule allosteric inhibitor of AKT, targeting all 
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three isoforms of AKT. MK2206 has shown broad preclinical anti-tumour activity. It inhibits 
both T308 and S473 phosphorylation. MK2206 also inhibits the downstream effects of insulin 
on Glut4 translocation and glucose transport (Tan, Ng et al. 2011). MK2206 is or has been in 
several clinical trials, either as single agent or in combination with other small molecule 
inhibitors or chemotherapeutic drugs. It has been evaluated in phase I studies in patients 
with advanced solid tumours. MK-2206, as a single agent, is demonstrating good efficacy 
and tolerance level in phase I clinical trials (Yap, Yan et al. 2011). Currently, safety and 
efficacy of MK2206 in combination with different anti-cancer drugs is evaluated in several 
clinical studies (www.clinicaltrials.gov). In a phase I clinical study, combination of MK2206 
with weekly paclitaxel was shown to be safe in patients with solid tumours (Chien, Truong et 
al. 2013). Also MK2206 plus carboplatin and paclitaxel, docetaxel, or erlotinib was well-
tolerated in patients with solid advanced tumours (Molife, Yan et al, 2014).  
 
1.8.3.6.4.1.3 API-2 
 
Triciribine (API-2) is a small molecule AKT inhibitor which was synthesised in 1980s. API-2 
is a synthetic tricyclic nucleoside initially known as a DNA synthetic inhibitor demonstrating 
anti-tumour and anti-viral activities (Schweinsberg, Smith et al. 1981). API-2 has been tested 
as a cytotoxic agent in several phase I and II clinical trials in patients with advanced 
malignancies but, despite the efficacy of this compound in inhibiting the growth of several 
cell lines in vitro, clinical studies with this compound were discontinued due to poor efficacy 
and poor toxicity profile of this drug, including hyperglycemia, thrombocytopenia and 
hypertriglyceridemia at high doses in clinic (Schweinsberg, Smith et al. 1981, Feun, Blessing 
et al. 1993). In 2004, API-2 was rediscovered as an effective AKT inhibitor following 
screening a chemical library of 1992 compounds in the National Cancer Institute Diversity 
Set (Yang, Dan et al. 2004). API-2 suppresses phosphorylation of AKT on both S473 and 
T308 residue. It inhibits kinase activity of all three AKT isoforms. The mechanism of action of 
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API-2 is poorly understood. There is evidence, however, that it may act via the PH domain of 
AKT. It has been suggested that following entering the cells, API-2 converts into the active 
TCN-P by adenosine kinase. Active TCN-P then interacts with the PH domain of AKT. This 
binding inhibits interaction of PIP3 with AKT, leading to prevention of phosphorylation of AKT 
(Yang, Dan et al. 2004). 
 
1.8.3.6.4.1.4 GSK690693 
 
GSK690693 is an ATP competitive, nanomolar pan-AKT kinase inhibitor, which belongs to 
the aminofurazan family of compounds (Rhodes, Heerding et al. 2008). It is selective for all 
isoforms of AKT. However, it is also selective towards 13 other kinases including other 
members of the AGC kinase family and members of the group II PAK kinase family. 
GSK600693 reduced phosphorylation of down-stream target of AKT including PRAS40, 
GSK3β and p70S6K in a dose-dependent manner in tumour cells (Rhodes, Heerding et al. 
2008). In pre-clinical studies, GSK690693 has shown moderate activity in ALL tumours 
resulting in a reduction of phosphorylation of down-stream substrates of AKT (Carol, Morton 
et al. 2010). In addition, daily administration of GSK690693 inhibited tumour growth in 
BT474 and HCC-1954 breast cancer, SKOV3 ovarian cancer and LNCaP prostate cancer 
xenogafts (Rhodes, Heerding et al. 2008). The first time in human (FTIH) phase I clinical 
study for safety, tolerability, pharmacodynamics and pharmacokinetics of GSK690693 was 
terminated before completion of the study and a following planned phase I study in refractory 
haematological malignancies was withdrawn prior to enrolment. The reasons for the 
withdrawal of GSK690693 have not been made public (www.clinicaltrials.gov). Treatment 
with GSK690693 resulted in hyperglycemia in mice (Crouthamel, Kahana et al. 2009). 
Hyperglycemia following the treatment with AKT inhibitors is due to the role of AKT in insulin 
signalling. AKT2 has been suggested to profoundly affect insulin signalling, compared to 
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other isoforms of AKT (Yang, Tschopp et al. 2004), suggesting that isoform selective 
compounds may be required to minimise the toxicity of AKT inhibitors.  
 
1.8.3.6.4.1.5 GSK2141795 
 
GSK2141795 is a novel member of the N-alkyl pyrazole class of orally available kinase 
inhibitors. It is a potent, pan-AKT inhibitor, with potency (Ki) values for human AKT 1, 2 and 
3 kinases of 0.066nM, 1.4nM and 1.5 nM, respectively (GlaxoSmithKline unpublished data). 
The safety and efficacy of oral GSK2141795 was evaluated for the first time in human in 
2009, in a phase I clinical study in patients with solid tumours or Lymphomas. This study 
showed that GSK2141795 is well tolerated at the dose of ≤ 75 mg (H. A. Burris 2011). 
GSK2141795 is currently evaluated in several phase I clinical trials in combination with the 
MEK inhibitor Trametinib (www.clinicaltrials.gov).  
 
1.8.3.6.4.2 PI3K inhibitors 
` 
 
1.8.3.6.4.2.1 LY294002 and wormannin 
 
LY294002 and wormannin are the two most well-known isomer non-specific PI3K inhibitors. 
LY294002 is a classical reversible, ATP competitive PI3K inhibitor while wormannin is an 
irreversible inhibitor which forms a covalent bond with a conserved lysine residue involved in 
the phosphor-binding reaction. Both inhibitors have unfavourable pharmaceutical properties. 
In addition, they have poor selectivity for PI3K and have crossover inhibition activity for other 
lipid and protein kinases, including mTOR and DNA-PK. In spite of these properties, both 
compounds have served important roles as research tools for better understanding the role 
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of PI3K in human cancers (Vlahos, Matter et al. 1994, Marone, Cmiljanovic et al. 2008, 
Cleary and Shapiro 2010).  
 
1.8.3.6.4.2.2 PX-866 
 
PX-866 is a modified analogue of wortmannin which has been evaluated in phase I and II 
clinical trials. PX-866 has been tested in a Phase I clinical trial in combination with docetaxel 
for solid tumours and in Phase I clinical trial in combination with cetuximab for colorectal 
cancer. Only mild side effects such as diarrhoea and nausea have been observed in those 
two clinical trials (Bartholomeusz and Gonzalez-Angulo 2012). PX-866 is currently being 
evaluated in about five clinical trials for melanoma, CRC, prostate cancer, NSCLC and other 
advanced cancers (www.clinicaltrials.gov). 
 
1.8.3.6.4.2.3 GDC-0941 
 
GDC-0941 is a more selective inhibitor of PI3K developed by Genetech (Folkes, Ahmadi et 
al. 2008). It targets both PI3K and hypoxia-induced factor-1 alpha (HIF-1-alpha) (Burrows, 
Babur et al. 2011). GCD-0941 synergised with the MEK inhibitor UO126 in inhibiting the 
growth of NSCLC (Zou, Zhang et al. 2012). This compound is currently being evaluated in a 
clinical trial for metastatic breast cancer or advanced cancers (www.clinicaltrials.gov). 
 
1.8.3.6.4.2.4 XL-147 
 
XL-147 is a PI3K inhibitor developed by Exelixis/Sanofi-Aventis. It is currently being 
evaluated in approximately 11 clinical trials, either as a single agent or in combination with 
chemotherapy, hormonal therapy, and erlotinib for various cancers (www.clinicaltrials.gov). 
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1.8.3.6.4.2.5 NVP-BKM120 
 
NVP-BKM120 is a pan-class I PI3K inhibitor developed by Novarits. NVP-BKM120 behaves 
synergistically when combined with cytotoxic agents such as docetaxel or temozolomide 
(Maira, Pecchi et al. 2012). It is currently in at least 36 clinical trials, either as a single agent 
or in combination with other drugs, with patients having advanced cancers such as breast, 
prostate, endometrial, CRC, NSCLC, melanoma and advanced leukaemia 
(www.clinicaltrials.gov). 
 
Some have questioned whether PI3K inhibitors will be effective in cancer therapy due to the 
complicated feed-back loop which results in the activation of certain receptor molecules (Tan 
and Yu 2013). 
 
1.8.3.6.4.3 mTOR inhibitors 
 
1.8.3.6.4.3.1 Rapamycin 
 
Rapamycin (Rapamune, Pfizer) is an allosteric mTORC1 inhibitor and doesn’t directly affect 
the mTOR catalytic site. Rapamycin associates with the FK506 binding protein 12 (FKBP-
12). This association leads to the disassembly of mTORC1, leading to repression of its 
activity (Sabatini 2006). Rapamycin has been examined in various clinical trials for different 
cancers including breast, brain, prostate, lymphoma, pancreatic, NSCLC and leukaemia 
(Faivre, Kroemer et al. 2006, Liu, Cheng et al. 2009).  
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1.8.3.6.4.3.2 Afinitor 
 
 Afinitor is a rapamycin analogue and an inhibitor of mTORC1 which has been approved to 
treat patients with pancreatic neuroendocrine tumours (Yao, Phan et al. 2013).  
 
1.8.3.6.4.3.3 OSI-027 
 
OSI-027 is a pan mTOR kinase inhibitor developed by OSI Pharmaceuticals/Astellas 
Pharma Inc. Pan-mTOR inhibitors effectively inhibit both mTOR complexes therefore block 
signalling cascades down-stream of both mTORC1 and mTORC2. Using pan-mTOR 
inhibitors has advantages over using inhibitors of mTORC1 only.  Inhibition of mTORC2 
prevents increased AKT phosphorylation which is a result of inhibition of mTORC1 and loss 
of the S6K1-mediated negative feedback loop to IRS1. OSI-027 has been shown to be 100-
fold more selective for mTOR relative to PI3K and DNA-PK. This mTOR inhibitor has 
effectively induced apoptosis in different types of cancer including breast cancers (Bhagwat, 
Gokhale et al. 2011). OSI-027 has been evaluated in clinical trials with patients with 
lymphoma and advanced solid tumours (www.clinicaltrials.gov).  
 
1.8.3.6.4.3.4 AZD8055 and AZD2014 
 
AZD8055 and AZD2014 (Astra Zeneca) are other potent pan mTOR inhibitors (Pike, Malagu 
et al. 2013) which have been evaluated in glioma patients who had not responded to 
standard treatments (www.clinicaltrials.gov).  
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1.8.3.6.4.3.5  PP-242 and INK-128 
 
PP-242 (Intellikine) is a potent inhibitor of both mTORC1 and mTORC2. PP-242 but not 
rapamycin caused cell death in acute leukemia cells (Janes, Limon et al. 2010). INK-128 is a 
derivative of PP-242 which has been shown to prevent prostate cancer invasion and 
metastasis (Hsieh, Liu et al. 2012). INK-128 is been evaluated in phase I clinical trials for 
patients with relapsed MM or patients with solid malignancies (www.clinicaltrials.gov). 
 
Despite promising pre-clinical and early clinical results, feed-back PI3K activation as a result 
of mTOR inhibition limits the application of mTOR inhibitors in clinic.  
 
1.8.3.6.5 AKT/DNA-PK interaction as a mediator for platinum resistance 
  
Activation of AKT upon induction of DNA-damage leads to platinum resistant in cancer cells. 
Several studies have reported activation of AKT in response to cisplatin in several cancer 
cell types (Winograd-Katz and Levitzki 2006).  
 
Cisplatin induces mitochondrial release and nuclear translocation of apoptosis-inducing 
factor (AIF), leading to AIF-dependant apoptosis in chemo-sensitive ovarian cancer cells but 
not in chemo-resistant cells. AKT activation was found to confer resistance to cisplatin 
induced AIF-dependant apoptosis by blocking this pathway (Yang, Fraser et al. 2008). In 
addition, AKT activation is important for survival after UV irradiation (Feng, Tamaskovic et al. 
2004). All these findings place AKT as an important mediator of DNA-damage signalling.  
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In 2008, Bozulic et al reported direct interaction between AKT and DNA-PK in response to 
DNA-damage. They demonstrated the presence of active AKT in the nucleus of γ-irradiated 
cells adjutant to DNA-double strand breaks and suggested phosphorylation of AKT by DNA-
PK at S473, in response to DNA damage leading to pro-survival signal for the cell by 
affecting DNA damage (Bozulic, Surucu et al. 2008). However, kinase activity of DNA-PK for 
AKT had been already proposed by Feng el al (Feng, Park et al. 2004). 
 
In 2011, it was reported by this lab that DNA-PKcs phosphorylates at S473 in response to 
cisplatin induced DNA damage in platinum resistant high-grade serous ovarian cancer cells 
but not in clinically matched platinum sensitive cells. Furthermore, co-localisation and 
binding of DNA-PKcs and AKT in response to cisplatin induced DNA-damage was 
demonstrated in nuclei of platinum resistant cells. This observation was not found in 
platinum sensitive cells (Stronach, Chen et al. 2011).  
 
In addition, increase in the amount of nuclear phospho-AKT (S473), in response to 
doxorubicin in breast and ovarian cancer models, has been demonstrated in breast and 
ovarian cancer models. This increase is well correlated with synergy between inhibitors of 
PI3K pathway and doxorubicin (Wallin, Guan et al. 2010).  
 
Studies on DNA-PK deficient mice have revealed that DNA-PK is not required for insulin and 
growth factor-induced AKT activation. In addition, DNA-PK is not essential for the 
maintenance of glucose metabolism. In contrast, DNA-PK is required for activation of AKT 
upon DNA-damage induced by γ-irradiation. These findings reveal stimulus-specific 
regulation of AKT activation by specific up-stream kinases (Surucu, Bozulic et al. 2008). 
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AKT/DNA-PK interaction is an attractive therapeutic target for reversal of platinum 
resistance. 
 
1.9 Pharmacodynamic (PD) biomarkers in drug development 
 
Despite technological progress and the development of ‘targeted agents’ in oncology, drug 
advancement still remains a slow, expensive and high risk process. Toxicity, inadequate 
therapeutic activity, poor bioavailability and pharmacokinetics (PK) and also mimicking of the 
tumour microenvironment in vitro have been reported as main reasons for the poor success 
in drug development(Neidle 2008). Hence, paying greater attention to optimising these 
properties in pre-clinical development is crucial. One of the other critical elements in 
improving the success rate in drug discovery is the identification of pre-clinical 
pharmacodynamic (PD) biomarkers of drug effects that will correlate with clinical effects. PD 
biomarkers may include cellular, molecular, histopathological and imaging parameters 
(Sarker, Pacey et al. 2007, Sarker and Workman 2007). PD biomarkers are used to assess 
the engagement of the drug with the target and the effect of the drug on down-stream 
pathways during the process of treatment and should not be confused with predictive 
biomarkers which are used to predict how well a patient will respond to treatment before 
initiation of the treatment. PD biomarkers are used to characterise functional and molecular 
effects of a drug, ideally in a quantitative manner. PD endpoints can be used at all stages of 
drug development from the in vitro assessment of action on the target, through to preclinical 
development and clinical trials. PD biomarkers can be used to provide proof of mechanism 
of action and to select the optimal dose and schedule of administration for the drug. They 
also have other potential applications in various levels of drug development, such as 
designing effective combination therapies and predicting the outcome of therapy in selected 
individuals. In addition, they can provide us with better understanding of response/resistance 
mechanisms. Incorporation of PD biomarkers enables sensible ‘Go/No-Go’ decisions to be 
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made regarding a drug candidate, and so facilitate drug development to proceed in a 
rational, efficient, hypothesis-testing manner (Sarker, Pacey et al. 2007, Sarker and 
Workman 2007) .  
 
1.9.1 PET imaging as a PD biomarker  
  
In recent years, the application of metabolic imaging with positron emission tomography 
(PET) has increased dramatically in oncology. PET measures the three-dimensional (3D) 
distribution of a positron emission-labelled compound within the living system in a surgically 
non-invasive manner. The most frequently used radiotracer in oncology is 2-deoxy-2-
(18F)fluoro-D-glucose ([18F]FDG): a glucose analogue that is ‘trapped’ in high metabolic 
activity cells, such as malignant cells. [18F]FDG PET imaging is therefore a useful technique 
for functional imaging of glucose turnover in cells and thus [18F]FDG uptake can be used as 
a marker of the glucose metabolism in malignant cells. This information can be used to 
assess the number of viable cells in a malignant tissue and the proliferation capacity of those 
cells. Therefore, quantification of changes in [18F]FDG uptake, following drug treatment, can 
provide a sensitive and early PD marker of the cytostatic or cytotoxic activity of anti-cancer 
agents in pre-clinical and clinical level studies, and can therefore be applied to monitor the 
tumour response to the anti-cancer drug more rapidly and effectively (Aboagye and Price 
2003, Boss, Olmos et al. 2008). In the case of development of AKT inhibitors, [18F]FDG PET 
is particularly suited to assessing the activity of the inhibitor within the malignant tissue as 
AKT is, itself, involved in regulation of glucose metabolism (LoPiccolo, Blumenthal et al. 
2008, Ma, Jacene et al. 2009) . Therefore [18F]FDG uptake measured by PET can be used 
as a PD biomarker through the development processes of AKT and PI3K inhibitors. Also, as 
mentioned above, [18F]FDG is increased in most of malignant tumours. Alterations in 
[18F]FDG uptake can also be used as a marker of tumour response to anti-cancer drugs 
(Young, Baum et al. 1999).  
72 
 
1.10 Aims of the thesis 
 
The aim of this thesis was to explore the effect of inhibition of AKT, PI3K or DNA-PK on the 
reversal of platinum resistance in ovarian cancer in vitro and in vivo and also to determine 
the impact of those inhibitions on downstream signalling pathways, and whether 3D in vitro 
models are more predictive models than traditional 2D monolayer models in determining 
dose and schedule optimisation, prior to in vivo experiments. 
 
The specific aims of this thesis were:  
 
1. To examine the effect of the AKT inhibitor GSK2141795 on re-sensitisation of 
platinum resistant tumour cells to cisplatin in 2D and 3D in vitro models, and in vivo, 
to determine the potential utility of GSK2141795 for clinical development. (Chapter 3) 
 
2. To evaluate the utility of FDG-PET imaging as a PD biomarker, for the clinical 
development of the AKT inhibitor GSK2141795. (Chapter 4)  
 
 
3. To study the effect of AKT inhibition by GSK2141795 as a single agent or in 
combination with cisplatin on the broader AKT pathway, and other cellular signaling 
pathways, to identify canonical or non-canonical PD biomarkers. (Chapter 6). 
 
4. To understand the role of PI3K in activation of AKT in response to DNA damaging 
agents and to investigate whether the nuclear DNA-PK mediated activation of AKT, 
in response to cisplatin, is dependent on activation of PI3K. (Chapter 5)  
 
5. To explore the effectiveness of DNA-PK inhibition using NU7441 to restore platinum-
sensitivity in platinum-resistant ovarian cancer cells in vitro and in vivo. (Chapter 5) 
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6. To explore the effects of DNA-PK inhibition with NU7441, alone or in combination 
with cisplatin, on cellular protein signalling cascades in vitro and in vivo, to identify 
candidate PD biomarkers for clinical development. (Chapter 7)  
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2 Materials and Methods 
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2.1 Human samples, cell lines and drugs 
.  
Cell lines 
High grade serous ovarian cell line PEO1, PEO4, PEA1 and PEA2 was obtained from Dr. 
Simon Langdon (Edinburgh, UK). SKOV3 cells were obtained from ECACC. All cancer cell 
lines were originated from patients with high grade serous (HGS) ovarian cancer. PEO1/4 
and PEA1/2 cells were isogenically derived from two HGS ovarian cancer patients before 
and after platinum resistant relapse. PEO1 and PEA1 were platinum sensitive and PEO4 
and PEA2 were platinum resistant. IC50 of each sensitive cell line and resistant cell line for 
cisplatin was around 2 µM and 10 µM respectively. Additional information regarding mutation 
status of each cell line is shown in table 2.1. All cell lines were maintained in RPMI1640 
(Sigma) supplemented with 10% foetal calf serum, 50U/ml penicillin, 50 µg/ml streptomycin 
and 0.2 mM L-glutamine (all from Sigma), at 37°C/5% CO2 in a humidified atmosphere.  
Table 2-1 Summary of know mutations found in cell lines included in this thesis 
 
Cell line P53 status 
ERBB2 
amplification 
Other mutations 
PEO1 mutant No 
ABCB1 
VEGF 
PEO4 mutant No 
ABCB1 
VEGF 
PEA1 mutant No VEGF 
PEA2 mutant No ABCB1 
SKOV3 mutant Amplified 
MLH1 
PIK3CA 
CDKN2A 
 
Mutational analysis of PEO1/4 and PEA1/2 was performed by Katherine Stemke-Hale at the 
‘ Characterised Cell Line Core’ at the MD Anderson Cancer Centre, Texas, USA, in 
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collaboration with the group of Robert Bast using the same method as described in (Stemke-
Hale, Gonzalez-Angulo et al. 2008). Mutation data for SKOV3 cell line was obtained from 
catalogue of somatic mutations in cancer (COSMIC) 
(http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/). Copy number data retrieved 
from the Cancer Genome Project website 
(https://www.sanger.ac.uk/research/projects/cancergenome/). 
 
Drugs 
 
The AKT inhibitor GSK2141795 and the PI3K inhibitor GSK2126458 were obtained from 
GlaxoSmithKline (Collegeville, PA and Research Triangle Park, NC, USA). Cisplatin was 
obtained from Hammersmith Hospital’s pharmacy as 1mg/ml sterile saline solution. The 
DNA-PK inhibitor NU7441 was purchased from Selleck Chemicals LLC (Houston TX, USA). 
Chemicals used in making buffers or gels were purchased from Sigma (UK).  
 
Human samples 
 
All human biological samples were sourced ethically and their research use was in accord 
with the terms of the informed consents. 
 
Clinical tumour biopsies from patients treated on a Phase I trial of GSK2141795 in patients 
with gynaecological malignancies, described in Gungor et al (Gungor H 2011) were used to 
determine signalling changes using RPPA. In summary 12 patients with gynaecological 
malignancies were enrolled in three cohorts. Patient’s characteristics are shown in Table 2.2. 
Eligible patients had a histologically or cytologically confirmed diagnosis of FDG-
PET-positive recurrent or persistent ovarian cancer or endometrial cancer. Eligible 
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subjects also had measurable disease of at least 2 cm. Patients received  75 mg 
GSK2141795 daily. The efficacy of the compounds was assessed by dynamic FDG-PET 
scans and serial PK sampling performed at baseline, Week 2, and Week 4. Tumour Biopsies 
were taken pre-treatment and week 4 after initiation of the treatment. Protein lysates were 
extracted and analysed as described in 2.5 for xenograft samples.  
 
Table 2-2 characteristics of patients whose tumour samples were used for RPPA 
analysis 
 
Trial 
ID 
cohort Dose 
GSK795 
RECIST CA125 
(4wk) 
Response 
group 
(4wk) 
Histology FIGO grade Mutations 
          
100 1 50mg PD 9.402138 poor Serous 3c 3 none detected 
101 1 50mg SD 20.72649
6 
good Adeno 4 3 (BRCA1) 
102 1 50mg SD 36.48233
4 
good Serous 4 3 PHLPP2_L1016S 
103 1 50mg SD -18.07622 poor Endo 4 unkow
n 
PIK3R1_M326I 
1200 2 75mg SD 58.53658
7 
good Clear Cell 2a 3 PIK3CA_H1047RL, 
PIK3R1_M326I 
1201 2 75mg SD 39.88289 good Serous 3b 3 none detected 
1202 2 75mg PD 26.38889 good Serous 3c 3 KRAS_G12SRC 
1203 2 75mg SD -15 poor Serous 4 1 none detected 
1206 3 25mg 2wk-
>75mg 2wk 
PD 7.682619
6 
poor Serous 3c 3 MET_N375S 
1207 3 25mg 2wk-
>75mg 2wk 
PD 32.65306 good Endo 
(endometrial) 
4b 2 PIK3CA_H1047RL 
1205 3 25mg 2wk-
>75mg 2wk 
SD -25 poor Clear Cell 3c 3 KRAS_G12DAV, 
PIK3CA_H1047RL, 
PIK3R1_M326I 
1208 3 25mg 2wk-
>75mg 2wk 
SD 11.875 poor Serous 3 2 PHLPP2_L1016S 
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2.2 In vitro methods 
 
2.2.1  Apoptosis, cell viability and combination assays 
 
Cells were seeded in white-walled 96 well plates for caspase 3/7 apoptosis assays and in 
parallel in clear 96 well plates for 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide MTT cell viability assays (3 x 103 – 10 x  103 in 100 µl per well)  and incubated at 
37°C / 5% CO2. After 24 hours, cells were treated with AKT, PI3K or DNA-PK inhibitors 
diluted in RPMI 1640. Cells were pre-incubated with the inhibitor at 37°C / 5% CO2 for 1 
hour, prior to addition of cisplatin (cddp). After 24, 48 or 72 hours, caspase 3/7 activity was 
measured by luminescence using the Caspase-Glo 3/7 apoptosis assay (Promega, UK) as 
per the manufactures instructions. Briefly, equal volume of a luminogenic caspase 3/7 
substrate (100 µl) was added to each well and plates were incubated at room temperature 
for 1 hour. Plates were read on a LUMIstar optima micro-plate reader (BMG LABTECH). 
Relative cell viability across treatments was measured by 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay (Sigma, UK). Media was aspirated from wells and 
was replaced by 100 µl MTT at the concentration of 10 µg/ml. Plates were incubated at 
37°C/ 5% CO2. After 2.5 hours formazan was dissolved in 10% sodium dodecyl sulphate in 
0.01% hydrochloric acid (HCl) solution. Plates were read at 570 nm on a SPECTRA MAX 
190 plate reader (Molecular Devices). Data obtained from the caspase assays were 
normalised to the MTT cell viability data following the same treatment. Each treatment 
included three replicates, and each experiment was performed in triplicate.  
 
2.2.2 Apoptosis and Cell cycle analysis using propidium iodide  
 
Cells were treated with GSK2141795 (1 μM or 5 μM) or cisplatin (25 μM) as either single 
agents or in combination. Control cells were treated with PBS alone. In the combination 
treatment, cells were pre-treated with GSK2141795 1 hour prior to addition of cisplatin. After 
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24 hours of cisplatin treatment, cells were harvested with 0.25% trypsin, and combined with 
floating cells in the media, prior to centrifugation. Cells were fixed in 70% ethanol, at a 
density of 1 x 106, and stored at –20oC overnight. The next day, cells were washed once with 
PBS, and then incubated with propidium iodide (PI) (0.05 mg/ml PI, 0.2 mg/ml RNase A in 
PBS) for 30 minutes at 4°C in the dark. Samples were analysed with a FACScalibur flow 
cytometer (Becton Dickinson). Ten thousands events per sample were collected and DNA 
content was measured based on the PI fluorescence (excitation at 488 nm, emission 585 
nm; FL2). Data was analysed using the Flowjo software (Tree Stan. Inc). All cells were 
included in the analysis and cells were not gated to include the apoptotic sub-G1 population 
into the cell cycle profile. Sub-G1 cells were included in the cell cycle analysis as the 
apoptotic population.  
 
2.2.3 Small interfering RNA (siRNA) transfection 
 
Cells were grown to 60% confluency in 6 well plates prior to transfection with On-Target Plus 
siRNA (Thermo Scientific, UK) directed to PIK3CA ( L-003020), PIK3R1 (L-003028), or non-
targeting control (D-001810), as per manufactures protocol. SiRNAs in 1x siRNA buffer were 
mixed with 2 μL transfection-reagent #1 (Dharmacon, USA) per transfection in a total volume 
of 400 μL with OptiMEM media. The transfection reaction was incubated at room 
temperature for 30 minutes. The siRNAs were then added to cells in 1600 μL antibiotic free 
RPMI1640/10%FCS.  
 
For western-blot analysis, siRNA transfected cells were treated with cisplatin or kinase 
inhibitor, combination of both or were left untreated. Protein lysates were collected 2 hours 
after the treatment.  
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For MTT cell viability and caspase 3/7 assays, 48 hours after transfection, cells were re-
seeded into opaque and clear 96 well plates, for apoptosis and cell viability assays, 
respectively and were treated identically with cisplatin and/or kinase inhibitors. For each 
transfection condition, 24 hours after seeding, 3 replicate wells were treated with 25 μM 
cisplatin or kinase inhibitor or combination of both. Also three wells were left untreated. After 
24 hours, caspase activation was measured by caspaseGlo 3/7 (Promega, UK) assay and 
cell viability was assessed by MTT assay (Sigma, UK). Caspase activity was normalised to 
cell density for each treatment.  
 
2.2.4  Protein Extraction and Western Blot analysis 
 
Cells were grown in 35 mm × 10 mm tissue culture dishes (Corning, NY, USA) for protein 
extraction for western blotting. Cells were washed twice with ice-cold PBS prior to  lysis on 
ice in 250 µl of protein lysis buffer (2.2% SDS, 68 mM Tris, 11% glycerol and 1x complete 
protease inhibitor cocktail (Roche, UK) and 1X phosphatase inhibitor (Pierce, USA). Lysates 
were cleaned by centrifugation for 10 minutes at 4ºC at 10000 x g and quantified by BCA 
protein assay according to the manufactures protocol (Pierce, USA). Samples were stored at 
-80ºC Dithiothreitol (DTT) (100mM final concentration) was added prior to denaturation at 
95C for 5 minutes. Twenty micrograms of cleared lysate was electrophoresied at 20 mA, 
100 V for 2 hours through 8-12% SDS polyacrylamide gels (Table 2.1 and 2.2) then 
transferred onto nitrocellulose membranes by electroblotting. Membranes were blocked with 
5% Bovine serum albumin (BSA) or non-fat milk in PBS/0.1% TritonX100 at room 
temperature for 2 hours. Membranes were probed using a 1:1000 dilution of primary 
antibody (in 5% Bovine serum albumin (BSA) or non-fat milk in PBS/0.1% TritonX100) 
(Table 2.3) overnight at 4C, and then were washed for 10 minutes in PBS/0.1%  TritonX100 
three times . Membranes were incubated with secondary antibodies (1:2000, Dako 
Cytomation, Denmark) for 2 hours at room temperature and again washed with PBS/0.1% 
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TritonX100 three times. After washing, bound antibodies were visualized by Immobilon 
enhanced chemiluminesence (Millipore, UK) and photographic film.  
2.2.5 Stripping western blot membranes for re-probing 
 
 
Western blot membranes were stripped to re-probe for additional proteins. A stripping buffer 
containing 20 ml SDS 10%, 12.5 ml 0.5 M Tris HCl pH 6.8 (in 100 ml) and β-
mercaptoethanol (0.8 ml/100 ml buffer) warmed to 50ºC, was used. The membrane was 
stripped for 45 minutes, and then washed in PBST for 40 minutes.  
 
Table 2-3 Separating gel components for western blotting 
 
 Stock Solutions  8%  10%  12%  
30% acrylamide/0.8% 
bisacrylamide  
4 ml  5 ml  6 ml  
4X Tris-Cl/SDS, pH=8.8 
(1.5 M Tris-Cl, pH 8.8  
0.4% SDS)  
3.75 ml  3.75 ml  3.75 ml  
H
2
O  7.25 ml  6.25 ml  5.25 ml  
10% ammonium 
persulfate  
50 μl  50 μl  50 μl  
TEMED  10 μl  10 μl  10 μl  
 
 
Table 2-4Stacking gel (3.75%) components for western blotting 
Stock Solutions 
30% acrylamide/0.8% bisacrylamide  0.65 ml  
4X Tris-Cl/SDS, pH=6.8 (0.5M Tris-Cl, 
pH 6.8, 0.4% SDS) 
1.25 ml  
H
2
O  3.05 ml  
10% ammonium persulfate  25 μl  
TEMED  5 μl  
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Table 2-5 list of antibodies used in western blot analysis  
 
Antibody Dilution MW Isotype Manufactory 
PI3 Kinase p110α 1 in 1000 in 5% 
dry milk, 1% 
TBS,0.1%Tween 
 
110 KDa Rabbit, 
polyclonal 
Cell Signalling 
Technology, Cat. No: 
4255 
PI3 Kinase p85 α 1 in 1000 in 5% 
BSA, 1% TBS, 
0.1% Tween-20 
85 KDa Rabbit, 
polyclonal 
Cell Signalling 
Technology, Cat. No : 
4292 
AKT Total 1 in 1000 in 5% 
BSA, 1% TBS, 
0.1% Tween-20 
60 KDa Rabbit, 
monoclonal 
Cell Signalling 
Technology, Cat. No: 
9272 
AKT pS473 1 in 1000  in 5% 
BSA,1% 
TBS,0.1%Tween-
20 
60 KDa Rabbit, 
monoclonal 
Cell Signalling 
Technology, Cat. No : 
4060 
β-tubulin 1 in 10000 in 5% 
dry milk, 1% 
TBS,0.1%Tween 
55 KDa Rabbit, 
Polyclonal 
Cell Signalling 
Technology, Cat. No: 
2146 
 
Anti-Rabbit 
Immunoglobulins 
1 in 20000 in 5% 
BSA,1% 
TBS,0.1%Tween-
20 
-   Goat. 
Polyclonal 
Dako, Cat. No: 
P044801-2 
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2.2.6 Enzyme-linked immunosorbent assays (ELISA) 
 
Levels of phospho-PRAS40 (pT246) and total PRAS40 were assessed using ELISA kits 
(Invitrogen, KHO0421) according to the manufacturer’s instructions. SKOV3 monolayers and 
MTS’s were treated with GSK2141795 (0.01 – 5 µM) or GSK2126458 (0.1 – 40 nM) for 24 – 
72 hrs. After treatment, cells were lysed in cell extraction buffer (Invitrogen FNN0011) 
according to the manufacture’s instruction, and samples were diluted 1 in 50 in diluent buffer 
provided in the kit. Absorbance was measured at 450 nm using a SPECTRA MAX 190 plate 
reader (Molecular Devices). PRAS40(pT246) levels were normalised to total PRAS40 levels 
(Invitrogen, KHO0411). The level of pAKTS473 and pAKTT308 compared to total AKT were 
also assessed using similar ELISA kits (Invitrogen, KHO0111, KHO0101, KHO0201).  
 
2.2.7 Multicellular tumour spheroids (MTS) 
 
SKOV3 tumour cells were trypsinised from monolayer culture, and cell suspensions seeded 
at a density of 10000 cells per well in 24-well (1% agarose-coated) plates. Spheroids were 
grown at 37°C/5% CO2 for 7 days, in 200 µl of culture media.  
 
To make the 1% agarose plates, 5 mg agarose was dissolved in 500 ml ddH2O and the 
solution was autoclaved. While still warm, 0.5 ml agarose solution was dispensed in each 
well of 24-well tissue culture plate in a tissue culture cabinet and plates were allowed to set 
at room temperature. Plates were stored at 4ºC and before use the plates were incubated 
with 500 ml warm culture media and were incubated at 37ºC incubator for 1 hour prior to cell 
seeding.  
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2.2.8 In vitro radioligand binding studies 
 
For time-course studies, SKOV3 monolayers and spheroids (MTS) were treated with two 
concentrations of GSK2141795 (1 and 5 µM) for 48 hours and incubated at 37°C, 5% CO2. 
Twenty four hours into the incubation, SKOV3 monolayers and MTS’s were incubated with 
culture media (0.5 ml per well), containing [3H]FDG (296 kBq) for between 0 – 24 hours in 24 
well plates. For dose-response studies, SKOV3 monolayers and MTS’s were treated with a 
range of concentrations of GSK2141795 (0.001 - 5 µM) for different lengths of time 
(monolayers for 24 hours; MTS’s for 48 hours). Two or six hours prior the end of incubation, 
monolayers and MTS’s were incubated with 0.5 ml medium per well containing [3H]FDG 
(296 kBq).  
 
Following incubation with [3H]FDG, monolayers and MTS’s were washed twice with PBS, 
and cells solubilised in 1ml 0.1M NaOH at 37°C overnight prior to transfer to 5ml tubes and 
addition of 4ml scintillation fluid (4ml; Packard Ultima Gold MV). Radioactivity was 
determined by liquid scintillation counting (Perkin Elmer, TriCarb2900). For each MTS, 100 
μl of the last wash was measured as a background. Data were analysed by iterative non-
linear regression curve fitting using Prism v5.0 (GraphPad Software, San Diego, California, 
USA). Each experiment was done in triplicate and analysed individually. 
 
2.3 In vivo xenograft experiments 
 
All animal studies were ethically reviewed and carried out in accordance with Animal 
(Scientific Procedures) Act 1986 and the GSK Policy on the Care, Welfare and Treatment of 
animals.  
85 
 
2.3.1 Mouse strain  
 
Female Mice strain Crl: Nu/Nu – foxn1, age approximately 11 weeks weighing 25 – 30 g 
were utilised in this study. 
2.3.2 Establishment of xenografts 
 
Two tumour xenografts were established in each animal, by injecting 10x107 SkOV3 tumour 
cells / 100µL sub-cutaneously (sc) in each flank, using a 25-G needle, under light isoflurane 
anaesthesia. The cell suspensions for inoculation were prepared in PBS, warmed to 37oC 
following trypsinisation of cells in monolayer culture.  
 
2.3.3 Tumour Growth and Toxicity Monitoring 
 
Tumour size and tumour volume were calculated by measuring two perpendicular tumour 
diameters, and using the 3D ellipsoid tumour volume formula below. 
Volume = (width2 × length)/2 
From the day after inoculation, mice were monitored for tumour size, and twice a week 
thereafter. Monitoring of each animal’s well-being occurred daily, based on body weight and 
food/water consumption from the day of inoculation.  
 
2.3.4 Treatment Procedure 
 
Treatments were started when tumour xenografts reached approximately 80mm3. Animals 
were then randomly assigned to one of 4 treatment groups, with 5 animals per group. The 4 
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groups were: vehicle only, GSK2141795 or NU7441 only, Cisplatin (cddp) and cddp + 
GSK2141795 or NU7441. 
 
Group 1: Control (vehicles):  
Conscious animals received 10 ml/kg 20% PEG / 1% DMSO daily for 14 days at noon. 
Animals were sacrificed by exsanguination on day 14 at 5 pm.   
 
Group2: GSK2141795 or NU7441 only: 
Conscious animals received 30 mg/kg (10 ml/kg) of GSK2141795 by oral gavage or 10 
mg/kg NU7441 by intraperitoneal injection (IP) daily, at noon for 14 days. Animals were 
sacrificed by exsanguination on day 14, at 5 pm, 5 hours following administration of the final 
dose of the drug.  
 
Group 3: cddp: 
Conscious animals received single IP injection of cisplatin in saline (1.5 mg/kg in AKT study 
or 1 mg/kg in DNA-PK study (10 ml/kg), twice a week (Tuesdays and Fridays) at 2 pm, for 14 
days. Animals received an extra dose of cisplatin on day 14 before being sacrificed at 5 pm.   
 
Group 4: cddp + GSK2141795 or NU7441 
Conscious animals received 30 mg/kg of GSK2141795 by oral gavage or 10 mg/kg NU7441 
by IP injection daily for 14 days at noon and single IP injection of cisplatin in saline (1.5 
mg/kg in AKT study or 1 mg/kg in DNA-PK study), at 2 pm (2 hours following oral 
administration of GSK2141795 or NU7441), on Tuesdays and Fridays. Animals were 
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sacrificed by exsanguination on day 14 at 5 pm and blood was collected. The glucose level 
in blood was measured using a glucose meter. Tumour and muscle tissues were harvested 
and frozen at -80 for further studies. 
 
2.3.5 In vivo PET imaging studies 
 
For time-course studies, following overnight fasting mice were treated with GSK2141795 (30 
mg/kg) for 1 - 72 hours, prior to [18F]FDG administration (~8 MBq) via a jugular vein cannula. 
For dose-response studies, following overnight fasting, mice received either vehicle (20% 
PEG / 1% DMSO) or GSK2141795 (10, 20 or 30 mg/kg) by oral gavage, 5 hours prior to 
[18F]FDG (~8 MBq) administration.  
 
All animals were subsequently scanned 120 minutes after FDG administration, on a 
dedicated small animal PET scanner (Siemens Inveon PET/CT module, Siemens Molecular 
Imaging Inc. UK). Animals were kept under isofluorane anaesthesia throughout the imaging 
period with constant monitoring of vital signs. Whole blood was drawn immediately before 
sacrificing the animals and variable tissues were collected for pharmacokinetic analysis. 
Dynamic emission scans were acquired in list mode format over 60 minutes. Following 
completion of the scanning period, animals were sacrificed by exsanguination. Standardised 
uptake values (SUV) of radioactivity were calculated for the tumour region of interest (ROI) 
for each image of a dynamic series using the formula below:  
 
SUVmean(30-60 min)  =   
 
  Tissue radioactivity concentration at time (Ct) 
       Injected dose at t0 (Bq) / body weight (g)  
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Tumour time radioactivity curves (TAC) were generated by calculating a ratio of the tumour 
to plasma uptake and by calculating the SUV at 60 minutes post administration of the 
[18F]FDG for each animal. [18F]FDG uptake in GSK2141795 treated xenografts were 
subsequently compared to the untreated control animals.  
 
2.4  Pharmacokinetics 
 
All blood and tumour samples taken for pharmacokinetic analysis were stored at -80°C prior 
to analysis. Samples collected at the same nominal times were pooled for analysis. Prior to 
bio analysis, blood samples were mixed 1:1 (v:v) with HPLC grade water, and tissue 
samples were mixed 1:4 with HPLC grade water (w:v; tissue: water) and homogenised using 
a probe-type homogeniser. Mouse tissue homogenates, plasma and blood samples were 
analysed for GSK2141795 using LC/MS/MS. Tissue homogenate concentrations (ng/mL 
homogenate) were converted to tumour tissue concentrations (ng/g tissue) by calculating the 
product of the measured homogenate concentration and the dilution factor incurred during 
sample processing. This conversion assumes complete extraction of the analyte from the 
tissue homogenate samples during bioanalytical sample preparation. The in-life portion of 
this study was performed at the GSK Clinical Imaging Centre, UK, and the mass 
spectrometry (MS) analysis of this study was carried out by GSK, USA. 
 
2.5 Reverse Phase Protein Array (RPPA) 
 
SKOV3 and PEO4 cells after drug treatments were washed twice with cold PBS and lysed 
using 100 μL RPPA lysis buffer (1% Triton X-100, 50mM HEPES, pH 7.4, 150 mM NaCl, 1.5 
mM MgCl2, 1 mM EGTA, 100 mM NaF, 10 mM Na pyrophosphate, 1 mM Na3VO4, 10% 
glycerol, containing freshly added protease and phosphatase inhibitors (Roche Applied 
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Science) in 6-well plates. Tumours recovered from in vivo experiments or clinical biopsies 
were crushed in 100 µl cold RPPA lysis buffer using an electric pellet pestle (Sigma, UK). 
Lysates were centrifuged at 14000 rpm for 15 minutes and incubated on ice for 30 minutes. 
Supernatants were collected and pellets discarded. Protein concentration was determined 
using the BCA assay (Invitrogen, UK). Lysates were analysed by RPPA as described at MD 
Anderson Cancer Centre (Tibes, Qiu et al. 2006) (Figure. 2.1). RPPA data was normalised, 
median centred and analysed in Microsoft Excel. For proteins regulated by direct 
phosphorylation, in addition to the total and phospho-proteins, phospho/total normalised 
level was also assessed as an individual expression. Proteins with significantly expression 
levels (t-test; p<0.05) between sample group were identified. Proteins showing less that 1.3 
fold difference between groups were discarded on the basis of unlikely biological relevance 
despite statistical significance. Venn diagrams were used to compare protein expression 
levels from different treatment groups and Venn groups were determined as shown in 
Figure. 2.2.  
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Figure 2-1 RPPA Process 
Following the protein extraction, cellular protein will be denatured by SDS sample buffer. Cell 
lysates are arrayed on nitrocellulose coated slides followed by being probed with different 
antibodies. Figure from www.mdanderson.org  
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Figure 2-2 Venn groups used for analysis of the RPPA data.  
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2.6 Statistical analysis  
 
RPPA data were processed using the Microsoft Excel. Raw data were log transformed, 
normalised and median centred. Significant changes in protein levels were tested by 
student’s t-test, two-sample unequal variance (heteroscedastic). The significant changes 
were defined as more than 1.6-fold with adjusted P < 0.05. For non-parametric tests, Mann-
Whitney U test was used. Levene’s test was used to assess the equality of variances for two 
or more groups.  
 
Normalisation to an experimental control, normally un-treated or vehicle, was done by 
dividing the mean of replicates to the mean of controls. Caspase 3/7 data were further 
normalised to cell density.  
 
The standard deviation (SD) was calculated to measure of how widely values are dispersed 
from the average value (the mean). Standard error of mean ( SEM) was calculated to 
measure how distant the sample mean is  from the population mean and to indicate the 
standard deviation of sampling distribution. Both SD and SEM were calculated in Microsoft 
Excel.  
 
IC50 values were calculated) with 95% confidence interval using as the GraphPad Prism 
software (GraphPad Software, Inc). Relative IC50 values (the concentration required to bring 
the dose-response curve down to point half way between the top and bottom plateaus of the 
curve) were calculated by selecting ‘non-linear regression (curve-fit), log [inhibitor] v 
response, (variable slop, four parameter)’ option in Graph-pad Prism. Significant changes in 
IC50 values were tested by student’s t-test. One-way ANOVA was used to test significant 
differences between more than two groups of samples. If there were two independent 
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variables in the experiment, two-way ANOVA was used to test differences between groups 
of samples. The significant changes were defined as P < 0.05. 
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3 Utility of the pan AKT inhibitor 
GSK2141795 in overcoming 
platinum resistance in ovarian 
cancer 
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3.1 Introduction 
 
 
One of the most frequently activated signalling pathways in EOC is the PI3K/AKT axis. PI3K, 
KRAS and PTEN  mutations underlie activation in Type I tumours, whereas Type II tumours 
exhibit frequent copy number changes and over-expression of PI3K/AKT pathway 
components (Bast and Mills 2012). Work in our laboratory has shown activation of the 
PI3K/AKT pathway in platinum-resistant cells (as evidenced by increased phosphorylation of 
AKT at serine 473 by DNA-dependent protein kinase (DNA-PK) (Stronach, Chen et al. 2011) 
in response to DNA damage, which directly links the established role of AKT in chemo-
resistance to the DNA damage caused by platinum agent therefore AKT inhibition represents 
a potentially useful strategy for platinum sensitisation in ovarian cancer.  
 
GSK2141795 is a novel member of the N-alkyl pyrazole class of orally available kinase 
inhibitors. It is a potent, pan-AKT inhibitor, with potency (Ki) values for human AKT 1, 2 and 
3 kinases of 0.066nM, 1.4nM and 1.5 nM, respectively (GlaxoSmithKline unpublished data).  
 
In this chapter, the effect of inhibition of AKT using GSK2141795 as single agent and in 
combination with cisplatin on tumour growth and apoptosis, using both in vitro and in vivo 
ovarian cancer models will be assessed, to determine the potential utility of this compound 
for clinical implementation. In vitro assays were performed using both 2-dimensional (2D) 
and 3-dimensional (3D) spheroid cell culture models to determine if 3D models better model 
in vivo results of GSK2141795. Efficacy was assessed using both apoptosis and growth 
assays. In vivo assays also enabled a degree of toxicity assessment. 
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3.2 Results 
 
3.2.1 Effect of AKT inhibition using GSK2141795 as single agent or in 
combination with cisplatin on platinum resistance in vitro 
 
 
3.2.1.1 Single agent 2D activity 
 
In order to examine the effect of the inhibition of AKT by GSK2141795 on apoptosis, 
platinum resistant SKOV3 cell monolayers were treated with a range of clinically relevant 
concentrations of GSK2141795 (0.075-5.0 µM) for 24, 48 and 72 hours. The level of 
caspase 3/7 activation was used to measure apoptosis induction after GSK2141795 
treatment. GSK2141795 as a single agent did not induce caspase activation greater than 
vehicle controls over the selected range of concentrations (0.1 µM-5 µM) and incubation 
times (24 – 72 hours)(Figure.3.1a and 3.2). Similar results were obtained with single agent 
GSK2141795 in the platinum resistant PEO4 ovarian cancer cell line (Figure. 3.1b).  
  
3.2.1.2 GSK2141795 in combination with cisplatin 
 
By contrast, treatment with GSK2141795 in combination with cisplatin increased the 
induction of caspase 3/7 activity in both SKOV3 and PEO4 monolayers after 24 hours 
(Figure 3.1a and b. respectively). With a combination of GSK2141795 (5 µM) and cisplatin 
(25 µM) for 24 hours, there was a 3-fold and 8-fold increase in induction of caspase 3/7 
activity in PEO4 and SKOV3 cells respectively (Figure. 3.1a and b).  
 
 
 
97 
 
A
B
V
eh
ic
le M
0.
1
M1
M
 

2.
5
M
 
5 cd
dp
M
+ 
cd
dp

0.
1
M
 +
 c
dd
p
1
M
 +
 c
dd
p

2.
5
M
 +
cd
dp
5
0
2
4
6
8
10
*
[GSK2141795] (M)
N
o
rm
a
li
s
e
d
 c
a
s
p
a
s
e
 3
/7
 a
c
ti
v
it
y
ve
hi
cl
e M
0.
1 
M
1 
M
2.
5 
M
5 cd
dp
M
 +
 c
dd
p

0.
1
M
+ 
cd
dp

1 
M
+c
dd
p

2.
5 
M
+c
dd
p
5
0
10
20
30
***
[GSK2141795] (M)
N
o
rm
a
li
s
e
d
 c
a
s
p
a
s
e
 3
/7
 a
c
ti
v
it
y
 
 
 
 
Figure 3-1 Caspase 3/7 activity in SKOV3 (a) and PEO4 (b) monolayers exposed to 
GSK2141795 as a single agent or in combination with cisplatin (cisplatin) for 24 hours  
SKOV3 and PEO4 monolayers were pre-treated with a range of concentrations of 
GSK2141795, 1 hour prior to treatment with 25 μM cisplatin . Induction of caspase 3/7 activity 
was assessed at different time points following the initiation of the treatment. Combination of 
GSK2141795 with cisplatin increased apoptotic response to cisplatin treatment in a dose 
dependent manner. Treatment with GSK2141795 as a single agent for the same length of time 
did not result in any significant increase in the apoptotic activity. Data shown are the means ± 
SEM of 3–4 experiments performed in triplicate. *P < 0.05  **P < 0.01. ***P < 0.001. 
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The effect of GSK2141795 on platinum sensitisation in SKOV3 cells was also assessed after 
treatment for 48 and 72 hours. GSK2141795 re-sensitised SKOV3 monolayers to cisplatin in 
a time and dose dependant manner, with maximal induction of caspase 3/7 after 72 hours of 
treatment (fold change ~ 4, P < 0.001)(Figure 3.2).  
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Figure 3-2 Caspase 3/7 activity in SKOV3 monolayers exposed to GSK2141795 as a 
single agent or in combination with cisplatin (cddp) for 48 (a) and 72 (b) hours 
 SKOV3 monolayers were pre-treated with a range of concentrations of GSK2141795, 1 hour 
prior to treatment with 25 μM cisplatin. Induction of caspase 3/7 activity was assessed at 
different time points following the initiation of the treatment. Combination of GSK2141795 
with cisplatin increased apoptotic response to cisplatin treatment in a dose dependent 
manner in SKOV3 cells at 48 and 72 hours. Treatment with GSK2141795 as a single agent 
for the same length of time did not result in any significant increase in the apoptotic activity. 
). Data shown are the means ± SEM of 4 experiments performed in triplicate. *P < .05  **P < 
.01. ***P < .001. 
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In contrast in platinum sensitive PEO1 cells (isogenically matched to PEO4 resistant cells), 
treatment with GSK2141795 for 24 hours in combination with cisplatin, resulted in only a ~ 
1.5 -fold increase in caspase 3/7 activity at a GSK2141795 concentration of 5 µM, which 
was not significant compared to the cisplatin only treated cells (Figure 3.3). 
 
The effect of AKT inhibition using GSK2141795, on platinum re-sensitisation was further 
assessed in another isogenically matched cell line pair, PEA1 and PEA2. Treatment with 
GSK2141795 and cisplatin for 24 hours increased the sensitivity to cisplatin in the sensitive 
PEA1 line, by ~ 1.5 -fold at 10 µM compared to cisplatin only, but this increase was not 
significant (p = 0.26) (Figure 3.4a). In contrast treatment with GSK2141795 at 10 µM re-
sensitised the platinum resistant pair, PEA2, with 2.3 -fold induction in caspase 3/7 activity 
compared to cisplatin alone (p=0.01) (Figure 3.4.b).  
 
Furthermore, to test if the increase in apoptosis with combination treatment was additive or 
synergistic, isobologram analysis was performed. This demonstrated that the effect of 
combining GSK2141795 with cisplatin was synergistic in both the SKOV3 and PEO4 cells 
(Figure.3.5).  
 
3.2.1.3 3-D spheroid culture 
 
To further determine the activity of GSK2141795 in 3D culture, SKOV3 tumour cell spheroids 
were treated with a range of concentrations of GSK2141795 (1-10 µM) as a single agent, or 
in combination with 25 µM cisplatin for 72 hours. Combination of GSK2141795 and cisplatin 
significantly increased the induction of caspase 3/7 activity, in comparison to cisplatin-only 
treated controls (P< 0.01) (Figure 3.6). PEO4 cells could not be grown as spheroids.  
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As the AKT inhibitor GSK2141795 was mostly effective on reversal of platinum resistance in 
SKOV3 platinum resistant cells, this cell model was chosen for further pre-clinical 
investigation of the compound.  
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Figure 3-3 Caspase 3/7 activity in PEO1 monolayers exposed to GSK2141795 as a 
single agent or in combination with cddp (cisplatin) for 24 hours 
 Platinum sensitive PEO1 monolayers were pre-treated with a range of concentrations of 
GSK2141795, 1 hour prior to treatment with 5 μM cddp. Induction of caspase 3/7 activity 
was assessed 24 hours after the initiation of the treatment. Combination of GSK2141795 
with cddp did not result in any significant increase in the apoptotic activity in PEO1 cells. 
Data shown are the means ± SEM of 3 experiments performed in triplicate. 
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Figure 3-4 Caspase 3/7 activity in platinum sensitive PEA1 monolayers (A) and their isogenically 
matched pair platinum resistant PEA2 cells (B) exposed to GSK2141795 as a single agent or in 
combination with cisplatin (cddp) for 24 hours. 
 PEA1 and PEA2 monolayers were pre-treated with a range of concentrations of GSK2141795, 1 hour 
prior to treatment with 5 and 25 μM cddp respectively. Induction of caspase 3/7 activity was assessed 24 
hours following the initiation of the treatment. Combination of GSK2141795 with cddp increased apoptotic 
response compared to cddp only treatment in a dose dependent manner in PEA2 cells but not in PEA1 
cells. Treatment with GSK2141795 as a single agent for the same length of time did not result in any 
significant increase in the apoptotic activity in neither PEA2 nor PEA1 cells. Data shown are the means ± 
SEM of 4 experiments performed in triplicate. . *P < .05  
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Figure 3-5 GSK2141795 and cisplatin (cddp) interaction in SKOV3 (A) and PEO4 
(B) cells 
 Isobologram generated from GSK2141795 and cddp IC50 values taken from the 2D 
monolayer studies. The IC50 values of combinations were determined with the 95% 
confidence limit and plotted. The x and y intercepts represent the IC50 values of either 
cddp or GSK2141795 as single agents. The line connecting the IC50 values represents 
the additivity line. Combination drug points occurring on or around the line represent 
additivity whereas points above the line represent antagonism. Points below the line 
represent synergy. All of the IC50 values for the GSK 2141795 and cddp combination in 
SKOV3 and most of the values in PEO4 were below the line suggesting synergy 
between these two compounds in these two cell lines.  
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Figure 3-6 Caspase 3/7 activity in SKOV3 multi-tumour spheroids (MTS’s). 
 SKOV3 MTS’s were treated with a range of concentrations of GSK2141795 
either as a single agent or in combination with 50 μM cddp for 72 hours. 
Combination of GSK2141795 with cddp resulted in a dose dependent increase 
in the apoptotic activity in response to cddp whereas treatment with 
GSK2141795 as a single agent had no effect on the caspase activity in SKOV3 
MTS’s. ). Data shown are the means ± SEM of 3 experiments performed in 
triplicate. **P < .01. 
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3.2.2 Growth-inhibitory effect of GSK2141795 in ovarian cancer cells 
 
Based on the above activity of GSK2141795 on apoptosis, the effect of GSK2141795 as a 
single agent on cell growth and viability of SKOV3 and PEO4 cells was also assessed using 
the MTT assay. Treatment with GSK2141795 reduced cell growth in a dose-dependent 
manner over 72 hours of treatment (approx. 3 X cell doubling time). For combination studies, 
a range of concentrations of GSK2141795 (0.075 – 5 µM) was combined with cisplatin (25 
μM). Cell viability was found to be reduced in SKOV3 cells treated with single agent 
GSK2141795, and this was found to be further decreased in a GSK2141795 dose-
dependent manner when the drugs were combined (Figure. 3.7). The half-maximal effective 
concentration of GSK2141795 in the combination with cisplatin (25 μM) treatment was 3 μM.   
 
3.2.3  Effect of GSK2141795 on cell cycle progression in ovarian cancer cells 
 
In view of the role of the PI3K-AKT pathway on regulation of the cell cycle via p16, p21 and 
CCND1 phosphorylation, cell cycle analysis by flow cytometry following treatment of cells 
with GSK2141795 was performed. This revealed cell cycle arrest at G1 in SKOV3 cells 
treated with 5 µM GSK2141795 for 24 hrs. This arrest was abrogated when the cells were 
co-treated with 25 μM cisplatin. In contrast, a 6% increase in sub-G0 cell population was 
observed in cells following the combination treatment, compared to single agent cisplatin 
treatment (Figure. 3.8) suggesting augmentation of cisplatin induced apoptosis by 
GSK2141795.  
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Figure 3-7 Cell viability effect of GSK2141795 as a single agent or in 
combination with cddp in SKOV3 monolayers 
 SKOV3 monolayers were treated with a concentration range of GSK2141795 as 
either a single agent or in combination with 25 µM cddp for 72 hours. Treatment 
with GSK2141795 resulted in a dose-dependent reduction in cell viability either as a 
single agent or in combination with cddp). Data shown are the means ± SEM of 3 
experiments performed in triplicate. **P < .01. 
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Figure 3-8 Cell cycle analysis of SKOV3 cells after treatment with DMSO (A) cddp 25 
μM (B) GSK2141795 5 μM (C) or combination of GSK2141795 (5 μM) and  cddp (25 
μM) (D) 
After 24 hours treatment, cells were labelled with propidium iodide PI and analysed by flow 
cytometry. The data shows the percentage of cells in each phase of the cell cycle. 
Treatment with GSK2141795 resulted in a G1 cell cycle arrest. This growth inhibitory effect 
was reduced when GSK2141795 was combined with cddp. An increase in sub-G0 
population was observed in cells treated with the combination treatment compared to the 
single agent cisplatin treatment. Cells were not gated to include the apoptotic sub-G1 cell 
population into the analysis therefore small size debries in samples were also detectable 
(first peak in profiles) 
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3.2.4 In vivo xenograft studies 
 
 
3.2.4.1 Efficacy of GSK2141795 
 
The combination of GSK2141795 and cisplatin was investigated in vivo using a human 
SKOV3 ovarian cancer xenograft model. After implantation of cells into mice, tumours were 
allowed to reach a mean volume of 50 – 100 mm3. Cisplatin (1.5 mg/kg) was administrated 
twice weekly intraperitoneally and GSK2141795 orally daily at 30 mg/kg for 14 days. On the 
days in which animals received both drugs, GSK2141795 was administrated 2 hours before 
cisplatin. Single agent GSK2141795 was found to inhibit tumour growth (Figure. 3.9). The 
combination of cisplatin with GSK2141795 reduced tumour sizes below that achieved with 
cisplatin alone. The combination therapy resulted in 90% reduction in tumour sizes in 14 
days compared to the vehicle control (p<0.01). Single agent GSK2141795 and cisplatin also 
reduced tumour growth relative to the time-matched vehicle control tumours by 63% and 
70% respectively. Of note, single agent GSK2141795 treatment did not result in tumour 
shrinkage relative to day 0 but prevented the tumours from growing larger.  
 
3.2.5 Toxicity of GSK2141795 
 
GSK2141795, cisplatin and the combination were well tolerated, and mice body weights 
were not significantly different among treatment groups (Figure 3.10).  
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Figure 3-9 Effect of GSK2141795 either alone or in combination with cddp on  
tumour growth of SKOV3 cells. 
 SKOV3 tumour-bearing mice were dosed daily with GSK2141795 (30 mg/Kg; oral) or 
vehicle ± biweekly cddp (1.5 mg/Kg; intraperitonal) for 14 days. Data shown the mean ± 
SEM for n = 8 tumours/treatment, *p<0.05, **p<0.01, ***p<0.001, where the symbols *, # 
and + represent significant differences when compared to vehicle, cisplatin and 
GSK2141795 data, respectively.  
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Figure 3-10  Mean body weights from efficacy study.  
The doses of GSK2141795 (30 mg/kg), cddp (1.5 mg/kg) and their combination were 
well tolerated, and body weights were not significantly different among the treated 
groups. Data shown the mean ± SEM for n = 8 animals.  
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3.3  Discussion 
 
 
Several studies have linked the PI3K/AKT pathway to platinum and taxol resistance in 
ovarian cancer. Constitutive activation of AKT-2 leads to cisplatin resistance in some ovarian 
cancer cell models. Moreover, treatment with the PI3K inhibitor, LY294002 reverses 
resistance in cisplatin-resistant ovarian cancer cell lines (Yuan, Feldman et al. 2003). In 
addition, constitutively active PI3K induces taxol resistance in xenograft models and 
reversed by LY294002 (Hu, Hofmann et al. 2002).  PIK3CA genomic alternations are more 
frequent in ovarian cancer patients who relapsed with platinum resistance disease within 6 
months (platinum resistant) than in those with more than 6 months of progression-free 
survival (platinum sensitive), or in patients with complete response to platinum. For 
examples, ovarian clear cell carcinoma (CCC) which is one of the most lethal types of 
ovarian cancer and often resistant to platinum based chemotherapy is characterised by 
frequent activating mutations of PIK3CA (35 – 45 %) (Kuo, Mao et al. 2009). Moreover, 
PTEN expression is associated with chemo-sensitivity in ovarian cancer cell lines (Stronach, 
Cheraghchi-Bashi et al. 2011). In 2010, Wallin et al. explored the use of a potent PI3K 
inhibitor in combination with the DNA-damage agent doxorubicin (Wallin, Guan et al. 2010). 
They found that PI3K inhibition increased apoptosis and enhanced the anti-tumour effects of 
doxorubicin in a subset of ovarian and breast cancer cell lines. They reported that in most 
cell lines where combination synergy was observed, there was an increase in the expression 
of nuclear p-AKT S473 in response to doxorubicin treatment alone suggesting that inhibition 
of AKT pathway in combination with cytotoxic agents  is mostly effective in the set of tumour 
cells that rely on the PI3K/AKT pathway for survival (Wallin, Guan et al. 2010).  
 
In this chapter, the efficacy of a novel specific ATP-competitive pan-AKT inhibitor agent, 
GSK2141795, to restore platinum-sensitivity in clinically derived platinum resistant ovarian 
cancer models was investigated.  
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GSK2141795 as a single agent had a strong growth inhibitory effect both in vitro and in vivo. 
In addition, flow cytometric analysis indicated G1 cell cycle arrest following treatment of the 
SKOV3 cells with this compound. These results are consistent with the reported growth 
inhibitory effects and G1 arrest induced by AKT inhibitors by others. For example Mandal et 
al reported that a small molecule inhibitor of AKT, KP372-1, induced a G1 cell cycle arrest in 
thyroid tumour cells in vitro and in vivo (Mandal, Kim et al. 2005). Hirai el al also reported 
inhibition of cell proliferation by another allosteric inhibitor of AKT in lung and ovarian tumour 
cells both in vitro and in xenograft models (Hirai, Sootome et al. 2010). In addition, growth 
inhibitory effect of GSK690693, a pan AKT inhibitor with the same mechanism of action of 
GSK2141795, has been reported in acute lymphoblastic leukaemia cell lines (Levy, Kahana 
et al. 2009, Altomare, Zhang et al. 2010). In addition, inhibition of AKT pathway by API-2, 
another small molecule AKT pathway inhibitor, resulted in inhibition of cell growth and 
induction of apoptosis in several types of AKT-overexpressing human cancer cells (Yang, 
Dan et al. 2004). 
 
The in vivo data suggest that GSK2141795 as a single agent may have pre-dominantly 
cytostatic effect, limiting its clinical utility. This is consistent with the in vitro data of the lack of 
apoptosis induction by GSK2141795 as single agent in the examined cell lines in this study, 
including SKOV3 ovarian cancer cells which express a high level of constitutively activated 
p-AKT (Arboleda, Lyons et al. 2003).  
 
GSK2141795 as a single agent also did not induce apoptosis in either platinum sensitive 
and platinum resistant ovarian cancer cells in 2D and 3D models. In contrast GSK2141795 
combined with cisplatin increased apoptosis in platinum-resistant 2D and 3D ovarian cancer 
cell models in a dose and time dependent manner.  
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Multi-tumour cell spheroid models resemble in vivo tumour cell microenvironment more 
closely than 2D models. Many factors could reduce the sensitivity of cells within the 3D 
environment to certain drugs or treatments compared to cells grown in a monolayer culture. 
These factors include hypoxia, cell cycle differences, drug penetration, micro-environmental 
variations and PH in cells grown in a 3D microenvironment compared to cells grown as a 
monolayer. Drug penetration is thought to be a major factor (Knuchel, Hofstadter et al. 
1989). MTS mimics in vivo tumour proliferative heterogeneity, hypoxic and necrotic 
conditions. These conditions can alter expression of numerous genes in vivo and in 3D 
cultures compared to 2D monolayers. In this study the effect of GSK2141795 as single agent 
and in combination with cisplatin on cell viability and apoptosis was assessed in MTS prior to 
in vivo xenograft experiments. The purpose of experiments performed in 3D cultures was to 
assess if GSK2141795 can increase apoptosis in combination with cisplatin in platinum 
resistant cells in a 3D micro-environment, as it was seen in 2D monolayers, before testing 
the combination treatment in animals. This step was done to avoid unnecessary use of 
animals if the combination treatment was not effective in a 3D micro-environment.  
GSK2141795 increased platinum sensitivity in platinum-resistant MTS, as was seen in 2D 
monolayers.  
 
Treatment with GSK2141795 in combination with csiplatin resulted in tumour shrinkage in 
the platinum-resistant SKOV3 xenograft model. In the cell models examined, the enhanced 
apoptotic effect of cisplatin and GSK2141795 in combination was found to be synergistic. 
Notably, combination of GSK2141795 with cisplatin did not increase apoptotic response to 
cisplatin in platinum sensitive cell lines which were derived from the same patients as the 
resistant cells but before the onset of the platinum resistant relapse.  
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To date several signalling pathways have been reported to mediate resistance of cancer 
cells to AKT inhibitors. For example, Sommer et al have suggested that elevation of SGK1 
expression represents one mechanism resulting in resistance to distinct AKT inhibitors 
(AZD5363 and MK-2206) in breast cancer cells (Sommer, Dry et al. 2013). The authors have 
shown that SGK1 can promote survival of AKT inhibitor resistant breast cancer cells 
independently of AKT. SGK is closely related to AKT and is regulated by the same up-
stream regulators of AKT; PI3K, PDK1 and mTORC2. In addition, AKT and SGK show 
analogous substrate specificities and are likely to phosphorylate overlapping substrates 
(Kobayashi and Cohen 1999, Kobayashi, Deak et al. 1999, Murray, Cummings et al. 2005, 
Pearce, Komander et al. 2010).  
 
It should be noted that mechanisms other than SGK1 activity are also likely to contribute to 
the resistance to AKT inhibitors. Sera et al have demonstrated that overexpression of 
ribosomal S6 kinase RPS6KA2 (RSK3) and RPS6KA6 (RSK4) mediates resistance to PI3K 
pathway inhibitors in breast cancer cells in vitro and in vivo in part through the decrease of 
the apoptotic response and regulation of protein translation. They have demonstrated that 
addition of MEK or RSK inhibitors restored responsiveness of RSK-expressing cells to PI3K 
inhibitors (Serra, Eichhorn et al. 2013). Several studies have also shown that an elevated 
Extracellular signal regulated kinase (ERK) activation signal either through the activation of 
compensatory feedback loops observed following PI3K inhibition or through intrinsic KRAS 
mutations, limits the effectiveness of PI3K pathway inhibitors in clinic (Engelman, Chen et al. 
2008, Di Nicolantonio, Arena et al. 2010, Janku, Lee et al. 2011). It has also been suggested 
in a recent study that nuclear β-catenin confers resistance to the FOXO3a-mediated 
apoptosis induced by AKT and PI3K inhibitors in primary colon cancer cells (Tenbaum, 
Ordonez-Moran et al. 2012).  
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Overall, the findings in this chapter suggest that AKT inhibition alone is not sufficient to 
trigger apoptosis in the ovarian cancer in vitro and in vivo models used in this study. As 
suggested in several studies cancer cells may depend on several pathways parallel to 
PI3K/AKT pathway such as RAF/MEK/ERK for survival in absence of PI3K/AKT signalling 
(Dai, Chen et al. 2009, Yan, Dai et al. 2010, Aksamitiene, Kiyatkin et al. 2012). Further 
investigation is required to find the mechanism that mediates resistance to apoptosis by AKT 
inhibition in platinum resistant ovarian cancer cells. In conclusion it was demonstrated that 
AKT inhibition is sufficient to sensitise platinum resistant ovarian cancer cells to cisplatin in 
vitro and in vivo. These findings are in agreement with previous findings that resistance to 
platinum is mediated by AKT in ovarian cancer cells (Stronach, Chen et al. 2011).  
 
In summary, these findings suggest the potential ability of GSK2141795 to be used in the 
clinic specifically to restore sensitivity to platinum in ovarian cancer patients who have 
relapsed with platinum resistant disease. Therefore, GSK2141795 was selected as a 
candidate compound to be further developed in combination with platinum-based 
chemotherapy in a clinical trial in patients with relapsed resistant ovarian cancer. The pre-
clinical development of this compound prior to a phase I clinical trial in patients with ovarian 
cancer is described in the next chapter.  
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4 Utility of FDG-PET imaging as a 
pharmacodynamic marker of AKT 
inhibition using GSK2141795 
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4.1 Introduction  
 
The development of drugs for treatment of cancer remains a slow and high-risk process with 
many compounds failing due to unfavourable pharmacokinetic profiles, toxicity and and/or  
lack of therapeutic efficacy (Neidle 2008). The high failure rate contributes to the high cost in 
both financial and human terms of drug development. The reasons for the high failure rates 
have been extensively reviewed by Workman et al, and a ‘Pharmacological audit trail’ 
(PHAT) suggested to minimise failure risks (Workman 2002, Workman 2003) .  
 
A key area of increased focus aimed at improving the probability of success in the drug 
discovery process, is the identification and validation of reliable pharmacodynamic (PD) 
biomarkers of target modulation by the drug, that can be used both during  pre-clinical and 
clinical development, and ideally can also be correlated with clinical outcome. One approach 
clinically is to use tumour biopsies taken before and after drug treatment to measure 
modulation of PD makers. PD biomarkers may include cellular, molecular, histopathological 
and/or imaging parameters (Sarker, Pacey et al. 2007, Sarker and Workman 2007). It is 
anticipated that such PD biomarkers should clearly enable efficient and scientifically-driven 
“Go/NoGo” decisions allowing expediency of the drug development process. 
 
In the case of AKT inhibitors, AKT substrates such as phospho-PRAS40, are being used as 
PD biomarkers (Yan, Serra et al. 2013). However, the invasive nature of serial tumour 
biopsies in patients limits its application and recruitment in clinical trials. In addition, intra-
patient tumour heterogeneity can also limit the utility of tumour biopsies from single sites. 
The development of non- invasive PD biomarkers therefore has the potential to aid clinical 
drug development. 
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Positron emission tomography (PET) is a non-invasive imaging technology that measures 
the three dimensional spatial and temporal uptake of a radioligand in vivo, and is widely 
used in the field of oncology, with fluorine-18 radiolabelled fluorodeoxyglucose ([18F]FDG) 
being the most commonly used PET tool for diagnostic imaging of tumours. [18F]FDG is a 
glucose analogue. The hydroxyglutl group at the 2' of glucose is substituted by radioactive 
isotope fluorine-18 in this molecule. Both molecules are taken up by glucose transporters 
and follow the same path to pass into the cell. Inside the cell, glucose and FDG are both 
phosphorylated by hexokinases (HK) to glucose-6-phosphate and FDG-6-phosphate. The 2'-
hydroxyl group is needed for further metabolisation of glucose and as [18F]FDG lacks this 
hydroxyl group, it is trapped within the cell. As a result, the distribution of [18F]FDG is a good 
reflection of distribution of cellular glucose uptake (Aboagye and Price 2003). [18F]FDG is 
trapped in highly metabolically active cells, such as malignant cells which have high glucose 
uptake, thereby facilitating functional imaging and distinction between malignant and healthy 
tissue. However, some normal tissues with high glucose uptake such as the brain also 
display high [18F]FDG uptake. [18F]FDG uptake in tissues following drug treatment can 
provide a sensitive, qualitative and quantitative early PD readout of the cytostatic or cytotoxic 
action of cytotoxic drugs in vivo and in clinical practice. Given the role of AKT in the 
regulation of glucose metabolism, [18F]FDG-PET could also serve as a powerful tool in 
assessing the action of AKT inhibitors on tumour metabolism in vitro and in vivo (Aboagye 
and Price 2003, Boss, Olmos et al. 2008). AKT has an important role in cellular glucose 
uptake and metabolism regulation through the regulation of transcription and plasma 
membrane localisation of glucose transporter 1, the principle glucose transporter expressed 
in most cell types. AKT also mediates membrane translocation of GLUT4. PI3K/AKT 
pathway also regulates glycolysis by regulating hexokinase localisation into mitochondria 
and glucose phosphorylation. AKT also promotes glycolysis within the cell by 
phosphorylation of GSK3-β, therefore inhibition of glycogen synthesis.  
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In this chapter the utility of FDG-PET imaging as a non-invasive PD marker for AKT 
inhibition using GSK2141795 will be explored. The goal was to correlate changes in glucose 
metabolism (as measured by changes in FDG uptake) with changes in downstream 
biomarkers (phospho-PRAS40) of AKT inhibition in cell lines. If FDG-PET could be 
established as a marker of AKT inhibition in cell lines and this relationship confirmed in vivo, 
then FDG-PET could be used to guide individualised dose selection, thereby optimising the 
risk/benefit profile of the drug in clinical trials and clinical practice. 
 
Most pre-clinical approaches to PET tracer development in oncology use 2D monolayer 
cultures prior to in vivo studies. 2D monolayers lose their three dimensional cell contact and 
only communicate along a small proportion of their membrane therefore they may not be a 
very useful tool in predicting the efficacy of drug or radio-tracer up-take by cells in three 
dimensional in vivo micro-environment. Over the last two decades, 3D cultures (spheroids) 
have been used in studies involving angiogenesis, multicellular drug resistance, drug 
penetration and many other aspects of tumour biology (Frankel, Buckman et al. 1997, 
Desoize and Jardillier 2000, Oudar 2000, Sonoda, Kobayashi et al. 2003, Wartenberg, 
Schallenberg et al. 2003, Wrobel, Debnath et al. 2004). Nevertheless to date only one study 
has evaluated the use of 3D spheroid assays for optimisation of several PET tracers 
including FDG in the breast cancer cell line MCF7, exposed to doxorubicin, paclitaxel, 
docetaxel, tamoxifen or imatinib (Monazzam, Josephsson et al. 2007). 
 
The aim of this chapter was to access the potential utility of FDG-PET as a PD biomarker of 
AKT inhibition using GSK2141795 in vivo and the relative merits of in vitro optimisation using 
2D and 3D MTS. A translational imaging approach was used to provide pertinent 
translational information regarding the AKT inhibitor, GSK2141795, prior to its clinical 
assessment. Such data was essential in the design of clinical studies incorporating this drug. 
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Multi-cellular ovarian tumour spheroids (MTS; 3D) as well as 2D cell monolayers were used, 
initially, to determine the optimum dose and scheduling for GSK2141795, and also to predict 
the in vivo response. Subsequently, pre-clinical [18F]FDG PET studies using ovarian cancer 
mouse xenograft models were conducted, and the results of these studies were used to 
translate the does and optimal time to scan into the clinical study design. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
121 
 
4.2 Results 
 
4.2.1 Effect of inhibition of AKT by GSK2141795 on phosphorylation of the 
pharmacodynamic biomarker PRAS40 in 2D and 3D in vitro models 
 
To confirm the ability of GSK2141795 to inhibit AKT signalling in SKOV3 cells, 2D 
monolayers and 3D MTS were treated with GSK2141795 for 48 and 72 hours and analysed 
for phosphorylation of its downstream substrate PRAS40 with enzyme-linked 
immunosorbent assays (ELISA). Treatment with GSK2141795 resulted in a concentration-
dependent reduction in the ratio of phosphorylated PRAS40 (Thr246) to total PRAS40 in 
both SKOV3 monolayers and 3D MTS (Figure. 4.1 and 4.2). Phosphorylation of PRAS40 at 
Thr246 was reduced to <1% pre-treatment level in SKOV3 monolayers treated with 
GSK2141795 (5 µM) for both 72 hours (Figure. 4.1, b) and 48 hours (Figure. 4.1, a) but this 
reduction in phosphorylation was only partial (~50% of the pre-treatment level) in the 3D 
model at 5 µM, perhaps reflecting incomplete penetration of the compound into the 3D 
spheroids (Figure. 4.2).  
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Figure 4-1 Concentration-dependent effect of AKT inhibition by GSK2141795 on phospho-
PRAS40 (Thr246) expression in SKOV3 monolayers following 48 (A) and 72 (B) hours 
exposure 
Protein concentration of phospho-PRAS40 (Thr246) and total PRAS40 was determined by 
enzyme-linked immunosorbent assay (ELISA) after treatment with a range of concentrations of 
GSK2141795 (0.01 – 5 µM) in monolayers, where treatment resulted in a concentration-
dependent decrease in expression of phospho-PRAS40 (Thr246). Data are presented as a 
phospho-PRAS40 / total PRAS40 decrease relative to untreated samples. Data are the means ± 
SEM of n = 2 experiments performed in triplicate 
SKOV3 monolayer culture 
48 hours 
72 hours 
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Figure 4-2Concentration-dependent effect of AKT inhibition by GSK2141795 on phospho-
PRAS40 (Thr246) expression in SKOV3 MTS’s following 48 (A) and 72 (B) hours exposure. 
 Protein concentration of phospho-PRAS40 (Thr246) and total PRAS40 was determined by 
enzyme-linked immunosorbent assay (ELISA) after treatment with a range of concentrations of 
GSK2141795 (0.01 – 5 µM) in MTS’s, where treatment resulted in a concentration-dependent 
decrease in expression of phospho-PRAS40 (Thr246). Data are presented as a phospho-
PRAS40 / total PRAS40 decrease relative to untreated samples. Data are the means ± SEM of n 
= 2 experiments performed in triplicate (B) and n=1 experiment performed in triplicate (A). 
SKOV3 MTS 
 72 hours 
48 hours 
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4.2.2 Effect of AKT inhibition by GSK2141795 on [3H]FDG uptake in 2D and 3D in 
vitro models of ovarian cancer  
 
 
The influence of GSK2141795 on [3H]FDG uptake in SKOV3 2D monolayers and 3D MTS 
was assessed. In order to define the optimum incubation time with [3H]FDG in vitro, SKOV3 
MTS were grown for 7 days and then treated with GSK2141795 (1μM or 5μM) for 48 or 72 
hours. MTS were then incubated with [3H]FDG for between 30 minutes to 24 hours prior to 
the measurement of the [3H]FDG levels in each spheroid. The same experiment was done 
using SKOV3 2D monolayers except cells were treated with GSK2141795 for 24 hours prior 
to the measurement of [3H]FDG levels in cells instead of 48 hours due to the greater growth 
inhibitory effect of GSK2141795 on 2D monolayers compared to MTS.  
 
[3H]FDG uptake into vehicle treated monolayers and MTS reached a plateau at 6 and 10 
hours, respectively (t½ = 0.52 hours (monolayers) and 3.04 hours (MTS) (Figures 4.3 and 
4.4).  Treatment with GSK2141795 resulted in a dose-dependent decrease in the rate of 
FDG uptake with  treatment (t½ = 0.41 and 0.53 hours for 1 and 5 µM, respectively 
(monolayers); and 5.79 and 4.30 hours for 1 and 5 µM, respectively (MTS) (Figures 4.3 and 
4.4).  
 
Although maximal uptake of [3H]FDG into SKOV3 monolayers and MTS occurred at 
approximately 6 and 10 hours respectively, it is not possible to use these time points when 
scanning patients in the clinic, i.e. they are not clinically feasible due to the short half-life of 
18F (110 minutes), Therefore, in addition, concentration-response studies utilising 
GSK2141795 were repeated in SKOV3 monolayers at 2 hours (optimum time for clinical 
scanning; Figure 4.5) and MTS at both 2 and 6 hours (6 hours = optimum time for  
incubation of the tumours with radio-tracer; Figure 4.6). A small 25% concentration-
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dependent decrease in [3H]FDG uptake was observed in the SKOV3 monolayers (ED50 = 
0.22 µM; Figure 4.5) which plateaued at ~1 µM GSK2141795. In contrast, a 78% - 80% 
dose-dependent decrease in FDG uptake was observed in the SKOV3 MTS at both the 2 
and 6 hour time-points, again reaching a plateau at ~1 μM. The ED50 values were similar for 
monolayer (EC50 = 0.22 µM) and MTS culture (ED50 = 0.42 µM (2 hours) and 0.18 µM (6 
hours); (Figure 4.6).  
 
4.2.3 Decrease in FDG uptake with GSK2141795 correlates with the decrease in 
PRAS40 phosphorylation – a biomarker of AKT inhibition 
 
 
The relationship between decreases in FDG uptake in cells and changes in downstream 
markers of AKT pathway inhibition (phospho-PRAS40/total PRAS40) induced by 
GSK2141795 were evaluated in SKOV3 monolayers and MTS. The decreases in FDG 
uptake and phospho-PRAS40/total PRAS40 were strongly positively correlated over the 
range of GSK2141795 concentrations in both SKOV3 monolayers (R2=0.910) (Figure 4.7 A) 
and MTS’s (R2=0.979, Figure 4.7 B). Given that PRAS40 phosphorylation is a validated PD 
biomarker of AKT inhibition by GSK2141795, as shown in figures 4.1 and 4.2, this suggests 
that FDG uptake may also be used as a PD biomarker for GSK2141795 mediated AKT 
inhibition. 
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Figure 4-3 Time-course of [3H]FDG uptake in SKOV3 monolayers pre-incubated with 
either vehicle or GSK2141795 (1 and 5 µM) for 24 hours. 
SKOV3 monolayers were pre-incubated with either vehicle or GSK2141795 (1 and 
5 µM) for 24 hours and were exposed to [3H] FDG for a range of time intervals (1 – 24 
hours). Treatment with GSK2141795 reduced the amount of FDG uptake in SKOV3 
monolayers in a dose and time dependent manner.  DPM = decays per minute. n=1.  
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Figure 4-4 Time-course of [3H] FDG uptake in SKOV3 MTS pre-incubated with GSK-
2141795 for 48 hours.  
SKOV3 MTS were pre-treated with GSK2141795 (1 or 5 µM) and were exposed to [3H] 
FDG for a range of time intervals. [3H]FDG uptake into SKOV3 MTS reduced following 
exposure of SKOV3 spheroids to GSK2141795 in a concentration-dependent manner. 
The optimum in vitro incubation time with [3H]FDG was determined to be from 6 hours . 
Data are the means ± SEM of n = 3 experiments performed in triplicate. 
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Figure 4-5 Dose response decrease in [3H]FDG uptake in SKOV3 monolayers 
treated with GSK2141795. 
 SKOV3 monolayers were exposed to GSK2141795 for 24 hours and incubated with 
[3H]FDG for 2 hours. Treatment with GSK2141795 reduced the amount of FDG 
uptake in SKOV3 monolayers in a dose and time dependent manner. Data are the 
means ± SEM of n = 3 experiments performed in triplicate. 
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Figure 4-6 Concentration-dependent decrease in [3H]FDG uptake in SKOV3 
MTS’s treated with GSK2141795.  
SKOV3 MTS’s were exposed to GSK2141795 for 48 hours and incubated with 
[3H]FDG for 2 hours  and 6 hours .  Data shows a clear dose-response in MTS 
incubated with [3H]FDG for either 2 hours (clinical scan time following FDG 
administration) or 6 hours (favourable in vitro time-point for optimum signal to noise). 
Data are the means ± SEM of n = 3 experiments performed in triplicate. 
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Figure 4-7 Correlation between expression levels of phospho-PRAS40 (Thr246) and 
[3H]FDG uptake into SKOV3 monolayers (A) and MTS’s (B) following treatment with 
GSK2141795.  
SKOV3 monolayers and MTS’s were treated with GSK2141795 for 48 hours. Analysis 
revealed expression levels of pPRAS40 in SKOV3 monolayers and MTS’s exposed to 
GSK2141795 correlated closely with [3H]FDG uptake, R2 values = 0.910 and 0.979, 
respectively. 
 
Monolayers 
MTS 
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4.2.4 Effect of GSK2141795 on [18F]FDG uptake in ovarian cancer tumour xenografts 
 
The utility of [18F]FDG uptake as a PD biomarker for GSK2141795  was assessed in vivo 
using SKOV3 xenografted mice. Mice bearing subcutaneous SKOV3 xenografts were fasted 
overnight and treated with 10mg/kg, 20mg/kg or 30mg/kg of GSK2141795 for 5 hours. 
Control animals were treated with vehicle (DMSO/PEG) for the same length of time. 
GSK2141795 treatment resulted in a dose-dependent decrease in tumour FDG uptake 
compared to control animals (Figures. 4.8 and 4.9). Analysis of the effect of GSK2141795 on 
[18F]FDG uptake into SKOV3 xenografts indicated a reduced [18F]FDG signal compared to 
vehicle reaching a maximum of 68% at the highest dose of 30 mg/kg of GSK2141795 
(p<0.05) used in this study.  
 
The relationship between the duration of the treatment and FDG uptake was also 
investigated. SKOV3 tumour bearing mice were treated with 30 mg/kg of GSK2141795 for 
time ranging from 1 to 72 hours prior to [18F]FDG administration (one animal per time point). 
Treatment with GSK2141795 at a dose of 30 mg/kg resulted in a rapid decline of [18F]FDG 
uptake in a time-dependent manner, reaching a maximum of 75% decrease at approximately 
50 hours and continued up to 72 hours post-treatment (Figure 4.10).  
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Figure 4-8 Positron emission tomography (PET) images of SKOV3 xenograft models 
treated with vehicle (a) or 30 mg/kg GSK2141795 (b) for 5 hours. 
SKOV3 xenografts were treated with vehicle or 30 mg/kg GSK2141795 for 5 hours before 
being subjected to 60 min dynamic [18F]FDG PET scan. A decrease in FDG uptake in 
tumours was observed in mice treated with GSK2141795 compared to the vehicle group 
Control PET images are co-registered with the CT images of the same animal to localise the 
PET signals. Images correspond to the same representative animal for each condition in 
three planes: axial, coronal and sagittal. The colour scale for all PET image data shows 
[18F]FDG uptake in units of %ID/g (the percent injected dose per gram of tissue), with red 
corresponding to the highest activity and blue to the lowest activity. Arrows indicate the 
location of tumours. 
 
A 
B 
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Figure 4-9Uptake of [18F]FDG into tumours of SKOV3 xenografted mice following 5 
hours drug treatment (10 - 30 mg/Kg).  
SKOV3 xenograft-bearing mice were treated with either vehicle or GSK2141795. 
Standardized uptake value (SUV) were determined via [18F]FDG imaging for each treatment 
group. Treatment of SKOV3 xenografts with GSK2141795 led to a dose-dependent 
decrease in mean [18F]FDG SUV in each treatment group compared to vehicle controls . n=3 
per dose except for 20 mg/Kg where n=1),  *p<0.05 compared to vehicle treated animals. 
Data shown are mean ± SEM. SUV = standardised uptake values; AUC = area under the 
curve. 
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Figure 4-10 Time-course of tumour [18F]FDG uptake in SKOV3 tumour xenografts in 
mice treated with GSK2141795. 
 SKOV3 xenograft bearing mice were treated with 30 mg/kg of GSK2141795 and tumours 
were imaged by small [18F]FDG PET at different time points  after treatment. Tumour time 
radioactivity curves were generated by calculating the ratio of the tumour to plasma uptake 
at each time point. GSK2141795 treatment resulted in a decrease in tumour FDG uptake 
compared to the control animals (t = 0) in a time-dependent manner (n = 1 animal / time 
point).  
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4.2.5 Pharmacokinetic analysis of GSK2141795 in the SKOV3 tumour xenograft 
model of ovarian cancer 
 
To determine the level of GSK2141795 in blood and tumours a pharmacokinetic analysis 
was performed. Concentrations of GSK2141795 in tumour and blood taken from the in vivo 
SKOV3 xenograft time-course studies were measured. GSK2141795 accumulated in the 
SKOV3 xenograft tumours during the first 24 hours after treatment, with the t½ of the drug in 
the tumour determined to be ~12.5 hours (Figure 4.11 A). In comparison, levels of 
GSK2141795 were found to be maximised in the blood after 60 minutes following dosing (> 
4000 ng/ml, decreasing rapidly to less than 1000 ng/ml within 4 hours (Figure 4.11 B). The 
ratio tumour to blood GSK2141795 concentrations showed a peak at 12 hours (ratio 22) 
declining to 9 by 24 hours and 2 by 48 hours (Figure 4.11 C).  
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Figure 4-11 Pharmacokinetic data for GSK2141795 accumulating in xenograft tumours (A) 
and xenograft blood (B) up to 72 hours; with the subsequent ratio of tumour to blood (C).  
SKOV3 tumour bearing mice were treated with 30 mg/kg GSK2141795 for 1, 4, 8, 12 ,24, 48 or 72 
hours and tumour and plasma samples were collected. Tumour or blood samples collected at the 
same nominal times were pooled and GSK2141795 concentration in each sample was determined 
using mass spectrometry (MS). Blood concentration of GSK2141795 peaks within the first 60 
minutes following the treatment and then decreases dramatically whereas the concentration of the 
compound in the tumour increases gradually following treatment.  
 
Ratio Tumour / blood 
Blood 
Tumour xenografts 
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4.2.6 Effect of inhibition of AKT inhibition by GSK2141795 on phosphorylation of the 
pharmacodynamic biomarker PRAS40 in human ovarian cancer xenografts 
 
To assess the effect of inhibition of AKT using GSK2141795 on the phosphorylation of the 
downstream target PRAS40 in vivo, mice bearing SKOV3 xenografts were treated with 30 
mg/kg GSK2141795, and after 5 hours animals were sacrificed, tumours harvested and the 
levels of total and pPRAS40 were determined in each sample by ELISA.  
 
In addition mice bearing xenograft tumours were treated with combination of 1.5 mg/kg 
cisplatin and 30 mg/kg GSK2141795 or only cisplatin. When two drugs were combined, 
animals were treated with GSK2141795 two hour prior to the receiving of the cisplatin. 
Tissues were harvested 3 hours after the dosing with cisplatin and total protein was 
extracted from each tumour. Level of pPRAS40 in each sample was determined using 
ELISA.  
 
Levels of phosphorylated PRAS40 were significantly reduced in SKOV3 xenografts following 
treatment with either GSK2141795 as a single agent (p<0.01) or in combination with 
cisplatin (p<0.05; Figure 4.12). This effect was not observed when cisplatin was used as a 
single agent in the xenografts, and therefore suggests that FDG-PET is a useful PD 
biomarker for AKT inhibition even in the context of combination cisplatin treatment.  
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Figure 4-12 Concentration-dependent effect of AKT inhibition by GSK2141795 on 
phospho-PRAS40 (Thr246) level in SKOV3 xenografts  
 
GSK2141795 (30 mg/Kg) abolished phosphorylation of PRAS40 at Thr246, both as single 
agent and in combination with cisplatin (cddp), in SKOV3 tumour xenografts, indicating the 
effective inhibition of AKT by GSK2141795 (mean of each treatment group is normalised to 
the mean of the vehicle group. n= 5 tumours). Data are presented as a phospho-PRAS40 / 
total PRAS40 decrease relative to untreated samples. Data are shown as the mean ± SEM for 
n = 5 animals (tumours) . *p<0.05 and **p<0.01, where the symbols * and # represent 
significant differences when compared to vehicle and cisplatin data, respectively.  
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4.3 Discussion  
 
Findings described in chapter 3 suggested the potential ability of GSK2141795 to be used in 
combination with cisplatin to restore sensitivity to platinum in ovarian cancer patients. 
However, combining anti-cancer agents in the clinic is not always easy; doses of drugs used 
in combination often have to be reduced compared to when they are given as mono-
therapies. Yet it is not always clear that the reduced dose will have the same effects on the 
target pathway, i.e. what is the minimal level of pathway inhibition required to maintain 
efficacy in a given situation. Ideally, quantification of pathway inhibition would be done with 
serial biopsies of a patient’s tumour before and after drug treatment, in order to evaluate 
levels of phosphorylated AKT substrates. However, clinical implementation of this approach 
is challenging due to the reluctance of many patients to undergo repeat biopsies, lack of 
biopsiable tumours in all patients and tumour heterogeneity amongst other reasons. 
Therefore having a way to measure pathway inhibition in a non-invasive fashion would be 
very helpful to this process. 
 
Positron emission tomography (PET) with [18F]fluorodeoxy glucose (FDG-PET) evaluates 
cancer cells glycolysis as a surrogate for tumour response to chemotherapy. Two 
independent studies in 2002 and 2003 showed that early changes in FDG-PET signal can be 
used to predict imatinib response in gastrointestinal stromal tumours (Van den Abbeele and 
Badawi 2002, Stroobants, Goeminne et al. 2003). These findings led to much interest in 
using FDG-PET imaging as a predictive marker of response in development of novel cancer 
drugs.  
 
Mechanistically, AKT activation causes increased transcription and plasma membrane 
localisation of Glucose Transporter 1 (GLUT1), a protein which facilitates transport of 
140 
 
glucose across the plasma membrane of mammalian cells. Membrane bound GLUT1 is an 
important mediator of FDG uptake in most of cancer cells (Brown, Goodman et al. 2002, 
Plas and Thompson 2005). Immunohistochemical studies have revealed decreased GLU1 
staining in both plasma membrane and cytosol following PI3K/AKT/mTOR pathway inhibition 
in pancreatic tumour cells indicating that AKT inhibition inactivated GLUT1 transcription (Ma, 
Jacene et al. 2009). In addition, immunohistochemical studies on pancreatic tumours from 
patients treated with the mTOR inhibitor, temsirolimus, indicated a higher cytosolic to plasma 
membrane fraction of GLUT1, suggesting that PI3K/AKT/mTOR pathway inhibition disrupts 
the translocation of GLUT1 to plasma membrane (Ma, Jacene et al. 2009). AKT also 
regulates the translocation of Glut4 to the plasma membrane. Given the role of AKT in the 
regulation of glucose metabolism, [18F]FDG-PET could serve as a powerful tool in assessing 
the effectiveness of AKT inhibitors in tumour cells.  
 
The preclinical FDG-PET studies described in this chapter provide the justification for using 
FDG-PET to evaluate the effects of GSK2141795 on tumour glucose metabolism in the 
clinic, as well as the confidence that inhibition of glucose metabolism correlates strongly with 
AKT inhibition. Identical FDG-PET studies were performed using SKOV3 cells as (1) 
monolayers, (2) MTS and (3) in vivo xenografts. This allowed for comparison of the data 
obtained with the three models in order to determine the inter-predictability of each model 
and the relationship between changes in phospho-PRAS40 and FDG uptake in various 
models. Data described in this chapter shows that although phospho-PRAS40 levels were 
decreased by >50% in all 3 model systems, only MTS and in vivo xenografts showed >50% 
decrease in FDG uptake, suggesting that MTS may be a better in vitro representation of in 
vivo physiology than monolayer cultures. The decreases in FDG uptake and phospho-
PRAS40/total PRAS40 were strongly positively correlated. Given that PRAS40 
phosphorylation is a validated PD biomarker of AKT inhibition by GSK2141795, this finding 
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suggests that FDG uptake can also be used as a PD biomarker for GSK2141795 mediated 
target inhibition. 
 
Although the decrease in FDG uptake by GSK2141795 was observed in both 2D and 3D in 
vitro models used in this study, the effectiveness of the compound was shown to be greater 
in the 3D model and more closely resembled the effects observed in vivo. This observation 
suggests that 3D models may be more suitable, efficient and predictive models than 2D 
models in determining dose and schedule optimisation prior to in vivo experiments. This may 
be important in minimising the cost of the studies and the use of animals in translational 
approaches.  
 
The MTS studies also demonstrated a concentration-dependent decrease in FDG imaging 
signal following GSK2141795 administration, which was reproduced in xenograft studies. 
These data, coupled with the PK data obtained from xenograft studies, predict that 
concentrations ≥1 μM GSK2141795 would be required to determine the maximal decrease 
in phospho-PRAS40 and FDG uptake.  
 
In summary, these results demonstrate that the pan-AKT inhibitor, GSK2141795, inhibits 
AKT signalling in platinum-resistant ovarian cancer cells lines in vitro and in vivo, and that 
[18F]FDG uptake could be used as a non-invasive pharmacodynamic marker for guiding 
dose selection in ovarian cancer patients in future studies. These results found the rational 
for a phase I clinical trial of GSK2141795, an open label study to investigate the 
pharmacokinetics and pharmacodynamics of repeat escalating doses of the oral AKT 
inhibitor GSK2141795 by 18F FDG PET analysis in subjects with ovarian cancer 
(www.clinicaltrials.gov).  
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5 Comparison of the effect of AKT, 
PI3K and DNA-PK inhibition, in 
combination with cisplatin on cell 
proliferation and apoptosis 
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5.1 Introduction 
 
Chapter 3 demonstrated that AKT inhibition with the small molecule GSK2141795 restored 
sensitivity to cisplatin in ovarian cancer platinum resistant cells both in vitro and in xenograft 
models. It has previously been shown that treatment of platinum resistant cells with csiplatin, 
results in AKT translocation into the nucleus where it is phosphorylated at S473 by catalytic 
subunit of DNA-dependent protein kinase (DNA-PKcs). This DNA-PK mediated pro-survival 
mechanism does not appear to occur in platinum sensitive cells, PEO1 and PEA1. DNA-PK 
inhibition was shown in this study to prevent cisplatin-induced phosphorylation of AKT at 
S473, but not at T308. Moreover it was found that cisplatin-mediated AKT activation is 
mTORC2 independent (Stronach, Chen et al. 2011). 
 
DNA-PK is a nuclear serine/threonine kinase. It is composed of two DNA binding proteins, 
Ku70 and Ku80 and a 470-kDa catalytic subunit, DNA-PKcs. DNA-PK plays a crucial role in 
nonhomologous end-joining (NHEJ) DNA repair. Ionizing radiation and radiomimic drugs 
induce double-strand breaks (DSB) that are mainly repaired by non-homologous end joining 
(NHEJ). In this process the two ends of DNA strand break are connected and resealed 
without the need for sequence homology between the ends (Mahaney, Meek et al. 2009). 
NHEJ double-strand DNA (dsDNA) break repair process is in contrast with the homologous 
recombination (HR) dsDNA break repair process in which DNA sequence from an intact 
DNA molecule, often the newly synthesised sister chromatid, is used to repair replication 
lesions (Arnaudeau, Lundin et al. 2001). In NHEJ DNA repair process each broken DNA end 
is first bound by one Ku 70/80 heterodimer and two heterodimer must come together to 
bridge matching ends to ensure efficient ligation. This complex is bound by the DNA-PK 
catalytic subunit which stabilises the protein/DNA binding therefore enabling the NHEJ DNA-
repair process to carry on. The ligation of the DNA ends is accomplished by the 
XRCC4/ligase IV complex subsequently attracting the DNA-PKcs subunit. Together with 
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ataxia-telangiectasia and Rad3 related (ATR) and ataxia-telangiectasia mutant (ATM), DNA-
PKcs forms a critical early component of the DNA damage response (Anderson and Lees-
Miller 1992, Collis, DeWeese et al. 2005, Chen, Uematsu et al. 2007). DNA-PKcs, ATM and 
ATR are members of the PI3K-related protein kinases family (PIKKs). Members of the PIKKs 
family phosphorylate target proteins on serine or threonine residues using a C-terminal 
region related to the catalytic domain of PI3K. Other members of this family include 
mammalian target of rapamycin (mTOR), the catalytically inactive 
transformation/transcription domain-associated protein (TRRAP) and suppressor with 
morphological effect on genitalia 1 (SMG1) (Cimprich and Cortez 2008). 
 
DNA-PK activation is regulated by phosphorylation. To date several phosphorylation sites of 
DNA-PK are identified which are differently phosphorylated dependent on the stimuli. For 
example, phosphorylation at Thr-2638/Thr-2647 is essential for radio-resistance conferred 
by DNA-PKcs (Soubeyrand, Pope et al. 2003).  
 
In the classical model of AKT activation, PI3K acts upstream of AKT by phosphorylating 
membrane bound phosphatidylinositol-4,5-bisphosphate (PIP2) to produce 
phosphatidylinositol-3,4,5-triphosphate (PIP3); a second messenger that binds to the 
plectstrin homology (PH) domain of AKT, recruiting AKT to the plasma membrane. AKT is 
then phosphorylated by phosphoinositide-dependent kinase 1 (PDK1) at Thr308. 
Phosphorylated AKT in turn regulates a wide range of target proteins that control cell growth, 
proliferation, survival, and glucose metabolism (Bellacosa, Kumar et al. 2005) . In this model 
it is believed that phosphorylation of AKT at T308 by PDK1 is required for activation of AKT.  
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In this chapter it was investigated if nuclear DNA-PK mediated activation of AKT in response 
to cisplatin in platinum resistant cells is dependent or independent of PI3K activation. In this 
chapter, firstly the effect of DNA-PK or PI3K inhibitions with small molecular inhibitors of 
DNA-PK (NU7441) and PI3K (GSK2126485) on cisplatin sensitivity in ovarian cancer cells 
was assessed in vitro and in xenograft models. Furthermore, PIK3CA and PIK3R1 depleted 
cells were used to investigate whether the nuclear DNA-PK mediated activation of AKT, in 
response to cisplatin, is dependent on activation of PI3K. 
 
 NU7441 (8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one) is a highly potent and 
selective DNA-PK inhibitor (IC50 = 14 nM), exhibiting ATP-competitive inhibition kinetics 
(Leahy, Golding et al. 2004, Zhao, Thomas et al. 2006). GSK2126458 is a highly potent 
inhibitor of PI3K which displays great selectivity for PI3K compared with other members of 
the PI3K-related protein kinase family. PI3K acts up-stream of AKT in the PI3K/AKT 
signalling cascade (Wang, Harris et al. 2008, Leung, Kim et al. 2011).  
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5.2 Results 
 
 
5.2.1 Effect of DNA-PK inhibition on sensitivity to cisplatin in vitro 
 
 
To assess the effect of DNA-PK inhibition on restoration of sensitivity to cisplatin in vitro, 
cisplatin resistant SKOV3 and PEO4, were treated with a range of concentrations of a potent 
DNA-PK inhibitor, NU7441 as a single agent or in combination with cisplatin for 24 hours. 
Effect of the treatment with NU7441 on apoptosis was assessed by measuring the activity of 
caspase 3/7. Inhibition of DNA-PK by NU7441 resulted in sensitisation to cisplatin in a 
concentration dependent manner in both cell lines. In addition, single agent NU7441 was 
also found to induce apoptosis at higher concentrations (Figure. 5.1). 
 
5.2.2 Effect of DNA-PK inhibition of DNA-PK on tumour growth in vivo  
 
To assess the effect of DNA-PK inhibition by NU7441 as a single agent or in combination 
with cisplatin in vivo, mice bearing SKOV3 tumour xenografts were treated with vehicle, 
cisplatin (1mg/kg twice weekly) or two different doses of NU7441 (7.5 mg/kg or 10 mg/kg 
daily) as a single agent or in combination with cisplatin for 14 days. Treatment of xenografts 
with single agent NU7441 did not have any effect on tumour growth and tumours grew at the 
same rate as the vehicle control groups (Figure. 5.2). In addition, treatment of tumours with 1 
mg/kg cisplatin twice weekly did not slow tumour growth either. In contrast, DNA-PK 
inhibition in combination with cisplatin decreased tumour growth at 14 days by 89% 
(7.5mg/kg NU7441) (p < 0.05) and 90% (10mg/kg NU7441) (p <0.05), relative to platinum 
only (Figure. 5.2).  
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Figure 5-1 Caspase 3/7 activity in SKOV3 cells treated with the DNA-PK inhibitor 
NU7441 as single agent or in combination with cisplatin 
Cells were pre-treated with NU7441 for 1 hour prior to exposure to cisplatin for 24 hours. 
Treatment with NU7441 resulted in a significant increase in caspase 3/7 activity in 
response to cisplatin compare to cells which were treated with cisplatin only. Data 
shown are the means ± SEM of 3 experiments performed in triplicate. 
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Figure 5-2 inhibition of DNA-PK restored response to cisplatin in chemo-resistant ovarian 
cancer cells in vivo 
SKOV3 tumour cells were injected subcutaneously into the flanks of nude mice and treated with A) 7.5 
mg/kg or B) 10 mg/kg DNA-PKcs inhibitor, NU7441 daily (5 days on/2 days off) for 2 weeks alone or in 
combination with 1 mg/kg cisplatin twice weekly. DNA-PK inhibition or cisplatin alone were ineffective 
however in combination decreased tumour growth at 14 days by 89% (7.5 mg/kg NU7441) and 90% 
(10 mg/kg NU7441), relative to platinum only treatment. Data shown are the mean ± SEM for n = 5 
animals (tumours) / treatment. **p<0.01, 
NU7441 7.5 mg/kg 
NU7441 10 mg/kg 
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5.2.3 Effect of PI3K inhibition using GSK2126458 on sensitivity to cisplatin 
 
In order to examine if inhibition of PI3K modulates cisplatin resistance in ovarian cancer 
cells, cisplatin resistant SKOV3 and PEO4 cell lines were treated with a range of 
concentrations of PI3K inhibitor GSK2126458 (0.1 nM - 40 nM) alone or in combination with 
25 μM cddp for 24 hours. The dose range for GSK2126458 was selected based on the IC50 
value of this compound in those two cell lines which was between 10 - 20 nM in both cell 
lines (Figure. 5.3). Treatment with GSK2126458 as a single agent resulted in either no 
increase, or a very slight increase in the induction of caspase 3/7 activity in both cell lines 
after 24 hours (Figure. 5.4a and 5.4b). This was similar to what was observed in the same 
cell lines where treated with the AKT inhibitor GSK2141795 for the same length of time 
(Figure. 5.4 a and 5.4.b).  
 
In contrast with the AKT inhibitor GSK2141795, combination treatment of GSK2126458 with 
25 µM cddp did not increase caspase-3/7 activity above levels measured in cells treated with 
cddp alone in either SKOV3 or PEO4 cells (Figure. 5.4c and 5.4d). Similar results were 
found when the treatment time was increased to 72 hours (Figure. 5.5). The growth-
inhibitory effect of GSK2126458 was also assessed. However, as a single agent 
GSK2126458 was found to reduce cell viability in a dose dependent manner after 72 hours 
(Figure 5.6.a). Inhibition of the PI3K pathway by GSK2126458 was confirmed by measuring 
changes in the level of phosphorylation of the PI3K/AKT pathway PD biomarker PRAS40, in 
response to GSK2126458 treatment, which decreased in a dose dependent manner (Figure 
5.6.b).  
 
The effect of the inhibition of PI3K by GSK2126458 on the cisplatin IC50 curve in platinum 
resistant SKOV3 and PEO4 cells was also assessed. Cells were pre-treated with 
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GSK2126458 one hour prior to the treatment with a range of concentration of cisplatin (0.01 
– 100 µM). Pre-treatment with GSK2126458 did not result in any significant change to the 
cisplatin IC50 curve in PEO4 and SKOV3 cells (Figure. 5.7).  
 
In addition, reverse sequencing of the PI3K inhibitor and cisplatin treatments and  increasing 
the treatment time also did not result in any shift in the cisplatin IC50 curves in PEO4 and 
SKOV3 cells (Figure 5.8) (PEO4 data not shown).  
 
In conclusion neither post-treatment nor pre-treatment with GSK2126458, affected the 
sensitivity to cisplatin in SKOV3 and PEO4 cells.  
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A  
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Figure 5-3 The half maximum inhibitory concentration of (IC50) of GSK2126458 in 
SKOV3 (A) and PEO4 (B) 
 Cells were treated with a range of concentration of GSK2126458 for 72 hours 
(approximately three doubling time). Cell viability was assessed by MTT assay after the 
completion of the treatment time. Data shown are the means ± SEM of n = 3 experiments 
performed in triplicate.  
SKOV3 
PEO4 
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Figure 5-4 Caspase 3/7 activity (normalised to cell number) in SKOV3 and PEO4 
monolayers treated with GSK2126458 and GSK2141795 – A and B: single agent 
treatments. C and D: combination with cddp 
 SKOV3 and PEO4 monolayers were treated with a range of concentrations of GSK2126458 
for 24 hours as a single agent or in combination with cddp. Caspase 3/7 activity in cells 
treated with GSK2126458 was compared to caspase activity in cells treated with 
GSK2141795. Treatment with GSK2126458 did not affect induction of caspase 3/7 as a 
single agent or in combination with cddp whereas treatment with GSK2141795 re-sensitised 
cells to cddp. Data shown are the means ± SEM of n = 3 experiments performed in triplicate.  
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Figure 5-5 Comparison of the effect of 72 hours exposure to GSK2141795 and 
GSK2126458 on sensitisation to cisplatin in SKOV3 cells 
 SKOV3 cells were exposed to a range of concentration of the AKT inhibitor GSK2141795 or 
the PI3K inhibitor GSK2126458 as single agents or in combination with cisplatin for 72 
hours. GSK2141795 significantly increased caspase 3/7 activity in response to cisplatin in 
SKOV3 cells but treatment with GSK2126458 did not have any effect on sensitivity to 
cisplatin in the same cell line. Data shown are the means ± SEM of n = 3 experiments 
performed in triplicate.  
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Figure 5-6 Effect of the treatment with GSK2126458 on the cell viability (A) and 
the phosphorylation levels of PRAS40 (B) in SKOV3 cells 
SKOV3 monolayers were treated with a range of concentrations of GSK2126458 for 
72 hours. Effect of the compound on the cell viability was assessed by MTT assay. 
GSK2126458 inhibited cell growth in a dose dependent manner (A, n = 3).Treatment 
with GSK2126458 also resulted in a dose dependent reduction in pPRAS40 level (B, 
n = 2). Data shown are the means ± SEM of n = 2/3 experiments 
MTT assay PRAS40 phosphorylation 
    
[GSK2126458] nM [GSK2126458] nM 
A B 
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Figure 5-7 Effect of the exposure to GSK2126458 on IC50 curve of cisplatin in A) 
SKOV3 cells and B) PEO4 cells  
Cells were pre-treated with different concentrations of the PI3K inhibitor GSK2126458 prior 
to exposure to a range of concentration of cisplatin. Treatment with GSK2126458 did not 
result in any significant change to the cisplatin IC50 curve in neither of the examined cell 
lines. Data shown are the means ± SEM of n = 3 experiments. 
A 
B 
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Figure 5-8  Effect of the post treatment with GSK2126458 on cddp IC50 curve A) 
24 hours and B) 48 in SKOV3 cells 
Cells were treated with different concentrations of the pI3K inhibitor GSK2126458 
one hour after exposure to a range of concentration of cisplatin. Post-treatment with 
GSK2126458 for 24 or 48 hours did not result in any significant change to the IC50 
curve of cisplatin in SKOV3 cells. Data shown are the means ± SEM of n = 3 
experiments. 
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5.2.4 Effect of siRNA mediated PI3K knockdown on sensitivity to cisplatin in vitro  
 
To confirm that the inhibition of PI3K has no effect on sensitisation to cisplatin in the 
assessed cell models as observed with GSK2126458 , siRNA knockdown of genes 
encoding for the regulatory subunit (p85,PIK3R1) and catalytic subunit (p110α, 
PIK3CA) of PI3K was performed and the effect of knockdown on sensitisation to 
cisplatin examined.  
 
Knockdown of PIK3CA or PIK3R1 did not enhance apoptotic responses to cisplatin in 
the either platinum resistant SKOV3 and PEO4 cells compared with transfection 
controls (Figure 5.9). SIRNA knockdown of PIK3CA and PIK3R1 was confirmed by 
western blotting (Figure 5.10).  
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Figure 5-9 Effect of PIK3CA and PIK3R1 knockdown on apoptotic response to cisplatin in A) 
PEO4 and B) SKOV3 cells 
After knockdown of PIK3R1 and PIK3CA in platinum resistant cells PEO4 A) and SKOV3 B), cells 
were treated with cisplatin for 24 hours and caspase 3/7 activity was assayed. PIK3CA and PIK3R1 
knockdown did not result in any significant change to apoptotic response to cisplatin in SKOV3 and 
PEO4 cell lines. Data shown are the means ± SEM of n = 3 experiments. 
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Figure 5-10 Confirmation of PIK3CA and PIK3R1 knockdown in SKOV3 cells in vitro 
by western blotting  
SKOV3 cells were transfected with siRNA directed to PIK3CA, PIK3R1 or non-targeting 
control. Protein lysates were collected after 48 hours and expression of p110α (encoded by 
PIK3CA) and p85α (encoded by PIK3R1) were assessed by western blotting analysis. 
Western blotting analysis confirmed knockdown of PIK3CA and PIKR1 genes. Beta-tubulin 
was used as loading control. Representative images from n=3 experiments.  
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5.2.5 DNA-PK modulates response to cisplatin independent of PI3K in cisplatin 
resistant ovarian cancer cells  
 
To examine if PI3K is involved in modulation of response to cisplatin by DNA-PK, expression 
of both p85α and p110α subunits of PI3K were down-regulated by siRNA transfection of 
platinum resistant cells PEO4 and SKOV3 cells. Treatment of the transfected cells with the 
DNA-PK inhibitor NU7441 resulted in an similarly enhanced response to cisplatin as was 
seen in the non-transfected control cells, indicating that the DNA-PK dependent sensitisation 
to cisplatin in platinum resistant cells is not dependent on the expression of PI3K (Figure. 
5.11). 
 
In addition, PIK3CA and PIK3R1 depleted SKOV3 cells were treated with cisplatin for 2 
hours and the induction of pAKT S473 in response to cisplatin compared with control SKOV3 
cells. Phosphorylation of pAKT at S473 was increased in response to cisplatin regardless of 
the siRNA treatment. Moreover, inhibition of DNA-PK by NU7441 abolished the 
phosphorylation at S473 in response to cisplatin in the PI3K wild type cells as well as in 
PIK3CA and PIK3R1 siRNA transfected cells indicating that knockdown of either subunits of 
PI3K does not affect phosphorylation of AKT at S473 by DNA-PK. Treatment with cisplatin, 
NU7441 or combination of cisplatin and NU7441 did not affect the level of expression of total 
AKT in SKOV3 cells (Figure. 5.12).  
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Figure 5-11 Inhibition of DNA-PK with NU7441 in combination with PIK3CA and PIK3R1 
knockdown in platinum treated and untreated A) PEO4 and B) SKOV3 cells. 
SKOV3 cells were transfected with siRNA directed to PIK3CA, PIK3R1 or non-targeting control 
for 48 hours. SiRNA transfected cells were treated with NU7441 or cisplatin or combination of 
NU7441 and cisplatin for 24 hours followed by caspase 3/7 activity assessment. siRNA 
knockdown of PIK3CA and PIK3R1 genes did not affect the enhanced response to cisplatin in 
cells treated with NU7441 in combination with cisplatin compared with transfection controls. 
Data shown are the means ± SEM of 3–4 experiments performed in triplicate. *p<0.05 
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Figure 5-12 Effect of knocking down the PIK3CA and PIK3R1 subunits of PI3K on 
phosphorylation of AKT at S473 by DNA-PK  
SKOV3 cells were transfected with siRNA directed to PIK3CA, PIK3R1 or non-targeting control for 
48 hours followed by exposure to NU7441 or insulin or cisplatin or combination of cisplatin and 
NU7441 for 2 hours. Whole cell lysates were subjected to western blotting using pAKT (S473) and 
total AKT antibodies. Inhibition of DNA-PK with NU7441 abolished phosphorylation of AKT at S473 
in non-transfected cells (A) as well as in PIK3CA (B) and PIK3R1 (C) siRNA transfected cells. 
Representative images from n=2 experiments.  
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5.3 Discussion 
 
In chapter 3 AKT inhibition with GSK2141795 was shown to effectively sensitise platinum-
resistant cells to cisplatin in both in vitro and in vivo models. In this chapter it was further 
investigated whether targeting PI3K or DNA-PK can also sensitise tumour cells to platinum 
treatment in vitro and in vivo. It was demonstrated that inhibition of DNA-PK with a potent 
DNA-PK inhibitor, NU7441, sensitised platinum resistant ovarian cancer cells to cisplatin 
both in vitro and in ovarian cancer xenograft models. In contrast, inhibition of PI3K with a 
potent and selective small molecule inhibitor GSK2126458 did not affect sensitivity to 
cisplatin in the same cell model in vitro. It was further demonstrated that the effects of DNA-
PK activation on modulation of tumour cell resistant to cisplatin was independent of 
activation of PI3K.  
 
Wallin et al. reported an increase in phosphorylation of AKT at S473 in the nucleus of breast 
cancer cell lines, and also in a breast cancer xenograft model, following doxorubicin 
treatment, and demonstrated that this phosphorylation was mediated by DNA-PK (Wallin, 
Guan et al. 2010). This is in agreement with recent findings in our laboratory showing that in 
response to cisplatin, AKT is translocated into the nucleus where it is phosphorylated at 
S473 by DNA-PK. (Stronach, Chen et al. 2011). This translocation was observed only in 
ovarian cancer platinum-resistant cells and not in sensitive cells (Stronach, Chen et al. 
2011). Moreover, DNA-PK inhibition was shown to prevent cisplatin-induced phosphorylation 
of AKT at S473, but not at T308 (Stronach, Chen et al. 2011). Studies using DNA-PKcs-/-  
mice have demonstrated that DNA-PKcs is required for γIR induced DNA damage mediated 
activation of AKT but not insulin or growth factor induced activation (Surucu, Bozulic et al. 
2008). No increase in blood glucose was detected in DNA-PKcs deficient mice compared 
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with wild-type controls when treated with either glucose or insulin suggesting that DNA-PKcs 
is not involved in glucose or insulin induced activation of AKT.  
 In this chapter it was further investigated if modulation of platinum resistant by DNA-PK and 
AKT was dependent on activation of PI3K, up-stream of AKT.  
 
In chapter 3 it was also demonstrated that GSK2141795 combined with cisplatin increased 
apoptotic response to cisplatin in platinum-resistant 2D and 3D ovarian cancer cell models, 
and also in a platinum-resistant xenograft model. In the cell models examined, the enhanced 
apoptotic effect of cisplatin and GSK2141795 in combination with cisplatin was found to be 
synergistic. It was demonstrated in this chapter that inhibition of DNA-PK with NU7441 also 
restored sensitivity to cisplatin in vitro and in vivo. The importance of the role of DNA-PK in 
phosphorylation of AKT at S473 and activation of AKT in response to cisplatin has been 
already shown by our group and other groups. (Stronach, Chen et al. 2011). In the classical 
models of activation of AKT, it is believed that activation of PI3K up-stream of AKT is 
required for activation of AKT through phosphorylation at T308. In this chapter it was 
investigated if activation of PI3K is required for activation of AKT and DNA-PK in response to 
cisplatin. Interestingly, it was demonstrated in this chapter that re-sensitisation to cisplatin 
which was observed by inhibition of AKT or DNA-PK, was not observed when PI3K was 
inhibited using a potent selective PI3K inhibitor, GSK2126458, in the same cell models. 
However, inhibition of PI3K using GSK2126458 resulted in reduction in cell proliferation in a 
dose dependent manner. Inhibition of the AKT pathway by this PI3K inhibitor was confirmed 
by assessing the level of phosphorylation of the down-stream target, PRAS40. This finding is 
not in agreement with those of Westfall et al. who reported that inhibition of PI3K/AKT 
pathway by a potent PI3K inhibitor, LY294002, can sensitise ovarian cancer cells to the toxic 
effect of carboplatin (Westfall and Skinner 2005). However, it is important to bear in mind 
that LY294002 doesn’t display a great selectivity for PI3K against other members of the 
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PI3K-related protein kinases and inhibits DNA-PK as well as PI3K (Muller, Blackburn et al. 
2007) due to the great similarity between the sequence and structure of the catalytic subunit 
of PI3K and members of PI3K-related protein kinases.  
In addition, siRNA knockdown of PIK3CA and PIK3R1 genes, encoding for catalytic and 
regulatory subunits of PI3Kα, p110α and p85α respectively, did not sensitise platinum 
resistant cells to cisplatin. Although PI3K family is a large family of enzymes categorised into 
three classes and several subunits of PI3K are identified within each class, PI3Kα in 
particular has emerged as an attractive target for cancer therapeutic due to the high 
frequency of mutation and over-expression of this enzyme in many types of human cancers. 
Many PI3K inhibitors including GSK2126458 target the ATP binding site within the catalytic 
subunit of PI3Kα (McNamara and Degterev 2011). Therefore, in this study catalytic and 
regulatory subunits of PI3Kα were targeted by siRNA as they seemed to be mostly 
compatible with the effect of GSK2126458. 
 
In this study it was demonstrated that PI3K knockdown, did not affect the phosphorylation of 
AKT at S473 in response to cisplatin in platinum resistant cell lines. Moreover, Inhibition of 
DNA-PK by NU7441 abolished phosphorylation of AKT at S473 in response to cisplatin in 
PI3K knockdown cells and controls alike, indicating that this phosphorylation is mediated by 
DNA-PK independently of PI3K.  
 
Together, the findings in this chapter suggest PI3K independence of the role of AKT in the 
pro-survival response to DNA damage in platinum resistant tumour cells and that PI3K may 
not be involved in DNA-PK mediated activation of AKT in response to cisplatin treatment in 
platinum resistant ovarian cancer cells. It was also suggested that inhibition of PI3K may be 
less effective than inhibition of AKT or DNA-PK on reversal of platinum resistance in ovarian 
cancer. Previous studies in our group demonstrated that DNA-PK is not involved in 
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activation of AKT in response to insulin, separating DNA damage mediated effects from 
other physiological roles of AKT(Stronach, Chen et al. 2011). 
 
Collectively, it can therefore now be hypothesised that AKT becomes activated through 
different protein signalling cascades dependent on the stimuli. It appears that AKT activation 
in response to DNA damage is mediated by DNA-PK, in a PI3K independent manner, 
whereas AKT activation in response to insulin and growth factors is distinct from this 
mechanism.  
 
 
 
 
 
 
 
 
 
 
 
 
 
167 
 
 
6 The effect of AKT inhibition on 
downstream pathway activation 
alone or in response to platinum-
induced DNA damage 
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6.1 Introduction  
 
The high rate of failure of drug development in oncology has led to an increased emphasis 
on establishing a pharmacological audit trail (PHAT) (Yap, Sandhu et al.). 
 
.The emphasis of the PHAT is on testing all steps necessary for drug success systematically 
and sequentially starting in vitro and progressing eventually to the clinic. The purpose of 
these studies is to validate the proposed mechanism of action of drugs, and in addition to 
identify PD biomarkers to enable drug-target interaction to be measured, and also to develop 
predictive markers of activity. The PHAT thereby enables early data driven decisions on the 
continuation of development of a drug to minimise failures during the clinical phase. 
 
In Chapter 4, AKT and PRAS40 phosphorylation were validated as PD biomarkers of AKT 
inhibition by GSK2141795. However, these are immediate endpoints of AKT inhibition. Since 
the downstream AKT pathway and feedback loops are complex and varied, identification of 
the dominant effecter pathways associated with GSK2141795 associated growth arrest and 
apoptosis in combination with cisplatin, has the potential to represent response associated 
PD and predictive biomarkers. 
 
The purpose of studies discussed in this chapter was to identify PD biomarkers that measure 
the optimal inhibitory effects of GSK2141795 in cell lines, xenograft models and clinical 
tumour samples. Also to identify predictive biomarkers to be used for selection of patients 
who are most likely to respond to GSK2141795 treatment. For this purpose, tumour biopsies 
from ovarian cancer patients participated in a GSK2141795 dose-escalation phase I clinical 
trial were used. Identification of PD biomarkers would be beneficial for selection of 
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biologically active doses of GSK2141795 to support moving forward into phase I/II 
combination studies.  
In addition, this chapter is aimed to understand effects of inhibition of AKT alone or in 
combination with cisplatin on cellular signalling cascades in ovarian cancer cells. This 
information would contribute towards better understanding of mechanism of platinum 
resistance in ovarian cancer and signalling cascades leading to reversal of platinum 
resistance.  
 
In this chapter, the effect of the AKT inhibitor GSK2141795 on protein expression, and 
signalling cascades was therefore assessed, using Reverse Phase Protein Arrays (RPPA) 
(Tibes, Qiu et al. 2006). Similarly, the effect of GSK2141795 in combination with cisplatin 
was also assessed in vitro and in vivo to validate PD biomarkers identified for GSK2141795 
in chapter 4, and also to identify other canonical and non-canonical pathway PD biomarkers.  
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6.2 Results 
 
6.2.1 Effect of GSK2141795 on signalling cascades in ovarian cancer in vitro 
 
SKOV3 monolayers were treated with GSK2141795 (5 µM) for 30 minutes and 8 hours. 
Thirty minutes and 8 hour time points were chosen to identify early and late response PD 
biomarkers for GSK2141795 respectively.  Protein extracts from cells was analysed for 
alterations in protein expression using RPPA. Proteins showing less than 1.3 -fold difference 
between groups were discarded on the basis of unlikely biological relevance (Figure. 6.1 and 
6.2).  
 
In SKOV3 monolayers treated with GSK2141795 for 0.5 hour or 8 hours, phosphorylation of 
AKT at S473 and T308 was increased by 2.1 and 2.9-fold, and PRAS40 decreased by 1.3 
and 1.8-fold respectively, consistent with previous data (Figure. 6.1). In addition to AKT, 
RPPA also revealed a dominant effect on the AKT-mTOR-p70S6K pathway with a consistent 
reduction(2-fold) in mTOR phosphorylation at pS2448, and the downstream pathway 
proteins p70S6K at T389 (2.6-fold in 0.5 hours; 2.5-fold in 8hours), S6 phosphorylation at 
pS235/S236 (4.1-fold in 0.5 hours and 14-fold by 8 hours), S240/S244 (3.7-fold in 0.5 hours 
and 7.8-fold by 8 hours) and 4EBP1 pS65 (1.3-fold in 0.5 and 8 hours) (Figure. 6.1).   
 
In addition, in SKOV3 samples treated with GSK2141795 for 8 hours down-regulation was 
also seen in the phosphorylation of GSK-alpha/beta at S21 (4.2-fold) (Figure. 6.1). 
Interestingly, increase in phosphorylation of AMPK at T172 by 1.4-fold was seen in both 
groups, suggesting a feedback loop.  
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Unexpected changes in levels of pYAP(S127), pYB-1 (pS102), pACC (S79), were observed 
suggesting novel AKT associated pathways or off-target effects of GSK2141795.  
 
To validate findings in SKOV3 cells in another platinum resistant ovarian cancer cell line, 
PEO4 monolayers were also treated with GSK2141795 for 0.5 hour and 8 hours. AKT-p308 
showed the greatest level of up-regulation in PEO4 monolayers treated with GSK2141795 
for 8 hours, as seen in SKOV3 monolayers (Figure. 6.2, b). In samples treated with the 
compound for 0.5 hour, the greatest decreases were seen in phosphorylation of S6 at 
S235/S236 (3.1-fold) and S240/S244 (3.1-fold), whereas the greatest increase were seen in 
phosphorylation of AMPK at T172 (1.66-fold) (Figure. 6.2, a) consistent with what seen in 
SKOV3 monolayers. In PEO4 monolayers treated with GSK2141795 for 8 hours 
phosphorylation of down-stream target of AKT, GSK-alpha/beta at S21 and S9 was 
decreased by 2.5 and 2.1-fold respectively. A two-fold reduction in phosphorylation of S6 at 
S235, down-stream of AKT, was also found in those samples. Findings in PEO4 cells 
suggest that changes in protein expression observed in SKOV3 monolayers in response to 
GSK2141795 were not cell line specific events.  
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A 
B 
Figure 6-1 Protein expression levels in SKOV3 monolayers treated with 
GSK2141795 in comparison with vehicle treated samples.  
SKOV3 monolayers were treated with 5 µM GSK2141795 for A) 0.5 hour and B) 8 hours. 
Proteins were filtered using 1.3-fold cut off between vehicle and GSK2141795 (n=1).   
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Figure 6-2 Protein expression levels in PEO4 monolayers treated with GSK2141795 
in comparison with vehicle samples 
 PEO4 monolayers were treated with 5 µM GSK2141795 for A) 0.5 hour and B) 8 hours. 
Proteins were filtered using 1.3-fold cut off between vehicle and GSK2141795 (n=1).   
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6.2.2 Effect of treatment with GSK2141795 on protein expression in vivo 
  
SKOV3 xenograft tumours treated with GSK2141795 (30 mg/kg) were harvested 5 hours 
after oral administration of GSK2141795, and protein expression measured by RPPA, was 
compared following DMSO and GSK2141795 treatments (Figure 6.3). Overall 18 proteins 
were up-regulated (1.3-fold, t-test p<0.05; Table 6.1) and 24 proteins were down-regulated 
(1.3-fold, t-test p<0.05; Table 6.2).  
 
Phospho-AKT308 and pAKTS473 with 5.8 and 4.8-fold increases in expression (p = 5.3 x 
10-5 and 6.3x10-5 respectively) showed the greatest level of increase in expression in 
response to single agent GSK2141795, while no significant change in total AKT expression 
was seen. These findings were consistent with previous in vitro data in SKOV3 and PEO4 
cells by ELISA and RPPA. 
 
S6-pS235/S236, S6-pS240/S244 and Cyclin-B1 showed the greatest reduction (4-5 fold; p= 
0.01, 0.015 and 0.0001 respectively) in expression in tumours treated with GSK2141795 
compared to DMSO only. In addition, a 1.3-fold increase in expression of AMPK was seen 
(Figure 6.3). A 2-fold increase in expression of both p-EGFR, and p38 at T180 were also 
seen in xenograft samples treated with GSK2141795, suggesting feedback loops. In 
addition, alteration in expression of extracellular matrix proteins P-cadherin and fibronectin 
were observed in response to inhibition of AKT, potentially consistent with the role of AKT in 
cell migration and invasion (Fig 6.3).   
 
GSK2141795 also affected expression of cell cycle proteins in vivo. In addition to cyclin B1, 
a 2-fold decrease in phosphorylation RB (retinoblastoma protein) was observed (Fig 6.3, 
Table 6.2). Interestingly, a 4-fold decrease in expression of cleaved caspase-7 and 1.3-fold 
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decrease in expression of cleaved caspase-9, was observed in xenograft samples treated 
with single agent GSK2141795, indicating a decrease in induction of apoptosis in response 
to GSK2141795. This may be due to the growth inhibitory effects of this compound as shown 
by reduction in expression of cell cycle progression proteins in this chapter and also 
demonstrated by MTT assay and FACS analysis in chapter 3 (Figure 6.3, Table 6.2).  
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Figure 6-3 Proteins with significantly different levels (1.3-fold, t-test; p<0.05) 
between DMSO (n=5) and GSK2141795 (n=5) treatment in SKOV3 xenografts 
 Mice were treated with 30 mg/kg GSK2141795 for 5 hours and differences in level of 
protein expression between two groups were measured by RPPA analysis. Data shown 
are the means ± SD of replicates.  
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Up-regulated proteins GSK795/DMSO Ratio p-value 
Akt_pT308  5.8 0.00002 
Akt_pT308/norm 5.7 0.00005 
Akt_pS473 4.8 0.00001 
Akt_pS473/norm 4.8 0.00006 
STAT5-alpha  2.7 0.003 
EGFR_pY1068/norm 2.2 0.004 
EGFR_pY1173/norm 2.2 0.0003 
p38_pT180_Y182 2.1 0.007 
p38_pT180_Y182/norm 2.0 0.03 
GSK3-alpha-beta_pS21_S9  1.5 0.009 
MAPK_pT202_Y204 1.5 0.02 
IGF-1R-beta 1.5 0.005 
YAP_pS127/norm 1.5 0.00007 
AMPK_pT172/norm 1.5 0.001 
YAP_pS127  1.4 0.0004 
GSK3_pS9  1.4 0.01 
AR 1.4 0.02 
EGFR_pY992/norm 1.3 0.02 
C-Raf_pS338 1.3 0.0003 
GAB2 1.3 0.03 
 
 
 
  
Table 6-1 Proteins showing more than 1.3-fold (t-test P<0.05) increase in 
expression in SKOV3 xenografts following treatment with GSK2141795 compared 
to DMSO (GSK795/DMSO ratio) treated animals  
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Table 6-2 Proteins showing more than 1.3-fold decrease (t-test P<0.05) in expression 
in SKOV3 xenografts following treatment with GSK2141795 compared to DMSO 
treated animals (GSK795/DMSO ratio) 
 
Protein GSK795/DMSO Ratio p- value 
S6_pS235_S236  0.20 0.01 
Cyclin_B1 0.24 0.0001 
S6_pS240_S244  0.26 0.01 
Caspase-7_cleavedD198  0.37 0.007 
EGFR  0.44 0.008 
Rb_pS807_S811  0.46 0.002 
53BP1  0.47 0.01 
IGFBP2  0.52 0.006 
NF2  0.58 0.008 
EGFR_pY992  0.59 0.02 
4E-BP1_pS65/norm 0.60 0.001 
VEGFR2  0.65 0.02 
4EBP1_pT37-T46/norm 0.65 0.03 
Tuberin  0.66 0.03 
4E-BP1_pS65  0.67 0.001 
P-Cadherin  0.68 0.002 
COX-2  0.69 0.1 
Fibronectin  0.69 0.05 
Caspase-9_cleavedD330  0.71 0.0001 
AMPK_alpha  0.74 0.008 
4EBP1_pT37-T46  0.74 0.009 
beta-Catenin  0.75 0.08 
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To confirm the identity of the proteins where expression altered in response to GSK2141795 
in both in vitro and in vivo model systems, changes in protein expression in SKOV3 
monolayers (both 0.5 and 8 hours) and in xenografts were compared. Six proteins were 
identified which were up-regulated and 4 proteins which were down-regulated in both time-
points in monolayer samples as well as in vivo (Figure. 6.4 and Table 6.3). Five proteins 
were up-regulated and 4 proteins were down-regulated in common in SKOV3 monolayer at 8 
hours and in SKOV3 xenografts but not in monolayer samples exposed to GSK2141795 for 
only 30 minutes (Figure. 6.4 and Table 6.3). Increased phosphorylation of AKT at S473 and 
T308 and increased phosphorylation of p38 at T180-Y182 was found to be common 
between in vivo SKOV3 xenografts and SKOV3 monolayers regardless of the duration of 
exposure to GSK2141795.  
 
To identify proteins changing expression in response to treatment with GSK2141795 at early 
time-points (early response) compared to those affected by the compound at later time 
points (late response), protein samples extracted at 30 minutes and 8 hours following 
exposure to GSK2141795 were compared in both SKOV3 and PEO4 cells. Three proteins 
were up-regulated and 10 proteins were down-regulated in common in both SKOV3 and 
PEO4 samples exposed to GSK2141795 for 8 hours. In contrast, only 1 protein was found to 
be up-regulated and 7 to be down-regulated in common in both PEO4 and SKOV3 samples 
exposed to GSK2141795 only for 30 minute (Figure 6.5, Table 6.4). The comparison of 
effects in PEO4 cells alone at both 30 min and 8 hour time-points is shown in Figure 6.6 and 
Table 6.5.   
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SKOV3 30min
0
01
6
5
13
SKOV3 In Vivo
SKOV3 8hrs
5
117
0
73
4
4
17
5
107
SKOV3 30min SKOV3 8hrs
SKOV3 In Vivo
A 
B 
Figure 6-4  Comparison of A) up-regulation and B) down-regulation of 147 
proteins in SKOV3 in vitro and in vivo models  
 Protein expression was compared in SKOV3 monolayers treated with GSK2141795 
for 30 minutes and 8 hours and with SKOV3 xenografts.  
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Table 6-3 Proteins expression in SKOV3 xenografts in response to treatment with 
GSK2141795 compared with the same treatment in SKOV3 monolayers in vitro (0.5 
and 8 hours) relative to DMSO 
Up-regulated proteins in vitro 0.5 hours in vitro 8hours in vivo Venn 
group 
Akt_pS473 Yes Yes Yes 7 
Akt_pS473/norm Yes Yes Yes 7 
Akt_pT308 Yes Yes Yes 7 
Akt_pT308/norm Yes Yes Yes 7 
p38_pTYes80_Y182 Yes Yes Yes 7 
p38_pT180_Y182/norm Yes Yes Yes 7 
AMPK_pT172/norm No Yes Yes 5 
Bim No Yes Yes 5 
EGFR_pY1068/norm No Yes Yes 5 
EGFR_pY992/norm No Yes Yes 5 
YB-1 No Yes Yes 5 
 
Down-regulated proteins in vitro 0.5 hours in vitro 8hours in vivo Venn 
group 
4E-BP1_pS65 Yes Yes Yes 7 
4E-BP1_pS65/norm Yes Yes Yes 7 
S6_pS235_S236 Yes Yes Yes 7 
S6_pS240_S244 Yes Yes Yes 7 
GSK3_pS9 Yes Yes No 4 
GSK3-alpha-beta_pS21_S9 Yes Yes No 4 
mTOR_ pS2448 Yes Yes No 4 
mTOR_ pS2448/norm Yes Yes No 4 
p70S6K_pT389 Yes Yes No 4 
p70S6K_pT389/norm Yes Yes No 4 
PRAS40_pT246 Yes Yes No 4 
4EBP1_pT37-T46/norm No Yes Yes 5 
ACC_pS79 No Yes Yes 5 
Rb_pS807_S811 No Yes Yes 5 
Tuberin No Yes Yes 5 
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6 1
PEO4 0.5 hours 795
8
132
SKOV3 0.5 hours 795
7 7
PEO4 0.5 hours 795
11
122
SKOV3 0.5 hours 795
13 3
PEO4 8 hours 795
3
128
SKOV3 8 hours 795
10 10
PEO4 8 hours 795
3
124
SKOV3 8 hours 795
D C 
B A 
Figure 6-5 Comparison of protein expression in SKOV3 and PEO4 monolyers in 
response to treatment with GSK2141795 
 One protein was up-regulated A) and 7 down-regulated C) in both SkOV3 and PEO4 
treated with GSK2141795 for 30 minutes. Three proteins were upregulated B) and 10 
proteins were down-regulated in both SKOV3 and PEO4 treated with GSK2141795 for 8 
hours.  
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Up-regulated proteins SKOV3 0.5h PEO4 0.5h Venn group 
Akt_pT308/norm Yes Yes 3 
 
Down-regulated proteins SKOV3 0.5h PEO4 0.5h Venn group 
4E-BP1_pS65 Yes Yes 3 
4E-BP1_pS65/norm Yes Yes 3 
GSK3_pS9-R-V Yes Yes 3 
GSK3-alpha-beta_pS21_S9 Yes Yes 3 
mTOR_ pS2448 Yes Yes 3 
S6_pS235_S236 Yes Yes 3 
S6_pS240_S244 Yes Yes 3 
 
Up-regulated proteins SKOV3 8h PEO4 8h Venn group 
ACC1-R Yes Yes 3 
Akt_pT308 Yes Yes 3 
Akt_pT308/norm Yes Yes 3 
 
Down-regulated proteins SKOV3 8h PEO4 8h Venn group 
C-Raf_pS338 Yes Yes 3 
GSK3_pS9 Yes Yes 3 
GSK3-alpha-beta_pS21_S9 Yes Yes 3 
mTOR_ pS2448 Yes Yes 3 
mTOR_ pS2448/norm Yes Yes 3 
p70S6K_pT389 Yes Yes 3 
p70S6K_pT389/norm Yes Yes 3 
PRAS40_pT246 Yes Yes 3 
S6_pS235_S236 Yes Yes 3 
S6_pS240_S244 Yes Yes 3 
 
 
 
Table 6-4 Proteins which showed alternation in expression in both SKOV3 and 
PEO4 monolayers treated with GSK2141795.  
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8 1
PEO4 8 hours 795
5
133
PEO4 0.5 hour 795
11 7
PEO4 8 hours 795
6
123
PEO4 0.5 hour 795
Figure 6-6 Comparison of protein expression alternation in PEO4 monolayers 
treated with GSK2141795 for 30 minutes or 8 hours 
 One protein was up-regulated A) and 7 proteins were down-regulated B) in both 
time-points.  
B 
A 
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Up-regulated proteins 0.5 hours 8 hours Venn group 
Akt_pT308/norm Yes Yes 3 
 
Down-regulated proteins 0.5 hours 8 hours Venn group 
C-Raf_pS338  Yes Yes 3 
C-Raf_pS338/norm Yes Yes 3 
GSK3_pS9  Yes Yes 3 
GSK3-alpha-beta_pS21_S9 Yes Yes 3 
mTOR_ pS2448  Yes Yes 3 
S6_pS235_S236  Yes Yes 3 
S6_pS240_S244 Yes Yes 3 
 
 
 
 
 
 
 
 
 
Table 6-5  Proteins which their expressions altered in response to GSK2141795 in PEO4 
monolayers at both 0.5 and 8 hours 
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6.2.3 Effect of treatment with GSK2141795 on protein expression in ovarian cancer 
patients 
  
In a phase I clinical trial of single agent GSK2141795 in ovarian cancer, 12 patients were 
treated with GSK2141795 for 4 weeks at a dose of 25-75 mg once daily orally. Tumour 
biopsies were taken prior to the start of treatment from all patients, and after 4 weeks on 
GSK2141795 from 10. Due to disease progression and death, week 4 biopsies could not be 
obtained from 2 patients. Biopsies were examined for differences in level of protein 
expression by RPPA. 
 
PD biomarkers 
Protein expression at week 4 was compared to protein expression in biopsies taken from the 
same patient prior to the start of treatment (week 0), in the ten evaluable patients, to identify 
PD biomarkers for GSK2141795. Proteins showing less than 1.3-fold alterations in protein 
expression in post-treatment samples compared with the pre-treatment samples were 
excluded. Phosphorylation of AKT at S473 and T308 was significantly increased in all 
samples treated with GSK2141795 regardless of tumour sub-type and the dose of the drug 
(6.4 and 4.5-fold respectively) (Table 6.6). This finding was consistent with findings in in vitro 
and in vivo ovarian cancer models suggesting that p-AKT is a robust PD biomarker for 
GSK2141795. In addition, a slight decrease (1.3-fold) in expression of total AKT was also 
observed (Table 6.6).  
 
In addition, increase in expression of p38-T180 and p70S6K-pT389, in response to 
GSK2141795, was observed in clinical samples, consistent with observations in vitro and in 
vivo. However, these alterations were not significant in clinical samples despite significant 
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changes for the same proteins observed in vitro and in vivo. This could be due to the small 
sample size and inter-tumour heterogeneity in tumour biopsies.  
 
In addition, tumour biopsies from the 10 patients treated with GSK2141795 for 4 weeks were 
classified into three different sub-groups based on their clinical diagnosis; serous (6 
samples), clear cell (2 samples) and endometrioid (2 samples), and protein expression 
compared. Proteins showing less than 1.3-fold alternation in protein expression in post-
treatment samples compared with the pre-treatment samples were excluded for further 
analysis (see Appendix Figures A.1, A.2 and A.3 and Table A.1).   
 
Phosphorylation of AKT at both phosphorylation sites S473 and T308 was greatly increased 
in all three tumour sub-types as was seen in vitro and in vivo.  
 
Expression of the epithelial tight junction protein,  Claudin 7 and the extracellular matrix 
protein E-cadherin in serous samples (1.4-fold), expression of VEGFR , up-stream of AKT 
and the down-stream target of AKT, phospho-PRAS40 in clear cell samples (1.4-fold) and 
expression of the extracellular matrix protein cadherin-P in endometrioid samples (3-fold) 
showed the most down-regulations (Figures A.1, A.2. A.3). Altogether, AKT-pS473, AKT-
pT308, Caveolin-1,HER2-pY1248 and p38-pT180/Y182 were found to be up-regulated in all 
three tumour types. Up-regulation of AKT-pT08, AKT-S473 and p38-pT180/Y182 was 
consistent with what was observed earlier in in vitro monolayers and in vivo xenografts. 
However, except alterations in expression of AKT and pAKT (p<0.05), other alterations in 
protein expression were not found to be significant due to the low number of samples and 
tumour heterogeneity.  
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Response biomarkers 
Ovarian cancer patients were treated with daily GSK2141795 for 4 weeks and pre and post-
treatment tumour biopsies were used for determination of response biomarkers. Response 
to the treatment was evaluated by measuring of the CA125 levels in the pre and post-
treatment blood samples. CA125 is a biomarker of ovarian cancer. Elevation of CA125 level 
correlates with poor response to treatment whereas a fall in CA125 level has been 
associated with response to treatment.  Prior to the analysis, tumour biopsies were divided 
into two groups, according to the changes in the level of expression of CA125 in response to 
treatment with GSK2141795. Patients showing more than 30% drop in the level of 
expression of CA125 were grouped as responders and the rest as non-responders. Protein 
expression profiles were determined using RPPA. Protein expression profiles in pre-
treatment and post-treatment samples taken from each patient were compared to determine 
expression alterations in response to the treatment in each patient. Alterations in protein 
expression 4 weeks after the initiation of the daily treatment with GSK2141795 were relative 
to levels prior to the start of treatment, were compared between responders (n=5) and non-
responders (n=5). Expression of RAF-C pS338, ER-alpha pS118 and EGFR pY1173 were 
significantly increased, and the expression levels of Cyclin B1 and SRC pY416 significantly 
decreased in responders compared to non-responders (Table 6.7).  Increase in AKT 
phosphorylation in response to GSK2141795 was observed in both responders and non-
responders groups (Figure 6.7). 
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Era protein 
Protein 
Ratio 
wk4/wk0 
p-value 
AKT_pS473/norm 6.4 0.02 
AKT_pS473 4.7 0.01 
AKT_pT308/norm 4.5 0.01 
AKT_pT308 3.2 0.007 
Rad50 2.2 0.2 
HER2_pY1248 1.9 0.1 
Caveolin-1 1.9 0.2 
Era 1.7 0.4 
CHK2_pT68/norm 1.6 0.3 
p38_T180_182/norm 1.6 0.4 
Tau 1.5 0.2 
HER2_pY1248 1.5 0.2 
p70S6K_pT389/norm 1.5 0.4 
p70S6K_pT389/norm 1.4 0.6 
Raf-C_pS338/norm 1.3 0.4 
ATM_ 1.3 0.8 
p70S6K_pT389/norm 1.3 0.7 
Raf-C__pS338/norm 1.3 0.3 
p27_pT198/norm 1.3 0.3 
PR 1.3 0.7 
MAPK_pT202_ 1.3 0.3 
EGFR 1.3 0.1 
FAK 1.3 0.4 
p27_pT198 1.3 0.3 
Cox-2 1.3 0.1 
Notch-1 1.3 0.2 
MAPK__pT202_204 1.3 0.2 
EGFR 1.3 0.1 
Xiap 1.3 0.2 
eEF2K 1.3 0.3 
AKT 0.7 0.01 
Cadherin 0.7 0.2 
 
  
Table 6-6  PD Biomarkers: Proteins showed more than 1.3-fold alteration in 
expression in response to treatment with GSK2141795 in ovarian cancer 
tumours  
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Protein Ratio p-value 
Raf.C_.pS338./norm 1.7 0.04 
ERa_pS118.V/norm 1.6 0.03 
ERa_pS118/norm 1.6 0.04 
EGFR.C. 1.4 0.05 
EGFR_pY1173 1.3 0.02 
TAZ_pS89 1.3 0.007 
YB1.V 1.3 0.03 
Snail.C 1.3 0.01 
PKca 0.7 0.04 
P27 0.7 0.04 
YB1_pS102./norm 0.7 0.03 
ChK2 0.7 0.04 
Src_pY416/norm 0.7 0.03 
Src_pY416 0.7 0 
Cyclin.B1 0.7 0.001 
Rb-pS809 0.6 0.05 
YAP-pS127 0.5 0.04 
 
 
 
 
Table 6-7  Response-biomarkers: significant response-dependent protein-change 
(more than 1.3-fold) as a result of treatment with GSK2141795 
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Figure 6-7  Phosphorylation of AKT (S473 and T308) was increased in response 
to treatment with GSK2141795 in both responder and not-responder groups 
 Ovarian cancer patients were treated with GSK2141795 daily for 4 weeks. Patients were 
divided into two groups according to the changes in the level of expression of CA125 in 
response to treatment with GSK2141795. Patients showing more than 30% drop in the level 
of expression of CA125 were grouped as responders and the rest as non-responders. Protein 
expression levels in pre-treatment and post-treatment tumour biopsies taken from patients   
were analysed using RPPA.  AKT phosphorylation level was increased in both groups in 
response to the treatment. Down-regulation is indicated by green whereas up-regulation is 
indicated by red.  
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Predictive biomarkers 
To find biomarkers which can be used to predict response to AKT inhibition by 
GSK2141795, protein expression in tumour biopsies taken just before the start of the 
treatment with GSK2141795 was compared between responders and non-responder groups. 
Expression of pMAPK (T202) was found to be significantly lower in responders compared to 
non-responders, suggesting that pMAPK (T202) may represent a predictive biomarker for 
GSK2141795 activity (Figure 6.8). Additional data for all assessed proteins are shown in 
Table A.15.  
 
  
 
Figure 6-8 Expression of pMAPK (T202) in responders and non-responders 
Protein expression profiles of tumour biopsies taken from patients prior to the treatment with 
GSK2141795 were compared between responders and non-responders.  Expression of pMAPK 
(pT202) was found to be significantly lower (1.4-fold) in responders compared to non-responders 
before the initiation of treatment with GSK2141795 suggesting pMAPK (T202) can be used as a 
predictive biomarker for response to GSK2141795. The data shows mean of n=5 samples ± SD, 
p = 0.02 
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6.2.4 Effect of treatment with cisplatin on signalling cascades  
 
 
In Vitro 
The effect of treatment with cisplatin on protein signalling cascades in SKOV3 and PEO4 
monolayers for 30 minutes or 8 hours was examined (see Appendix). Only 3 proteins were 
up-regulated and 2 proteins were down-regulated in SKOV3 cells treated with cisplatin for 30 
minutes (Figure A.4A). After 8 hours 5 proteins were up-regulated and 3 proteins were 
down-regulated in SKOV3 monolayers (Figure A.4B). More proteins showed alternation in 
expression in response to cisplatin in PEO4 monolayers. Eight proteins were up-regulated 
and 7 down-regulated in PEO4 monolayers treated with cisplatin for 30 minutes (Figure. 
A.5.A). After 8 hours 5 proteins were up-regulated and 12 proteins down-regulated in PEO4 
cells (Figure. A.5B). 
 
In Vivo 
To validate these effects in vivo, protein expression was analysed in platinum-resistant 
SKOV3 tumour xenografts treated with 1.5 mg/kg cisplatin and compared to DMSO vehicle 
treatment, by RPPA (Figure 6.9). Overall, 29 proteins were down-regulated (Table 6.9), and 
25 proteins up-regulated (Table 6.8).  
 
Up-regulation of ER-alpha-pS118 was common between PEO4 monolayers and SKOV3 
monolayers and xenografts (Figure A.4, A.5. 6.10).  AMPK-pT172 was up-regulated in both 
SKOV3 monolayers and xenografts, but not PEO4 cells (Figure A.4. 6.10). ER-alpha(total) 
and AMPK(total) were found to be down-regulated in SKOV3 xenografts (Figure 6.9). 
 
193 
 
Phosphorylation of EGFR at Y1173 (2.3-fold) and MEK1 at pS217 were increased (2.6 and 
1.3-fold respectively) suggesting activation of EGFR and MEK survival pathways in response 
to cisplatin in SKOV3 xenografts. The anti-apoptotic protein Bcl-2 was up-regulated, and 
consistent with this, a 2-fold decrease in expression of cleaved caspase-7 was observed. 
Down-regulation of p27 phosphorylation at T157 (1.3-fold) was found in cisplatin treated 
SKOV3 xenografts, suggesting increase in cell cycle progression at G1 but on the other 
hand, reduced expression of cyclin B1 in the same samples, suggested decrease in the 
proportion of cells in S-phase (Figure 6.9, Table 6.8, 6.9).  
 
Importantly, a four-fold decrease was found in expression of S6, down-stream of mTOR, in 
SKOV3 xenografts, suggesting down-regulation of AKT-mTOR signalling and decline in 
protein synthesis in response to cisplatin (Figure 6.8, Table 6.9). 
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Figure 6-9 Proteins with significantly different levels (t-test; p<0.05) between DMSO 
and cisplatin treatment in SKOV3 xenografts  
 SKOV3 xenografts were treated with 1.5 mg/kg cisplatin for 3 hours and differences in level 
of protein expression between two groups were measured by RPPA analysis. The graphs 
indicates proteins showing changes more than 1.3-fold in expression. The data shows mean 
of n=4 samples ± SD. 
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Up-regulated Proteins CDDP/DMSO Ratio p-value 
ACC1  2.6 0.02 
EGFR_pY1068/norm 2.3 0.01 
EGFR_pY1173/norm 2.2 0.05 
ER-alpha_pS118/norm 2.2 0.02 
HER3  2.1 0.02 
Bim  1.9 0.05 
EGFR_pY992/norm 1.9 0.03 
AMPK_pT172/norm 1.8 0.07 
p70S6K_pT389/norm 1.7 0.01 
c-Myc  1.7 0.02 
Akt_pT308/norm 1.5 0.09 
PR 1.5 0.003 
Beclin 1.5 0.001 
Bcl-2  1.4 0.01 
Chk1_pS345  1.4 0.001 
STAT5-alpha  1.4 0.1 
p70S6K_pT389  1.4 0.02 
Notch3  1.4 0.001 
NF-kB-p65_pS536  1.4 0.009 
YAP_pS127/norm 1.4 0.0009 
Chk1_pS345/norm 1.3 0.02 
p38_pT180_Y182  1.3 0.19 
MEK1_pS217_S221  1.3 0.01 
p38_pT180_Y182/norm 1.3 0.17 
Caveolin-1 1.3 0.06 
p27  1.3 0.01 
 
 
 
 
Table 6-8  Proteins showing more than 1.3-fold increase in expression in SKOV3 
xenografts following treatment with cisplatin (CDDP) compared with DMSO treated 
animals (CDDP/DMSO ratio) 
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Down-regulated proteins CDDP/DMSO Ratio p-value 
S6_pS235_S236  0.26 0.03 
S6_pS240_S244  0.37 0.06 
ACC_pS79/norm 0.41 0.03 
53BP1  0.42 0.03 
Tuberin  0.43 0.02 
NF2  0.44 0.01 
Caspase-7_cleavedD198 0.45 0.01 
HER3_pY1298/norm 0.48 0.02 
Cyclin_B1  0.48 0.01 
Annexin_I  0.48 0.08 
IGFBP2  0.49 0.01 
EGFR  0.49 0.06 
p21  0.50 0.17 
Akt_pS473  0.51 0.07 
ER-alpha  0.56 0.03 
COX-2  0.57 0.09 
AMPK_alpha  0.62 0.02 
MSH6  0.62 0.01 
Rb_pS807_S811  0.63 0.08 
Akt  0.63 0.15 
P-Cadherin  0.63 0.005 
GAB2  0.64 0.08 
beta-Catenin  0.64 0.07 
VEGFR2  0.68 0.11 
eEF2  0.69 0.26 
4E-BP1_pS65/norm 0.72 0.03 
4E-BP1_pS65  0.73 0.04 
p27_pT157/norm 0.75 0.03 
PTEN 0.76 0.11 
Akt_pS473/norm 0.77 0.25 
  
Table 6-9  Proteins showing more than 1.3-fold decrease in expression in 
SKOV3 xenografts following treatment with cisplatin compared with DMSO 
treated animals.  
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6.2.5 Effect of combination of GSK2141795 and cisplatin on protein signalling 
cascades in SKOV3 and PEO4 monolayers and xenograft models 
 
SKOV3 xenografts were treated with a combination of 30 mg/kg GSK2141795 and 1.5 
mg/kg cisplatin and protein expression data measured by RPPA (Figure 6.10).  The highest 
increase in phosphorylation was seen for AKT at both phosphorylation sites T308 and S473 
(4.9 and 4.3-fold respectively) (Table 6.10). In contrast, the greatest decrease in 
phosphorylation was seen for S6 at both phosphorylation sites S236 and S244 (4 and 3-fold 
decrease respectively) (Table. 6.11) as was seen in xenografts treated with single agent 
GSK2141795.  
 
In addition SKOV3 and PEO4 monolayers were treated with combination of 5 µM 
GSK2141795 and 25 µM cisplatin for 30 minutes or 8 hours (Figures A.8 and A9).  
 
In SKOV3 monolayers, phosphorylation of AKT at both phosphorylation sites T308 and S473 
was dramatically increased at both 30 minutes and 8 hours time points as it was seen in 
SKOV3 xenografts. GSK3 and P70S6K showed great decreases in both time points whereas 
decrease in phosphorylation of S6 was only observed in cells treated with the combination 
treatment for 8 hours. These findings showed down-regulation in AKT signalling pathway as 
a result of the combination treatment. In general, increase in phosphorylation of AKT at both 
S473 and T308 and decrease in expression of down-stream effectors of AKT including pS6, 
pGSK3, pmTOR, PRAS40 and 4EBP1 was observed in PEO4 monolayers and SKOV3 
monolayers and xenografts, treated with the combination of GSK2141795 and cisplatin, 
showing the efficacy of GSK2141795 in the combination treatment. (Figures. 6.10, A.8, A9).  
 
 
198 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S
6
_
p
S
2
3
5
_
S
2
3
6
-R
-V
S
6
_
p
S
2
4
0
_
S
2
4
4
-R
-V
C
yc
li
n
_
B
1
-R
-V
IG
F
B
P
2
-R
-V
N
F
2
-R
-C
T
u
b
e
ri
n
-R
-C
R
b
_
p
S
8
0
7
_
S
8
1
1
-R
-V
P
-C
a
d
h
e
ri
n
-R
-C
4
E
-B
P
1
_
p
S
6
5
-R
-V
4
E
-B
P
1
_
p
S
6
5
-R
-V
/n
o
rm
A
k
t_
p
S
4
7
3
-R
-V
/n
o
rm
A
k
t_
p
S
4
7
3
-R
-V
A
k
t_
p
T
3
0
8
-R
-V
/n
o
rm
A
k
t_
p
T
3
0
8
-R
-V
0
1
2
3
4
5
6
7
8
m
e
d
ia
n
 c
e
n
tr
e
d
 l
in
e
a
r 
n
o
rm
a
li
s
e
d
 r
a
ti
o
D M S O
Figure 6-10 Proteins with significantly different levels (t-test; p<0.05) between 
DMSO and combination of GSK2141795 and cisplatin treatment in SKOV3 
xenografts  
SKOV3 xenografts were treated with combination of 1.5 mg/kg cisplatin and 30 mg/kg 
GSK2141795.  Differences in level of protein expression between two groups were 
measured by RPPA analysis. The graphs indicates proteins showing significant 
changes in expression between DMSO and combination groups (n=4).  
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Up-regulated Proteins Ratio p-value 
Akt_pT308 4.9 0.00003 
Akt_pT308/norm 4.3 0.000002 
Akt_pS473  4.3 0.0003 
Akt_pS473/norm 3.8 0.00002 
Bim-R-V  2.0 0.22 
EGFR_pY1173/norm 1.8 0.24 
STAT5-alpha 1.7 0.1 
EGFR_pY1068/norm 1.7 0.08 
AMPK_pT172/norm 1.7 0.2 
ER-alpha_pS118/norm 1.6 0.3 
EGFR_pY992/norm 1.4 0.2 
Caveolin-1 1.4 0.2 
Caspase-7_cleavedD198 1.3 0.05 
Collagen_VI 1.3 0.1 
Beclin  1.3 0.06 
YAP_pS127/norm 1.3 0.06 
 
 
 
 
  
Table 6-10  Proteins showing more than 1.3-fold increase in expression in 
SKOV3 xenografts following treatment with combination of cisplatin and 
GSK2141795 compared with DMSO treated animals. 
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Down-regulated Proteins Ratio p-value 
S6_pS235_S236 0.25 0.01 
S6_pS240_S244 0.33 0.02 
Cyclin_B1 0.41 0.001 
IGFBP2 0.58 0.03 
NF2 0.61 0.04 
Tuberin 0.64 0.05 
53BP1 0.64 0.1 
EGFR 0.65 0.1 
Rb_pS807_S811 0.66 0.03 
COX-2 0.67 0.1 
P-Cadherin 0.69 0.01 
4E-BP1_pS65 0.69 0.01 
4E-BP1_pS65/norm 0.71 0.04 
Fibronectin 0.74 0.1 
beta-Catenin 0.76 0.2 
eEF2 0.76 0.3 
ER-alpha 0.76 0.2 
MSH6 0.76 0.1 
 
 
 
 
 
 
 
 
Table 6-11 Proteins showing more than 1.3-fold decrease in expression in 
SKOV3 xenografts following treatment with combination of cisplatin and 
GSK2141795 compared with DMSO treated animals. 
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Majority of proteins expression alterations found in samples treated with combination of 
GSK2141795 and cisplatin were common with the ones found in samples treated with either 
single agents. Therefore, to identify proteins alterations only specific to the combination 
treatment, up-regulation and down-regulation of protein expression levels in response to 
cisplatin and GSK2141795 and combination of two were compared in SKOV3 xenografts 
and SKOV3 and PEO4 monolayers. The purpose of this analysis was to identify proteins 
involved in the mechanism leading to sensitisation to cisplatin, as shown in chapter 3 as 
phenotypic effect of the combination treatment in vitro and in vivo and also to identify 
biomarkers for the combination treatment.  
 
Cleaved caspase-7 which was found to be down-regulated In SKOV3 xenografts treated with 
cisplatin only, but up-regulated in xenografts treated with the combination of cisplatin and 
GSK2141795 (1.3-fold, p=0.05), consistent with the increase in apoptosis in response to the 
combination treatment (Table 6.12). In addition, MSH6 was found to be down-regulated in 
xenografts treated with the combination treatment, suggesting decrease in DNA mismatch 
repair when cisplatin is combined with GSK2141795. However, down-regulation of MSH6 
was not found to be statistically significant (Table 6.13). Up-regulation of cellular membrane 
protein, caveolin-1 (1.4-fold) and collagen-VI (1.3-fold) were found to be up-regulated in 
response to the combination treatment in xenografts, suggesting involvement of the extra-
cellular matrix in cell senstitisation to cisplatin. However, these up-regulations were not 
statistically significant.  In addition, four proteins were found to be up-regulated and 5 to be 
down-regulated only in response to cisplatin not in combination with GSK2141795 (Figure 
6.11, Table 6.13, 6.14) and 11 proteins to be up-regulated and 7 to be down-regulated only 
in response to GSK2141795 not in combination with cisplatin (Figure 6.11, Table 6.12, 6.13).  
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In SKOV3 monolayers treated with the combination treatment for 30 minutes, six proteins 
were found to be up-regulated and 5 proteins were found to be down-regulated only in 
response to the combination treatment but not in response to cisplatin or GSK2141795 alone 
.Three proteins were identified to be up-regulated and 1 protein to be down-regulated only in 
cisplatin treated cells and 1 protein was found to be up-regulated and two proteins were 
down-regulated only in GSK2141795 treated cells not in the combination group (Figure. A13, 
Table. A.9).   
 
In SKOV3 monolayers treated with the combination of GSK2141795 and cisplatin for 8 
hours, 4 proteins were found to be up-regulated and 8 proteins to be down-regulated only in 
response to the combination treatment but not in GSK2141795 and cisplatin only treated 
cells. No protein was found to be up-regulated and only one to be down-regulated only in 
cisplatin treated cells and five to be up-regulated and two proteins to be down-regulated only 
in cells treated with GSK2141795 (Figure. A.14, Table A.10).   
 
Interestingly, the Yes Associated Protein (YAP) was found to be down-regulated in SKOV3 
monolayers treated with combination of GSK2141795 and cisplatin but not in samples 
treated with single agent GSK2141795 or cisplatin suggesting the Hippo signalling pathway 
may be involved in sensitisation of SKOV3 cells to platinum (Table A.11).  
 
In PEO4 monolayers treated with GSK2141795 or cisplatin or combination of both for 30 
minutes, 8 proteins were found to be up-regulated and 6 to be down-regulated only in 
response to the combination treatment and two proteins to be up-regulated and two proteins 
to be down-regulated in response to cisplatin alone and one protein to be up-regulated and 
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three proteins to be down-regulated only in response to GSK2141795 not in the combination 
treatment (Figure. A.15, Tables.A.12, A.13).  
 
In PEO4 monolayers treated with GSK2141795 or cisplatin or combination of both for 8 
hours, five proteins were found to be up-regulated and seven proteins to be down-regulated 
only in response to the combination treatment not in the GSK2141795 and cisplatin only 
treated cells (Figure. A.16, Table A.14).  
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Figure 6-11 Comparison of changes in protein expression in response to cddp or 
GSK2141795 as single agents or in combination in SKOV3 xenografts 
 SKOV3 xenografts were treated with cddp (3 hours) or GSK2141795 (5 hours) or combination 
of two drugs ( 2 hours pre-treatment with  GSK2141795 followed by 3 hours treatment with 
cddp). Up-regulations (A) or down-regulations (B) of protein expression in response to the 
three treatments were compared in Venn diagrams. 
B 
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Protein skov_vivo_cddp skov_vivo_795 skov_vivo_cddp_795 
Venn 
group 
AMPK_pT172/norm Yes Yes Yes 7 
Bim Yes Yes Yes 7 
EGFR_pYYes068  Yes Yes Yes 7 
EGFR_pY1068/norm Yes Yes Yes 7 
HER3  Yes Yes Yes 7 
STAT5-alpha  Yes Yes Yes 7 
YAP_pS127/norm Yes Yes Yes 7 
EGFR_pY1173/norm Yes Yes No 4 
EGFR_pY992/norm Yes Yes No 4 
Beclin  Yes No Yes 6 
ACC1  Yes No No 1 
c-Myc  Yes No No 1 
ER-alpha_pS118/norm Yes No No 1 
p70S6K_pT389/norm Yes No No 1 
Akt_pS473  No Yes Yes 5 
Akt_pS473/norm No Yes Yes 5 
Akt_pT308  No Yes Yes 5 
Akt_pT308/norm No Yes Yes 5 
AR-R No Yes No 2 
C-Raf_pS338  No Yes No 2 
GAB2  No Yes No 2 
GSK3_pS9  No Yes No 2 
GSK3-alpha-beta_pS21_S9  No Yes No 2 
IGF-1R-beta  No Yes No 2 
MAPK_pT202_Y204 No Yes No 2 
p38_pT180_Y182  No Yes No 2 
p38_pT180_Y182/norm No Yes No 2 
YAP_pS127  No Yes No 2 
YB-1  No Yes No 2 
Bcl-X No No Yes 3 
Caspase-7_cleavedD198  No No Yes 3 
Caveolin-1  No No Yes 3 
Collagen_VI  No No Yes 3 
Src_pY527  No No Yes 3 
Table 6-12 Comparison of up-regulations in protein expression in response to cddp 
and GSK2141795 as single agents or in combination in SKOV3 xenografts  
 
Protein skov_vivo_cddp skov_vivo_795 skov_vivo_cddp_795 
Venn 
group 
AMPK_pT172/norm Yes Yes Yes 7 
Bim Yes Yes Yes 7 
E FR_pYYes068  Yes Yes Yes 7 
EGFR_pY1068/norm Yes Yes Yes 7 
HER3  Yes Yes Yes 7 
STAT5-alpha  Yes Yes Yes 7 
YAP_pS127/norm Yes Yes Yes 7 
E FR_pY1173/norm Yes Yes No 4 
EGFR_pY992/norm Yes Yes No 4 
Beclin  Yes No Yes 6 
ACC1  Yes No No 1 
c-Myc  Yes No No 1 
ER-alpha_pS118/norm Yes No No 1 
p70S6K_pT389/norm Yes No No 1 
Akt_pS473  No Yes Yes 5 
Akt_pS473/norm No Yes Yes 5 
Akt_pT308  No Yes Yes 5 
Akt_pT308/norm No Yes Yes 5 
AR-R No Yes No 2 
C-Raf_pS338  No Yes No 2 
AB2  No Yes No 2 
SK3_pS9  No Yes No 2 
GSK3-alpha-beta_pS21_S9  No Yes No 2 
IGF-1R-beta  No Yes No 2 
MAPK_pT202_Y204 No Yes No 2 
p38_pT180_Y182  No Yes No 2 
p38_pT180_Y182/norm No Yes No 2 
YAP_pS127  No Yes No 2 
YB-1  No Yes No 2 
Bcl-X No No Yes 3 
Caspase-7_cleavedD198  No No Yes 3 
Caveolin-1  No No Yes 3 
Collagen_VI  No No Yes 3 
Src_pY527  No No Yes 3 
 Table. 6.17. Comparison of up-regulations in protein expression in response to cddp 
and GSK2141795 as single agents or in combination in SKOV3 xenografts.  
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Protein skov_vivo_cddp skov_vivo_795 skov_vivo_cddp+795 Venn 
group 
53BP1  Yes Yes Yes 7 
beta-Catenin Yes Yes Yes 7 
COX-2 Yes Yes Yes 7 
Cyclin_B1  Yes Yes Yes 7 
eEF2  Yes Yes Yes 7 
EGFR Yes Yes Yes 7 
IGFBP2  Yes Yes Yes 7 
NF2 Yes Yes Yes 7 
P-Cadherin  Yes Yes Yes 7 
Rb_pS807_S811  Yes Yes Yes 7 
S6_pS235_S236  Yes Yes Yes 7 
S6_pS240_S244  Yes Yes Yes 7 
Tuberin  Yes Yes Yes 7 
AMPK_alpha  Yes Yes No 4 
Caspase-7_cleavedD198  Yes Yes No 4 
ER-alpha Yes No Yes 6 
ACC_pS79/norm Yes No No 1 
Akt_pS473  Yes No No 1 
Annexin_I  Yes No No 1 
HER3_pY1298/norm Yes No No 1 
p21  Yes No No 1 
4E-BPYes_pS65  No Yes Yes 5 
4E-BP1_pS65/norm No Yes Yes 5 
Fibronectin  No Yes Yes 5 
4EBP1_pT37-T46  No Yes No 2 
4EBP1_pT37-T46/norm No Yes No 2 
ACC_pS79  No Yes No 2 
ACC1  No Yes No 2 
Caspase-9_cleavedD330  No Yes No 2 
EGFR_pY992  No Yes No 2 
VEGFR2 No Yes No 2 
MSH6 No No Yes 3 
 
 
 
Table 6-13  Comparison of down-regulations in protein expression in response to 
cddp and GSK2141795 as single agents or in combination in SKOV3 xenografts  
 
.  
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6.2.6 Validation of RPPA method using ELISA 
 
To validate the results of the RPPA analysis, showing increase in AKT phosphorylation at 
T308 and S473, the effect of treatment with GSK2141795 with or without cisplatin on the 
phosphorylation of AKT at S473 and T308 phosphorylation sites in xenograft tumours were 
assessed using ELISA. SKOV3 tumour bearing mice were treated with 30 mg/kg 
GSK2141795 as a single agent or in combination with 1.5 mg/kg cisplatin for 5 hours. 
Treatment with GSK2141795 resulted in an increase in phosphorylation of AKT at both 
phosphorylation sites, S473 and T308 compared to the untreated or only cisplatin treated 
animals (Figure 6.12), consistent with previous data  using RPPA, validating the previous 
results and the RPPA method for PD discovery. 
 
 
 
 
 
 
 
 
 
 
 
 
208 
 
 
 
 
 
 
 
 
 
 
 
 
 
B A 
Figure 6-12 Effect of treatment with GSK2141795 as single agent or in 
combination with cddp on the level of phosphorylation of AKT at S473 (A) and 
T308 (B) in SKOV3 xenograft mouse models 
SKOV3 tumour bearing mice were treated with vehicle, or cisplatin (1.5 mg.kg) or 30 
mg/kg GSK2141795 or combination of GSK2141795 and cisplatin for 5 hours. Level of 
AKT phosphorylation at T308 and S473 in protein lysates extracted from tumours was 
determined using ELISA. Treatment with GSK2141795 resulted in an increase in the 
phosphorylation of AKT at both phosphorylation sites, S473 and T308. Data are the 
means ± SEM of n = 3 
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6.3 Discussion  
 
One of the main goals in oncology drug development is to improve the specificity and 
efficacy of targeted therapy, through the identification and evaluation of predictive and PD 
response biomarkers for such agents. The aim of this chapter was to identify specific 
molecular biomarkers for efficacy of GSK2141795 as a single agent or in combination with 
cisplatin. To achieve this aim, in vitro, in vivo and ovarian cancer clinical samples treated 
with GSK2141795 as a single agent or in combination with cisplatin were screened with 170 
validated antibodies against total and activated proteins involved in canonical and non-
canonical pathways of AKT activation using RPPA.  
 
Single agent GSK2141795 – PD biomarkers 
In vivo PD biomarkers were investigated by comparison of tumour samples from untreated 
animals and samples from animals treated with GSK2141795. Clinical PD biomarkers for 
GSK2141795 were investigated by comparison of tumour biopsies taken from patients 
before and after treatment with GSK2141795. Analysis of ovarian cancer tumours from 
patients and in vivo tumour xenografts along with cell monolayers following treatment with 
GSK2141795 revealed several alterations within the AKT pathway. Phosphorylation of AKT 
at T308 and S473 was found to be increased following treatment with GSK2141795 in in 
vitro monolayer cell models, in tumour xenografts and also in tumour samples from ovarian 
cancer patients, regardless of the histology of tumour or the level of clinical response to AKT 
inhibition. The same result was achieved by ELISA using the same xenograft samples. 
These findings suggest that phosphorylation of AKT at T308 or S473 can be used as a 
potential PD biomarker for GSK2141795 in vitro, in vivo and in ovarian cancer patients, and 
validates RPPA’s utility for PD biomarker discovery.  
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Consistent with the above, AKT hyper-phosphorylation also has been reported using other 
ATP competitive AKT inhibitors such as A-443654 (O'Reilly, Rojo et al. 2006, Han, Leverson 
et al. 2007).  Two hypotheses prevail to explain this. Firstly inhibition of mTOR signalling 
downstream of AKT may alleviate a negative feedback loop exerted through p70-S6K/IRS-1 
mediated inhibition of PI3K (O'Reilly, Rojo et al. 2006, Han, Leverson et al. 2007). Secondly, 
occupancy of the nucleotide binding pocket of AKT kinases by ATP competitive inhibitors 
enables intermolecular interactions that restrict phosphatase access, and sustain AKT 
phosphorylation (Chan, Zhang et al. 2011).  In this study, increased phosphorylation of 
P70S6K at T389 was also observed in in vitro, in vivo and in ovarian cancer tumours 
suggesting increased activation of this protein, supporting the effect of the mTOR feedback 
loop. The increased phosphorylation of AKT in this study might be a result of the 
combination of both hypotheses as GSK2141795 is an ATP competitive inhibitor of AKT.   
 
Decreased pPRAS40 (T246) expression was observed in both PEO4 and SKOV3 
monolayers treated with GSK2141795 for 8 hours, but not in samples treated with 
GSK2141795 for 30 minutes, suggesting that alterations in expression of pPRAS40 is a late 
cellular events in response to GSK2141795. This finding was in agreement with results of 
ELISA experiment in chapter 4 showing down-regulation of pPRAS40 in response to 
treatment with GSK2141795 both in vitro and in vivo. PRAS40 is a negative regulator of 
mTORC1 (Sancak, Thoreen et al. 2007), and inhibits the activity of mTORC1 by preventing 
its binding to S6K1 and 4E-BP1. Phosphorylation of PRAS40 at T246 by AKT leads to the 
release of PRAS40 from the complex therefore stimulation of mTORC1 signalling (Wang, 
Harris et al. 2007, Wang, Harris et al. 2008). In keeping with this, a decrease in 
phosphorylation of mTOR and its down-stream targets 4E-BP1 and S6 was observed. 
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A decrease in phosphorylation of S6 and 4E-BP1 following treatment with GSK2141795 was 
found in both monolayer cell models and in vivo xenografts, and also in clinical samples. S6 
is a ribosomal protein required for protein translation and is phosphorylated at S235 and 
S240 by p70S6-kinase in the mTOR branch of the AKT pathway. 4EBP1 is a translational 
repressor protein that interacts with and inhibits initiation factor eIF4e. Both S6 and 4E-BP1 
are down-stream effectors of mTOR and mTOR controls cell growth and protein synthesis by 
mediating the regulation of these two proteins (Laplante and Sabatini 2012).  
 
As demonstrated in chapter 3, inhibition of AKT by GSK2141795 resulted in inhibition of cell 
proliferation and tumour growth in vitro and in vivo. This observation may be result of 
inhibition of mTOR mediated cell growth and proliferation signalling following inhibition of 
AKT, with a decrease in level of phosphorylation and therefore activation of S6 and 4E-BP1 
in response to treatment with GSK2141795, as seen here. 
 
 Moreover, decrease in phosphorylation of mTOR at S2448, GSK3 at S9 and GSK 
alpha/beta at S21, all down-stream targets of AKT, in response to GSK2141795 was found 
in all in vitro samples regardless of the length of the treatment. GSK-3 β phosphorylates cell 
cycle proteins such as cyclin D1 and c-Myc (Alt, Cleveland et al. 2000). Phosphorylation by 
GSK-3 β targets those proteins for destruction. On the other hand, AKT inactivates GSK-3 β 
by phosphorylation which promotes cell-cycle entry by stabilizing cell cycle proteins such as 
cyclin D1. Therefore, inhibition of AKT causes cell cycle arrest as was seen in chapter as a 
result of inhibition of AKT by GSK2141795 in vitro and in vivo.  
 
Increase in phosphorylation of p38 in response to GSK2141795 was found in SKOV3 in vitro 
monolayers and in vivo xenografts and also in clinical samples regardless of tumour sub-
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type. This may be due to cross talk between AKT/MAPK. Cross talk between AKT and 
MAPK pathways has been shown in various cell lines demonstrating that down-regulation of 
one pathway may result in up-regulation of the other pathway(Aksamitiene, Kiyatkin et al.). 
For example, Rane et al have demonstrated that down-regulation of AKT activation during 
hyperglycemia results in up-regulation of p38 MAPK activation. The same authors have also 
shown that inhibition of PI3K/AKT pathway with LY294002 or silencing AKT expression in 
vitro promoted p38 MAPK phosphorylation in the absence of hyperglycemia (Rane, Song et 
al. 2010). Therefore, in this study, up-regulation of p38 may be a direct result of inhibition of 
AKT by GSK2141795 
 
Expression levels of YB-1, pEGFR (Y992) and Bim were increased and expression levels of 
Tuberin and pACC (S79) were decreased in SKOV3 xenografts and also SKOV3 
monolayers treated with GSK2141795 for 8 hours but not at 30 minutes indicating that this is 
a late event. Overexpression of YB-1 and pEGFR (Y992) was found in the clinical samples 
in response to GSK2141795. YB-1 is a RNA-binding protein that is involved in regulation of 
mRNA transcription, splicing, translation, and stability. Evdokimova et al have demonstrated 
that AKT mediates phosphorylation of YB-1 (Evdokimova, Ruzanov et al. 2006) so down-
regulation of YB-1 here, is expected as a result of AKT inhibition by GSK2141795.  
 
EGFR is a receptor tyrosine kinase that acts upstream of AKT and controls survival, cell 
proliferation, migration and metabolism by activating the PI3K/AKT, ERK and RSK pathway. 
Up-regulation of EGFR in this analysis shows activation of compensatory survival pathways 
regulated by EGFR in the absence of AKT signalling. In addition, ER et al have 
demonstrated that AKT facilitates the endocytic trafficking of EGFR to promote its 
degradation. Inhibition of AKT signalling decreased both EGFR degradation and recycling 
within the cells resulting in increased activation of RSK and ERK pathways (Er, Mendoza et 
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al. 2013).  This finding is in agreement with findings in this study showing overexpression of 
pEGFR in response to treatment with GSK2141795. Phosphorylation of HER2 at Y1248 was 
also increased in response to GSK2141795 in clinical samples suggesting activation of 
similar compensatory pathways in response to the AKT inhibition by GSK2141795.  
Activation of compensatory survival pathways in response to AKT inhibition shows 
importance of considering cross-talking pathways in targeted therapy drug and development 
of rational combination therapies such as combination of AKT and MEK inhibitors. 
 
Overall, it can be concluded that increased phosphorylation of AKT at T308 and decreased 
phosphorylation of ribosomal protein S6 phosphorylation at S235 and S240 and translational 
repressor protein 4EPB1 at S65 which were seen in in vitro, in vivo and clinical tumour 
samples following treatment with GSK2141795 may represent stable molecular biomarkers 
of AKT inhibition. These biomarkers, subject to further validation, can be eventually used in 
clinic to assess the modulation of AKT pathway by GSK2141795. In addition, alterations in 
phosphorylation of GSK3 and PRAS40, immediate down-stream targets of AKT, showed 
effective inhibition of AKT by GSK2141795 and efficacy of this compound in vitro, in vivo and 
in patients. Figure 6.13 illustrates interactions between proteins that altered expression in 
response to GSK2141795.  
 
Single agent GSK2141795 ‘response biomarkers’ and ‘predictive biomarkers’ 
Tumour biopsies taken from patients who showed decline in CA125 level in response to 4 
week treatment with GSK2141795 were used for investigation of response biomarkers. 
Response biomarkers were investigated by comparison of protein expression profiles 
between tumour samples taken from patients before and after 4 weeks treatment with 
GSK2141795. Although the same approach was used to investigate the PD biomarkers but 
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unlike PD biomarkers which were investigated by comparison of samples from all participant 
before and after treatment with GSK2141795, regardless of CA125 level, here only samples 
from patients who showed more that 30% decline in CA125 level were used for the analysis.  
Significant increase in expression of RAF-C and YB-1, and phosphorylation of EGFR, TAZ 
and ER-alpha, and significant decreases in expression of cyclin B1, PKCa, p27 and 
phosphorylation of YB-1 and Src were observed in ovarian cancer patients showing more 
than 30% decline in expression of CA125, in response to treatment with single agent 
GSK2141795. While the effect of AKT inhibition on cyclin B1, EGFR and p27 has been 
discussed above, the relationship between AKT inhibition and changes in some of the other 
proteins, and their relationship to response requires further study. Although these 
biomarkers can be used to assess the modulation of AKT pathway with GSK2141795 and 
effects of inhibition of AKT on down-stream signalling cascades in two different groups of 
patients (the ones who showed decline in CA125 level in response to the treatment and the 
ones who did not), but due to the short length of treatment with GSK2141795 (4 weeks) in 
this clinical trial, longer treatment with GSK2141795 and later biopsies may be more 
informative for assessment of response and resistance to GSK2141795.  
 
Predictive biomarkers were investigated by comparison between single pre-treatment 
tumour biopsies taken from patients who showed more that 30% decline in CA125 levels 
and the ones who did not. Expression of pMAPK (T202) was found to be significantly lower 
in tumour biopsies taken from responder patient prior to the initiation of the treatment with 
GSK2141795 compared to biopsies taken from non-responders. This finding suggests that 
pMAPK (T202) may represent a predictive biomarker for GSK2141795 activity. This 
predictive biomarker, subject to further validation in the following clinical trials for 
GSK2141795, can be used in advance of therapy to estimate the response of a specific 
patient to GSK2141795 treatment. This is particularly important for selection of patients who 
are most likely to response to the treatment with GSK2141795. High level of pMAPK (T202) 
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expression also suggests the potential benefit of combining GSK2141795 with inhibitors of 
MAPK pathway to maximise the effect of AKT inhibition by GSK2141795 in clinic.  
 
 
 
 
 
 
 
 
 
 
 
Figure 6-13  Interactions between proteins showed alteration in expression in 
response to GSK2151795. 
 In general, down-stream effectors of AKT down-regulated in response to GSK2141795 
while proteins involved in compensatory survival signalling pathways such as RAS/MAPK 
pathway up-regulated. In addition, some proteins up-stream of AKT, such as EGFR, 
showed up-regulations suggesting a feedback loop.  
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Cisplatin – PD Biomarkers  
More proteins were found showing altered expression in response to cisplatin in vivo 
compared with in vitro samples. Phosphorylation of ER-alpha was increased in SKOV3 in 
vivo xenografts and also in SKOV3 monolayers at both 30 minutes and 8 hour time points. 
Involvement of ER in apoptotic signalling in response to cisplatin has already been 
demonstrated. In 2003, Mandic et al reported a novel nucleus independent mechanism of 
action for cisplatin. They showed cisplatin induced apoptosis in the absence of DNA damage 
in enucleated cells and ER to be cisplatin’s non-nuclear target (Mandic, Hansson et al. 
2003).  
 
Increase in phosphorylation of p70S6K (T389) was seen in SKOV3 in vivo xenografts and 
also in SKOV3 monolayers 30 minutes after treatment with cisplatin. Dhar et al have 
demonstrated constitutive activation of p70S6K to be associated with intrinsic resistance to 
cisplatin (Dhar and Basu 2008). They showed the levels of phosphorylated p70S6K, but not 
total p70S6K was elevated in cisplatin resistant cells following treatment with cisplatin (Dhar 
and Basu 2008). This is in agreement with finding in this study, as SKOV3 cells are also 
known to be platinum resistant. However, in this study, down-regulation of S6-pS235 was 
found in xenografts treated with cisplatin, suggesting down-regulation of mTOR signalling 
and protein synthesis in response to cisplatin. Decrease in protein synthesis might be due to 
the down-regulation of S-G1 cell cycle progression and reduced cell proliferation as was 
indicated by reduced expression of cyclin-B in response to cisplatin in xenograft samples.  
 
Interestingly, the anti-apoptosis protein Bcl2 was found to be up-regulated in response to 
cisplatin in SKOV3 xenografts. Up-regulation of Bcl-2 has been previously reported in 
myeloma cells in response to exposure to other cytotoxic agents including etoposide and 
doxorubicin, and this up-regulation has been associated with resistance to the cytotoxic 
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agents (Tu, Xu et al. 1996).  In addition, reduced expression of cleaved caspase-7 in the 
same samples suggested resistance to platinum-induced apoptosis in SKOV3 xenografts. 
This finding is in agreement with findings in chapter 3, showing resistance to cisplatin in 
SKOV3 xenografts, and also in SKOV3 monolayers demonstrated by caspase 3/7 apoptosis 
assay. In addition, up-regulation of phospho-MEK (S217) and phospho-EGFR (Y1173) was 
found in SKOV3 xenografts treated with cisplatin, suggesting up-regulation of survival 
signalling in response to cisplatin in SKOV3 xenografts. Benhar et al have also shown 
activation of EGFR in response to cisplatin in human glioma and breast cancer cells, and 
they suggest the cisplatin-dependent EGFR activation to be a survival response that reduces 
the efficacy of cisplatin treatment (Benhar, Engelberg et al. 2002). 
 
Together, RPPA analysis of SKOV3 monolayers and xenografts treated with cisplatin, 
provided more evidence supporting resistance to cisplatin-induced apoptosis in this cell 
model both in vitro and in vivo, and identified several PD markers of cisplatin. 
 
Combination of GSK2141795 and cisplatin- PD Biomarkers 
Several proteins were found to change expression in the combination treatment with 
cisplatin and GSK2141795, but not following cisplatin or GSK2141795 as single agents. 
Identifying these proteins may help to understand mechanisms which led to increased 
induction of apoptosis in vitro and tumour size reduction in vivo, in response to the 
combination of cisplatin and GSK2141795, compared to treatment with single agent 
GSK2141795, as demonstrated in chapter 3.   
 
The apoptosis related protein cleaved caspase 7, was found to be up-regulated in SKOV3 
xenografts treated with combination of cisplatin and GSK2141795, but not in xenografts 
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treated with cisplatin or GSK2141795 only, indicating induction of apoptosis in xenograft 
tumours treated with the combination treatment. This finding suggest that reduction in 
tumour size observed in chapter 3 in the same xenografts in response to combination of 
GSK2141795 and cisplatin was a results of increased apoptosis.  
 
The DNA mismatch repair protein MSH6 was found to be down-regulated in SKOV3 
xenografts treated with the cisplatin and GSK2141795 combination treatment. This down-
regulation was not found in xenografts treated with cisplatin or GSK2141795 only suggesting 
decrease in DNA mismatch repair and increase in platinum induced DNA damage when 
cisplatin is combined with GSK2141795 compared to single agent cisplatin treatment.  
 
RAF/MEK/ERK pathway proteins were found to be down regulated in response to the 
combination of cisplatin and GSK2141795, in PEO4 and SKOV3 monolayers, suggesting 
decrease in cell proliferation and survival in samples treated with combination of 
GSK2141795 and cisplatin compared to single agent treatment.  
 
Together, the findings in this study show up-regulation of apoptosis signalling and down-
regulation of survival signalling via the mismatch repair and RAF/MEK/ERK pathways when 
cisplatin is combined with GSK2141795. This is in agreement with phenotypic observations 
in cell growth and apoptosis in both monolayers and 3D cell cultures and also in ovarian 
cancer xenografts, described in chapter 3.  
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Limitations of the study  
Several proteins were found to similarly change expression in response to the GSK2141795, 
cisplatin or the combination treatment in cell monolayers, xenografts and tumour samples 
from ovarian cancer patients. However, there were also differences in expression pattern 
between the in vitro, in vivo and in clinical ovarian cancer samples in response to the same 
treatments. This observation can be explained in several ways.  
 
Firstly, the in vitro, in vivo and clinical samples were collected on different time points and 
although care was taken to collect samples in relevant time-points but equivalent timing 
cannot be exactly estimated in the three models systems. Secondly, the number of samples 
collected was different for in vitro, in vivo and in clinical samples. The difference in the 
number of samples may result in statistical differences in calculation of significant changes.  
 
Moreover, in vitro monolayers and subcutaneous xenograft models may not fully mirror 
changes the happen within the cells in response to anti-cancer drugs in patients. This could 
be due to the differences in tumour cell microenvironment in cell monolayers, subcutaneous 
tumour xenograft and within the body in ovarian cancer patients, and inter-patient tumour 
heterogeneity.  
 
The advantage of using 3D microenvironment rather than 2D cell monolayers has been 
subject of many discussions in the last decades. In vivo cells form contacts and 
communicate with different cell types through the receptors distributed throughout the entire 
cell surface. However, in 2D monolayers, cells lose this three dimensional cell contact and 
only communicate along a small proportion of their membrane (Lin and Bissell 1993, 
Boudreau and Bissell 1998). It has been demonstrated that dissociation of non-malignant 
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mammary epithelial cells upon culture on plastic resulted in rapid loss of many features of 
the differentiated cells (Lin and Bissell 1993, Boudreau and Bissell 1998).  In the case of 
malignant cells it has been reported that the effects of inactivation of tumour-suppressor 
genes or activation of oncogenes are different in cells cultured in different 
microenvironments (Debnath, Mills et al. 2002, Wrobel, Debnath et al. 2004).  It has also 
been suggested that tumour cells grown in different microenvironments respond differently to 
chemotherapy and other factors (Teicher, Herman et al. 1990, Kobayashi, Man et al. 1993, 
Weaver, Lelievre et al. 2002, Neve, Chin et al. 2006).  The importance of cell-cell 
interactions in other tumour characteristics such as metastasis has also been demonstrated 
(Thiery and Chopin 1999). 
 
In addition, the novel PD biomarkers discovered in this study need to be verified with a follow 
up assay and the probability of false discovery has to be computed by multiple testing 
correction (Noble 2009). Response biomarkers investigated in this study are preliminary due 
to the short length of the phase I clinical trials (4 weeks) and has to be validated in the 
following longer clinical trials for GSK2141795. Repeat biopsies at longer time points than 4 
weeks may be more informative for investigation of response and resistance biomarkers for 
GSK2141795.  
 
Finally, findings in this chapter are another emphasis on tumour heterogeneity in ovarian 
cancer. The fact that the protein expression profile in response to the same treatment was 
different across ovarian cancer cells lines and tumour samples assessed in this study, 
shows that the same treatment may result in different responses in different ovarian cancer 
patients and even in different cells within the same tumour. Therefore, it is important to 
personalise treatment for each patient and even each tumour based on the unique and 
specific features of that tumour such as its protein or gene expression profile. 
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Conclusion 
In conclusion, in this chapter PD biomarkers for GSK2141795 were identified in vitro, in vivo 
and in ovarian cancer patients by applying RPPA protein analysis. These PD markers, 
specifically increased phosphorylation of AKT at T308 which was common in all in vitro, in 
vivo and clinical samples, can be used to assess the effectiveness of GSK2141795 in vitro, 
in vivo and in ovarian cancer patients. In addition, predictive response biomarkers for 
GSK2141795 were identified in ovarian cancer patients, potentially could be used to predict 
patient response to GSK2141795. It was also demonstrated that combination of 
GSK2141795 with cisplatin increased apoptotic signalling and decreased survival signalling 
in cultured cells and also in tumour xenografts compared to samples treated with 
GSK2141795 or cisplatin only.  These results support the further clinical development of 
GSK2141794 as a single agent and in combination with cisplatin in ovarian cancer, and the 
validation and use of the above PD, response and predictive biomarkers for treatment/trial 
optimisation. 
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7 The effect of DNA-PK inhibition, 
alone or in combination with 
cisplatin, on cellular signalling 
cascades 
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7.1 Introduction 
 
It was demonstrated in chapter 5 that inhibition of DNA-PK with NU7441 resulted in 
sensitisation of platinum resistant ovarian cancer cells to cisplatin in vitro and in vivo, while 
single agent NU7441 showed no activity. This shows the potential of DNA-PK inhibitors to be 
used in clinic to overcome platinum resistance in ovarian cancer.  
  
To facilitate development of DNA-PK inhibitors to be used in combination with cisplatin in 
clinic, it would be useful to identify PD biomarkers to monitor the activity of these agents in 
patients. The aim of this chapter was to identify PD biomarkers for NU7441 as single agent 
or in combination with cisplatin in vitro and in vivo, and key proteins involved in sensitisation 
of SKOV3 cells to platinum in response to combination of the DNA-PK inhibitor NU7441 and 
cisplatin. 
 
To achieve this aim, RPPA analysis was used to assess the effect of DNA-PK inhibition with 
NU7441, alone or in combination with cisplatin, on cellular signalling cascades in SKOV3 
monolayers and tumour xenografts.  
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7.2 Results 
 
 
7.2.1 Effect of single agent NU7441 or in combination with cisplatin on cellular 
protein signalling cascades in vitro 
 
To assess the effect of DNA-PK inhibition as single agent or in combination with cisplatin on 
cellular signalling cascades in vitro, SKOV3 monolayers were treated with 10 µM NU7441 
alone for 8 hours, or in combination with 25 µM cisplatin (NU7441 was added an hour prior 
to cisplatin), and protein lysates were analysed by RPPA, and normalised to DMSO treated 
cells.  
 
Expression levels of pMAPK (T202-Y182) and p38 (T180-Y182) increased (~1.5 and 1.4-fold 
respectively), whereas pS6 (S240 – S244) (S235 – S236) was down-regulated (~5-fold) in 
response to NU7441 (Figure 7.1).   
 
Phosphorylation of ER-alpha at S118, and ChK1 at S45 were increased (1.7 and 1.5-fold 
respectively), whereas expression of PI3K-p110, ER-alpha and YB-1 were decreased about 
2-fold in in response to single agent cisplatin, compared to DMSO treated cells (Figure 7.2).  
 
Twenty one proteins were found to be up-regulated and 13 to be down-regulated in samples 
treated with the combination of NU7441 and cisplatin, compared with vehicle controls. 
Among these proteins beclin, phospho-ER-alpha (S118), cleaved caspase-3 and pChK1 
(S345) showed the highest level of increase in expression (~2-fold), and pS6 (S235-S236) 
and pS6 (S240-S244) showed the decrease in expression (~4-fold) (Figure. 7.3).  
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To identify proteins which their expressions altered only in response to NU7441 and cisplatin 
combination treatment, but not in samples treated with each drug as single agent, protein 
expression levels were compared in samples treated with NU7441, or cisplatin, or 
combination of both (Figure 7.4; Table 7.1 and 7.2). Nine proteins were found to be up-
regulated and 16 to be down-regulated in samples treated with combination of NU7441 and 
cisplatin, which did not alter in response to NU7441 or cisplatin as single agents. Up-
regulation of beclin was seen in response to the combination treatment showing increase in 
cellular stress. Up-regulation of the pro-apoptotic protein, Bim and activated caspase-3 
which was only seen in response to the combination treatment, shows increase in apoptosis 
in cells treated with combination of cisplatin and NU7441 compared to the ones treated with 
cisplatin or NU7995 only. This was consistent with findings using the caspase 3/7 apoptosis 
assay in chapter 5, that increase in induction of apoptosis was observed in cells treated with 
combination of NU7441 and cisplatin. Interestingly, down-regulation of pTAZ and pYAP was 
found in cells treated with the combination of NU7441 and cisplatin. Down-regulation of 
pYAP was also seen in SKOV3 monolayers treated with combination of GSK2141795 and 
cisplatin in chapter 6 (Figure. A.17, Table.A.11), suggesting a potential role for the Hippo 
pathway in mechanism of sensitisation to cisplatin in platinum resistant cells.  
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Figure 7-1 Proteins showing up-regulation or down-regulation in SKOV3 monolayers 
treated with NU7441 compared with vehicles 
 SKOV3 monolayers were treated with 10 µM NU7441 and level of protein expression was 
compared with DMSO treated samples. The graph demonstrates proteins showing ≥ 1.3-fold 
increase or decrease in expression compared with DMSO treated samples, n=1.  
 
Figure 7.5 Proteins showing up-regulation or down-regulation in SKOV3 monolayers 
treated with NU7441 compared with vehicles. SKOV3 monolayers were treated with 10 
µM NU7441 and level of protein expression was compared with DMSO treated samples. 
The graph demonstrates proteins showing ≥ 1.3 fold increase or decrease in expression 
compared with DMSO treated samples. 
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Figure 7-2 Proteins showing up-regulation or down-regulation in SKOV3 monolayers 
treated with cisplatin compared with vehicles 
 SKOV3 monolayers were treated with 25 µM cisplatin and level of protein expression was 
compared with DMSO treated samples. The graph demonstrates proteins showing ≥ 1.3-fold 
increase or decrease in expression compared with DMSO treated samples, n=1. 
 
Figure 7.6 Proteins showing up-regulation or down-regulation in SKOV3 monolayers 
treated with cisplatin compared with vehicles. SKOV3 monolayers were treated with 25 
µM cisplatin and level of protein expression was compared with DMSO treated samples. The 
graph demonstrates proteins showing ≥ 1.3 fold increase or decrease in expression 
compared with DMSO treated samples. 
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Figure 7-3 Proteins showing down-regulation A) or up-regulation B) in SKOV3 
monolayers treated with combination of NU7441 and cisplatin compared with 
vehicles 
 SKOV3 monolayers were treated with combination of 10 µM NU7441 and 25 µM cisplatin 
and level of protein expression was compared with DMSO treated samples. The graph 
demonstrates proteins showing ≥ 1.3-fold increase or decrease in expression compared 
with DMSO treated samples, n=1. 
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Figure 7-4 Comparison of up-regulations a) and down-regulations b) in protein 
expression in SKOV3 monolayers treated with NU7441 or cisplatin or combination of 
both. 
 Nine proteins were up-regulated and 1 protein was down-regulated only in combination 
treatments but not in cddp and NU7441 treated samples.  
 
Figure 7.8. Comparison of up-regulations a) and down-regulations b) in protein 
A 
 
A 
B 
 
B 
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Up-regulated proteins CDDP + NU7441 NU7441 CDDP 
p38_pT180_Y182-/norm Yes Yes No 
Chk1_pS345 Yes No Yes 
Chk1_pS345/norm Yes No Yes 
ER-alpha_pS118-/norm Yes No Yes 
ACC_pS79/norm Yes No No 
Beclin Yes No No 
Bim Yes No No 
Caspase-3_active Yes No No 
Claudin-7 Yes No No 
EGFR_pY1173 Yes No No 
ER-alpha_pS118 Yes No No 
FAK Yes No No 
p27 Yes No No 
Akt_pS473 No Yes No 
Akt_pT308 No Yes No 
Fibronectin No Yes No 
MAPK_pT202_Y204 No Yes No 
MEK1_pS217_S221/norm No Yes No 
AMPK_pT172/norm No No Yes 
Caveolin-1 No No Yes 
 
 
 
 
 
 
 
 
 
Table 7-1Comparison of protein up-regulations in SKOV3 monolayers treated with 
NU7441 or cisplatin or combination of NU7441 and cisplatin.  
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Down-regulated proteins CDDP + NU7441 NU7441 CDDP 
p70S6K_pT389 Yes Yes No 
p70S6K_pT389/norm Yes Yes No 
S6_pS235_S236 Yes Yes No 
S6_pS240_S244 Yes Yes No 
YB-1_pS102-/norm Yes No Yes 
4EBP1_pT37-T46-/norm Yes No No 
ACC1  Yes No No 
Caveolin-1 Yes No No 
Cyclin_B1 Yes No No 
GAB2 Yes No No 
IGFBP2  Yes No No 
mTOR_ pS2448 Yes No No 
mTOR Yes No No 
NF2 Yes No No 
p27_pT157/norm Yes No No 
p27_pT198/norm Yes No No 
p38_MAPK Yes No No 
PTEN Yes No No 
Rb_pS807_S811  Yes No No 
TAZ_pS89  Yes No No 
YAP_pS127/norm Yes No No 
HER3_pY1298-/norm No Yes No 
ER-alpha No No Yes 
PI3K-p110-alpha No No Yes 
 
 
 
 
 
Table 7-2  Comparison of protein down-regulations in SKOV3 monolayers treated 
with NU7441 or cisplatin or combination of NU7441 and csiplatin.  
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7.2.2 Effect of inhibition of DNA-PK with NU7441 as single agent or in combination 
with cisplatin on cellular protein signalling cascades in vivo 
 
To investigate the effect of inhibition of DNA-PK with NU7441 as a single agent or in 
combination with cisplatin on protein signalling cascades in vivo, mice bearing SKOV3 
xenografts were treated with 10 mg/kg NU7441, or 1 mg/kg cisplatin, or combination of both 
drugs. Protein samples extracted from xenografts were analysed for changes in expression 
in response to each treatment by RPPA.  
 
Proteins with 1.3-fold increase or decrease in expression in xenografts treated with NU7441 
as single agent compared to xenografts treated with DMSO only are shown in Figure 7.5 and 
Table 7.3. Phosphorylation of AKT at S473 significantly decreased showing the effective 
inhibition of DNA-PK, as AKT in an immediate down-stream target of AKT. However, 
phosphorylation of down-stream targets of AKT, PRAS40 and GSK3, increased in response 
to DNA-PK inhibition suggesting that phosphorylation of AKT at S473 may not be required 
for activation of the mTOR branch of AKT signalling. A 1.5-fold increase in expression of the 
DNA mismatch repair protein, MSH6 was also observed. EEF2K and YAP phosphorylated at 
S127 showed the highest increase in expression (~1.5-fold, p< 0.05) and fibronectin and 
EGFR showed the greatest decrease (~ 2-fold, p < 0.05).  
 
In xenografts treated with 1 mg/kg cisplatin for 3 hours, very few proteins showed significant 
a change in expression (<1.3-fold, p<0.05) (Figure. 7.6 and Table 7.4). HER3 and p70S6K 
showed the highest increase, suggesting activation of cellular survival pathways in response 
to cisplatin and ER-alpha showed the highest decrease (~2-fold, p < 0.05) (Figure 7.2, Table 
7.2).  
 
233 
 
In xenografts treated with the combination of cisplatin and NU7441,  fibronectin expression 
decreased the most (2-fold, p<0.05) and eEF2K, MSH6 and cyclin_B1 showed the highest 
increase (1.5-fold). In addition, p38 and phospho-AKT(S473) were among the proteins 
showing significant down-regulation, and phospho-GSK3(S9), phospho-4EBP1, phospho-
YAP(S127), phospho-PRAS40(T246) and MEK1 were among the proteins showing the 
highest significant up-regulation (Figure 7.7 and Table 7.5).  
 
Alterations in protein expression in cisplatin or NU7441 single agent treated groups were 
identified and compared to alteration in protein expression in the combination group. This 
comparison was done to identify proteins which their level of expression changed in 
response to the combination treatment but remained unchanged in response to either 
cisplatin or NU7441 single agent treatment, to identify proteins involved in the mechanism of 
re-sensitisation to cisplatin (Figure 7.8; Tables 7.6 and 7.7). Up-regulation in expression of 
cyclin B1, MEK-1 and 4EBP1, and down-regulation of p21 and phospho-EGFR were only 
found in xenografts treated with combination treatment and not in xenografts treated with the 
single agent cisplatin or NU7441.  
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Figure 7-5 Proteins showing up-regulation A) or down-regulation B) in SKOV3 xenografts 
treated with NU7441 
 SKOV3 xenografts were treated with 10 mg/kg NU7441 and level of protein expression was 
compared with the DMSO treated xenografts. The graph demonstrates proteins showing ≥ 1.3-
fold increase or decrease in expression compared with DMSO treated xenografts. * indicates t-
test p values ≤ 0.05, n=9. Data shows mean of results for 9 samples  ± SD.  
 
Figure 7.1 Proteins showing up-regulation A) or down-regulation B) in SKOV3 xenografts 
treated with NU7441. SKOV3 xenografts were treated with 10 mg/kg NU7441 and level of 
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* 
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Protein Ratio NU7441/DMSO p-value 
Mre11 3.2 0.1 
ER.alpha 2.0 0.6 
eEF2K 1.6 0.002 
YAP_pS127 1.5 0.001 
MSH6 1.5 0.000 
PRAS40_pT246 1.4 0.001 
eEF2 1.4 0.2 
c.Myc 1.3 0.001 
GSK3_pS9 1.3 0.003 
p70S6K_pT389 1.3 0.006 
Annexin_I 0.7 0.00 
p38_MAPK 0.7 0.001 
ACC_pS79 0.6 0.02 
Akt_pS473 0.6 0.009 
AMPK_alpha 0.6 0.004 
S6_pS240_S244 0.5 0.09 
AMPK_pT172 0.5 0.00 
EGFR 0.5 0.08 
S6_pS235_S236 0.5 0.1 
IGFBP2 0.5 0.05 
Fibronectin 0.4 0.01 
 
 
 
 
 
 
 
 
 
 
Table 7-3 Proteins showing ≥ 1.3-fold increase or decrease in expression in 
SKOV3 xenografts treated with NU7441 compared with DMSO treated samples 
(n=9)  
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Figure 7-6 Proteins showing up-regulation A) or down-regulation B) in SKOV3 
xenogrfts treated with cisplatin compared with vehicles 
 SKOV3 xenografts were treated with 1 mg/kg cisplatin and level of protein expression was 
compared with DMSO treated xenografts. The graph demonstrates proteins showing ≥ 1.3-
fold increase or decrease in expression compared with DMSO treated xenografts. * 
indicates p values ≤ 0.05, Data shows mean of n=5 samples ± SD.  
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Proteins Ratio CDDP/DMSO p-value 
ACC1 1.8 0.1 
p70S6K_pT389 1.5 0.006 
HER3 1.5 0.08 
Bim 1.4 0.1 
PR 1.3 0.08 
EGFR 0.75 0.4 
Cyclin_B1 0.75 0.1 
NF2 0.72 0.06 
X53BP1 0.71 0.08 
Tuberin 0.71 0.06 
Annexin_I 0.69 0.1 
S6_pS240_S244 0.68 0.3 
ER.alpha 0.65 0.01 
S6_pS235_S236 0.62 0.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 7-4 Proteins showing ≥ 1.3-fold increase or decrease in expression in 
SKOV3 xenografts treated with cisplatin compared with DMSO treated 
samples (n=9) 
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Figure 7-7 Proteins showing up-regulation A) or down-regulation B) in SKOV3 
xenografts treated with combination of NU7441 and cisplatin compared with vehicles 
 SKOV3 xenografts were treated with 10 mg/kg NU7441 and 1 mg/kg cisplatin and level of 
protein expression was compared with DMSO treated xenografts. The graph demonstrates 
proteins showing ≥ 1.3-fold increase or decrease in expression compared with DMSO 
treated xenografts. * indicates P values ≤ 0.05, Data shows mean of n=9 samples ± SD.  
 
Figure 7.3 Proteins showing up-regulation A) or down-regulation B) in SKOV3 
xenografts treated with combination of NU7441 and cisplatin compared with vehicles. 
* 
 
* 
* 
 
* 
* 
 
* 
* 
 
* 
* 
 
* 
* 
 
* 
* 
 
* 
* 
 
* 
* 
 
* 
* 
 
* 
* 
 
* 
* 
 
* 
* 
 
* 
239 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protein Ratio NU7441+CDDP / DMSO p-value 
eEF2K 1.5 0.001 
Cyclin_B1 1.5 0.000 
MSH6 1.5 0.000 
PRAS40_pT246 1.4 0.01 
YAP_pS127 1.3 0.001 
4EBP1_pS65 1.3 0.0001 
MEK1 1.3 0.001 
GSK3_pS9 1.3 0.001 
c.Myc 1.3 0.005 
ACC_pS79 0.76 0.1 
EGFR_pY992 0.74 0.06 
p38_MAPK 0.74 0.001 
Akt_pS473 0.74 0.03 
p21 0.71 0.001 
AMPK_pT172 0.71 0.08 
IGFBP2 0.65 0.2 
S6_pS240_S244 0.65 0.2 
EGFR 0.64 0.2 
S6_pS235_S236 0.59 0.1 
Fibronectin 0.51 0.02 
Table 7-5 Proteins showing ≥ 1.3-fold increase or decrease in expression in 
SKOV3 xenografts treated with combination of NU7441 and cisplatin 
compared with DMSO treated samples (n=9)  
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Figure 7-8 Comparison of up-regulations A) and down-regulations B) in protein 
expression in SKOV3 xenografts treated with NU7441 or cisplatin or combination of both 
Three proteins were up-regulated and 2 proteins were down-regulated only in combination 
treatments but not in cddp and NU7441 treated samples.  
 
Figure 7.4. Comparison of up-regulations A) and down-regulations B) in protein 
expression in SKOV3 xenografts treated with NU7441 or cisplatin or combination of 
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Protein CDDP NU7441 NU7441+CDDP Venn group 
c.Myc No Yes Yes 5 
eEF2K No Yes Yes 5 
GSK3_pS9 No Yes Yes 5 
MSH6 No Yes Yes 5 
PRAS40_pT246 No Yes Yes 5 
YAP_pS127 No Yes Yes 5 
p70S6K_pT389 Yes Yes No 4 
Cyclin_B1 No No Yes 3 
MEK1 No No Yes 3 
 4EBP1_pS65 No No Yes 3 
eEF2 No Yes No 2 
ER.alpha No Yes No 2 
Mre11 No Yes No 2 
ACC1 Yes No No 1 
Bim Yes No No 1 
HER3 Yes No No 1 
PR Yes No No 1 
Table 7-6Comparison of protein up-regulations in SKOV3 xenografts treated 
with NU7441 or cisplatin or combination of NU7441 and csiplatin.  
 
Table 7.4. Comparison of protein up-regulations in SKOV3 xenografts treated 
with NU7441 or cisplatin or combination of NU7441 and csiplatin.  
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Sample CDDP NU7441 CDDP+NU7441 Venn group 
EGFR Yes Yes Yes 7 
S6_pS235_S236 Yes Yes Yes 7 
S6_pS240_S244 Yes Yes Yes 7 
ACC_pS79 No Yes Yes 5 
Akt_pS473 No Yes Yes 5 
AMPK_pT172 No Yes Yes 5 
Caspase-7_cleaved No Yes Yes 5 
Fibronectin No Yes Yes 5 
IGFBP2 No Yes Yes 5 
p38_MAPK No Yes Yes 5 
Annexin_I Yes Yes No 4 
EGFR_pY992 No No Yes 3 
p21 No No Yes 3 
AMPK_alpha No Yes No 2 
Cyclin_B1 Yes No No 1 
ER.alpha Yes No No 1 
NF2 Yes No No 1 
Tuberin Yes No No 1 
53BP1 Yes No No 1 
Table 7-7Comparison of protein down-regulations in SKOV3 xenografts treated 
with NU7441 or cisplatin or combination of NU7441 and cisplatin.  
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7.3 Discussion 
 
In chapter 5, it was demonstrated that combination of the DNA-PK inhibitor NU7441 and 
cisplatin, increased apoptotic response in ovarian cancer monolayers compared to the cells 
treated with cisplatin only.  Also it was shown in chapter 5 that combination of the DNA-PK 
inhibitor, NU7441, and cisplatin resulted in tumour shrinkage in SKOV3 xenografts. In this 
chapter, SKOV3 monolayers or xenografts treated with either NU7441 or cisplatin or 
combination of both drugs were assessed for alteration in protein expression in response to 
each treatment.  
 
Single agent NU7441 
Inhibition of DNA-PK with NU7441 led to a significant increase in expression of the mismatch 
repair protein MSH6 in vivo. As discussed in the introduction (Chapter 1), DNA-PK has an 
important role in DNA double strand break repair through the non-homologous end-joining 
(NEHJ) pathway. To initiate NEHJ, Ku70 binds to the broken end of DNA forming a complex 
together with Ku80. This complex recruits the catalytic subunit of DNA-PKCS to the broken 
end of DNA leading to the activation of NEHJ pathway  (Lieber, Ma et al. 2003). On the other 
hand MSH6 plays a fundamental role in the repair of mismatched DNA bases. Increase of 
MSH6 in response to DNA-PK inhibition suggests that in cancer cells when one DNA-repair 
pathway is disturbed, cells may rely on a different DNA repair pathway to repair DNA 
damages. Recently, Shahi et al have reported that MSH6 physically associates with Ku70 
and regulates DNA double-strand break repair (Shahi, Lee et al. 2011). In addition, an 
increase in expression of Mre11, another protein involved in initiation of NEHJ, was 
observed in xenografts treated with NU7441 although this increase was not statistically 
significant.  
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A significant decrease in phosphorylation of AKT at S473 was found in response to DNA-PK 
inhibition. This decrease was expected as DNA-PK is one of the known protein kinases 
which phosphorylates AKT at S473 alongside with mTOR-Rictor complex 2 and integrin-
linked kinase (ILK) (Dragoi, Fu et al. 2005). Interestingly, despite the decrease in 
phosphorylation of AKT at S473 in response to DNA-PK inhibition alone or in combination 
with cisplatin, a significant increase was found in expression of down-stream targets of AKT, 
pPRAS40 and pGSK3 suggesting that DNA-PK might not be involved in activation of AKT 
through the mTOR branch of the AKT pathway or for regulation of the glucose metabolic 
pathway mediated by AKT.  
 
In addition, expression levels of AMPK and pAMPK were significantly decreased in 
xenografts treated with NU7441. The inhibitory effect of AKT for AMPK has already been 
reported (Lee and Park 2010) suggesting that inhibition of phosphorylation of AKT via DNA-
PK inhibition in this study did not affect the inhibitory role of AKT on AMPK.  
 
Cisplatin 
Only a few proteins changed expression in response to 1 mg/kg cisplatin in SKOV3 
xenografts, compared to the higher dose of cisplatin (1.5 mg/kg) in chapter 6, reflecting the 
lower dose of cisplatin used on cellular signalling. This finding was in agreement with the 
phenotypic observation in chapter 5, that no significant difference was seen in tumour growth 
in 14 days between xenografts treated with DMSO only and the ones treated with 1 mg/kg 
cisplatin.  
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Combination of NU7441 and cisplatin 
MEK1 was significantly up-regulated in xenograft tumours treated with the combination of 
NU7441 and cisplatin, but not in tumours treated with either NU7441 or cisplatin. MEK1  has 
a key role in tumour cells survival through the RAS-MEK-ERK pathway, and cross talk 
between MEK and AKT pathways under cellular stress has been reported (Dai, Chen et al. 
2009). Therefore, overexpression of MEK observed here might be due to loss of AKT 
mediated survival signalling cascade as a result of DNA-PK inhibition.  
 
The cyclin-dependent kinase inhibitor, p21, was found to be significantly down-regulated 
only in xenograft tumours treated with the combination treatment. P21 is an inhibitor of 
proliferation, and is induced by both p53-dependent and -independent mechanisms following 
stress. Induction of p21 following cellular stress may cause cell cycle arrest. Cells are driven 
to apoptosis after caspase-3-induced cleavage of p21 (Gartel and Tyner 2002). Down-
regulation of p21 in response to the combination treatment suggests DNA-PK mediated 
activation of p21 in response to DNA damage. On the other hand, cyclin B 1, an important 
component of cells cycle machinery that controls G2 to M transition, is inhibited by p21 and 
in this analysis, up-regulation of cyclin B1 was found in xenograft samples treated with 
combination of cisplatin and NU7441.  
 
Up-regulation of proteins involved in apoptosis pathway such as cleaved caspase 3 and the 
pro-apoptotic protein BIM and also down-regulation of proteins involved in cell proliferation 
and survival pathways such as p38-MAPK, pmTOR and cyclin-B1 was found in SKOV3 
monolayers treated with combination of NU7441 and cisplatin but not in samples treated with 
cisplatin or NU7441 only. This finding supports findings in chapter 5 demonstrating that 
DNA-PK inhibition using NU7441 combined with cisplatin results in increase of apoptosis 
and decrease in cell survival compared to single agent cisplatin or NU7441 treatments. 
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Interestingly, down-regulation of YAP (Yes-associated Protein) and TAZ phosphorylation 
found in response to the combination of cisplatin and DNAPK inhibition by NU7441 was also 
observed in response to the combination of AKT inhibition by GSK2141795 and cisplatin in 
chapter 6. As these protein expression alterations were both specific to the combination 
treatments and were not found in samples treated with either single agents, and both 
combinations resulted in the same phenotype (ie senstitisation of SKOV3 platinum resistant 
cells to cisplatin), this suggest a potential role for the Hippo pathway as a mechanism of 
sensitisation to cisplatin. The Hippo pathway has a key role in controlling organ size by 
inhibiting cell proliferation and promoting apoptosis through phosphorylation of YAP. Recent 
studies suggest a potential cross talk between the Hippo and PI3K/AKT/mTOR pathways 
that leads to coordination between the two pathways to control cell growth (Tumaneng, 
Schlegelmilch et al. 2012). Regulation of Hippo pathway is not fully understood yet so 
gaining further knowledge about this pathway may lead to development of novel therapies to 
overcome platinum resistance in ovarian cancer.  
 
Conclusion 
In this chapter a core set of PD biomarkers for NU7441 was identified in vitro and in vivo. 
However, those PD biomarkers were found to be different in cell monolayers and xenografts. 
This difference may be due to the limitations were already discussed for RPPA analysis in 
chapter 6 such as different microenvironment in vitro and in vivo and difference in time and 
schedule of treatments in the two different models. Down-regulation of pS6 and up-
regulation of P38(p180) were identified as in vitro PD biomarkers while up-regulation of 
eEF2K, YAP(pS127), MSH6 and down-regulation of AKT(pS473) may represent in vivo PD 
biomarkers for NU7441. Although PD biomarkers reflect modulation of a defined biological 
target with a specific drug, biomarkers that correlate with the treatment outcome (such as 
predictive biomarkers) are required to translate biological changes into clinical benefits. 
247 
 
Therefore future clinical studies with DNA-PK inhibitors should include efforts to identify 
predictive biomarkers as well as PD biomarkers.  
Also, in this chapter it was demonstrated while single agent cisplatin or NU7441 showed no 
effect in triggering apoptosis in SKOV3 cells, down-regulation of survival signalling pathways 
and up-regulation of apoptotic signalling were observed when cisplatin was combined with 
NU7441. These findings and findings from chapter 5 encourage further pre-clinical and 
clinical development of NU7441 or other DNA-PK inhibitors to overcome platinum resistance 
in ovarian cancer.  
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8 Summary and future directions 
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Epithelial ovarian cancer (EOC) is the most lethal form of gynaecological malignancy. The 
prognosis of patients with ovarian cancer is poor, with 30-40% overall 5-year survival, due to 
the development of platinum resistance; the most active agent in this disease. Novel 
therapeutic strategies for reversal of platinum resistance and/or active agents in platinum 
resistant patients are urgently required. In addition, improvements in the efficiency of cancer 
drug development are also needed if the potential of the large number of candidate drugs in 
development is to rapidly and economically realised. The development of drugs for treatment 
of cancer remains a slow and high-risk process with many compounds failing due to 
unfavourable pharmacokinetic profiles, toxicity and and/or  lack of therapeutic efficacy 
(Neidle 2008). The high failure rate contributes to the high cost in both financial and human 
terms of drug development. One strategy, termed the PHAT (pharmacological audit trail) has 
advocated the preclinical development of effective pharmacodynamic (PD) biomarkers, to 
monitor drug activity and enable go/no-go decisions. 
 
In this thesis pre-clinical evaluation and development of a specific, ATP-competitive AKT 
inhibitor, GSK2141795 as potential therapeutic strategy in ovarian cancer, as single agent 
and to restore platinum sensitivity was assessed. Single agent GSK2141795 showed growth 
inhibitory effect in vitro and in vivo. In addition, GSK2141795 was also shown to restore 
platinum sensitivity in platinum-resistant ovarian cancer cell lines and tumour xenografts.  
 
A key area of increased focus aimed at improving the probability of success in the drug 
discovery process, is the identification and validation of reliable pharmacodynamic (PD) 
biomarkers of target modulation by the drug, that can be used both during  pre-clinical and 
clinical development, and ideally can also be correlated with clinical outcome. One approach 
clinically is to use tumour biopsies taken before and after drug treatment to measure 
modulation of PD makers. PD biomarkers may include cellular, molecular, histopathological 
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and/or imaging parameters (Sarker, Pacey et al. 2007, Sarker and Workman 2007). It is 
anticipated that such PD biomarkers should clearly enable efficient and scientifically-driven 
“Go/NoGo” decisions allowing expediency of the drug development process. 
 
In the case of AKT inhibitors, AKT substrates such as phospho-PRAS40, are being used as 
PD biomarkers (Yan, Serra et al. 2013). However, the invasive nature of serial tumour 
biopsies in patients limits its application and recruitment in clinical trials. In addition, intra-
patient tumour heterogeneity can also limit the utility of tumour biopsies from single sites. 
The development of non- invasive PD biomarkers therefore has the potential to aid clinical 
drug development. 
 
Positron emission tomography (PET) is a non-invasive imaging technology that measures 
the three dimensional spatial and temporal uptake of a radioligand in vivo. PET imaging 
using the glucose analogue [18F]FDG as a radio-tracer is widely used in the field of oncology, 
to monitor the tumour response to the treatments by measuring tumour metabolism. 
However, given the role of AKT in the regulation of glucose metabolism, [18F]FDG-PET can 
potentially be used as a non-invasive PD biomarker for AKT inhibitors.  In this project, to 
enable the clinical development of GSK2141795, the utility of FDG-PET imaging as a PD 
biomarker of GSK2141795 induced AKT inhibition was explored. The changes in glucose 
metabolism (as measured by changes in FDG uptake) were shown to correlate with changes 
in downstream biomarkers (phospho-PRAS40) of AKT inhibition in cell lines in vitro, and 
similar effects were demonstrated in vivo in xenograft experiments. These results formed the  
basis of a clinical trial of GSK2141795 in ovarian cancer, to validate the utility of FDG-PET 
as a clinically useful PD biomarker for individualisation of inter-patient dosing, thereby 
optimising the risk/benefit profile of the drug. 
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In this dose escalation study of GSK2141795 in cancer patients, an inverse relationship 
between maximum GSK2141795 plasma concentrations with the maximum decrease in 
[18F]FDG uptake in patient tumours was confirmed (Gungor H 2011). However, the lack of a 
clear dose response relationship in the latter study was likely due to a narrow dose range 
tested (25-75 mg, daily) coupled with large inter-patient variability in the pharmacokinetics of 
GSK2141795. Maximum GSK2141795 plasma concentrations observed in the clinical study 
ranged from approximately 300-800 ng/mL (0.70-1.86 μM), with >40% decrease in [18F]FDG 
uptake in 5 out of 6 patients achieving >1 μM Cmax on week 4 (Gungor, Saleem et al, 2011). 
The preclinical data reported in this thesis are in agreement with the clinical observations 
that AKT inhibition with GSK2141795 requires ≥1 μM concentration for optimal decreases in 
[18F]FDG uptake.  
 
PD biomarkers should ideally be incorporated as all stages of drug discovery from in vitro 
and preclinical studies to clinical trials. To identify additional PD biomarkers, the effect of 
inhibition of AKT using GSK2141795 as single agent or in combination with cisplatin on 
cellular signalling cascades in ovarian cancer cells was closely studied in vitro, in vivo and in 
tumour samples from ovarian cancer patients. This part of study was done to validate the PD 
biomarkers already known for AKT inhibition and also to find novel canonical and non-
canonical PD markers for GSK2141795 as a single agent or in combination with cisplatin. In 
general, down-stream targets of AKT such as PRAS40, S6, GSK3, mTOR and 4EPB1 were 
down-regulated in response to AKT inhibition by GSK2141795. In particular, alterations in 
phosphorylation of AKT at T308, S6 at S235 and S240 and 4EPB1 at S65 was consistent 
across all the in vitro, in vivo and clinical samples and these proteins may represent stable 
molecular PD biomarkers of AKT inhibition.  
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In addition, proteins involved in compensatory survival signalling pathways, such as MAPK 
and EGFR, showed up-regulation in response to GSK2141795 treatment, and may 
represent resistance mechanisms. This finding emphasises the importance of considering 
cross talks between signalling pathways in targeted therapy drug development and has 
implication in development of rational combination therapies, such as the combination of 
AKT and MEK inhibitors.  
 
Response biomarkers were also explored for GSK2141795 using pre and post-treatment  
clinical samples from the phase I trial of GSK2141795 (Gungor H 2011). Interestingly, some 
of these biomarkers such as YAP and TAZ were non-canonical biomarkers indicating the 
importance of signalling pathways other than PI3K/AKT/mTOR pathway on response to AKT 
inhibition. However, it should be considered that patients in this study were treated with daily 
GSK2141795 for only 4 weeks which may not be sufficient to observe the proteomic 
changes in response to the treatment. Later biopsies may be more informative to identify 
response biomarkers for GSK2141795. In addition, number of patients were relevantly low in 
this phase I clinical study and these markers merit further validation in larger Phase 2/3 
trials.  
 
In addition to PD biomarkers which are essential to provide reassurance that target and 
pathway modulation has been successful at all stages of drug development, predictive 
biomarkers are also required to identify a selected group of patients who may benefit the 
most from the treatment. Predictive biomarkers can be used to minimise the number of 
patients who may receive ineffective treatments. In this study predictive biomarkers for 
GSK2141795 were explored and pMAPK was found to be a potential predictive biomarker 
for clinical use of this drug.  
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The finding in this thesis that GSK2141795 synergises with platinum, to increase platinum 
sensitivity in in vitro and in vivo models, also merits further evaluation. A next step towards 
further clinical development of GSK2141795 may be the clinical assessment of safety and 
efficacy of this compound in combination with platinum based cytotoxic agents in recurrent 
ovarian cancer patients.  
 
Another strategy for restoration of platinum sensitivity explored in this thesis was DNA-PK 
inhibition with NU7441. Like GSK2141795, NU7441 also increased sensitivity to platinum, 
but did not show significant single agent activity. Protein analysis of in vitro and in vivo 
platinum resistant ovarian cancer samples treated with combination of either the DNA-PK 
inhibitor NU7441 or the AKT inhibitor GSK2141795 with cisplatin, showed up-regulation of 
apoptotic proteins such as caspase and down-regulation of survival pathways in the 
combination treatment compared to the single agent treatments. Overall, findings from 
protein analysis using either single agent NU7441 or GSK2141795 or in combination with 
cisplatin were in agreement with phenotypic observations using the same treatments in vitro 
and in vivo. The results suggest further development of NU7441 in ovarian cancer, in 
combination with cisplatin. 
 
Inhibition of PI3K was found to be less effective than inhibition of AKT in platinum resistant 
ovarian cancer cells lines. Knockdown of genes encoding for subunits of PI3K did not restore 
sensitivity to platinum in those cells lines. However, effect of PI3K inhibition on sensitivity to 
platinum has to be assessed in larger number of platinum resistant cell lines and also in 
patient derived tumour cells to validate findings from this study.  
 
It has previously been shown in our group that following platinum induced DNA damage, 
AKT is translocated to the nucleus, where it is phosphorylated by DNA-PK at S473 and this 
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DNA-PK mediated activation of AKT causes resistance to platinum. On the other hand, PI3K 
mediated phosphorylation of AKT at the other phosphorylation site, T308 is believed to be 
necessary for activation of AKT. As inhibition of PI3K did not restore sensitivity to platinum in 
this study, it was further investigated if PI3K is involved in platinum induced DNA-PK 
mediated activation of AKT. It was demonstrated that inhibition of DNA-PK by NU7441 re-
sensitised platinum resistant cells to cisplatin and knockdown of PIK3CA and PIK3R1 genes 
encoding for catalytic and regulatory subunits of PI3K respectively, did not affect the 
restoration of platinum sensitivity by DNA-PK inhibition. These findings suggest that PI3K 
may not be involved in DNA-PK modulated response to cisplatin in platinum resistant cells. 
However, further investigation is required to support this hypothesis. For examples, effect of 
PI3K inhibition or knockdown on sensitisation to platinum should be assessed in larger 
number of in vitro and also in vivo and clinical samples. One experiment for the next step of 
this study to show if or if not phosphorylation at both T308 and S473 are required for 
platinum induced DNA-PK mediated activation of AKT, would be using GFP-tagged T308 
and S473 mutant AKT constructs transfected into ovarian cancer cell lines. Effect of either of 
T308 and S473 mutations would be assessed on apoptotic response to cisplatin in platinum 
resistant and sensitive cells. In addition confocal microscopy will be used to locate AKT 
cisplatin treated cells. . 
 
In this thesis, it was also demonstrated that 3D MTS may be more informative and reliable 
cellular model than traditional 2D monolayers to be used for predicting tracer uptake by 
xenografts and determining dose and schedule optimisation prior to pre-clinical in vivo 
experiments in PET oncology. This may be important in minimising the cost of the studies 
and the use of animals in translational approaches.  
 
Together, the results of this study encourage further investigation into the potential clinical 
utility of AKT or DNA-PK inhibitors in combination with DNA-damage agents. Importantly, 
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these studies also demonstrate the value and potential of using 3D models in a fully 
translational preclinical setting in order to both predict and optimise dose and scheduling 
plans prior to translation of preclinical data such as these to the clinical setting. 
 
One of the major challenges in drug development is translating efficacy determined during 
the pre-clinical studies into efficacy in clinical trials. Therefore, it is important for clinical 
models to take into account both of the molecular nature of the target and also the tumour 
micro-environment in patients. Currently, tumour cell lines grown as monolayers are used as 
the first line of study during lead optimisations because apoptosis, cell proliferation and other 
cellular end-points can be easily measured using different techniques in a high through-put 
format using 2D in vitro models.  However, it is important to consider that adherent cells 
grown on a plastic dish may not reflect tumour biology. Phenotype, genetic and epigenetic 
alterations seen in these models may be induced by artificial environment of 2D cell culture. 
Therefore, in vitro models that mimic 3D tumour environment are required to bridge the gap 
between first line in vitro studies and pre-clinical in vivo experiments to reduce the in vivo 
failure and therefore to minimise the cost and use of animals in pre-clinical studies. Tumour 
cells grown as 3D spheroids may be more representative of tumour biology in the host 
organism. In this thesis, it was also demonstrated that 3D MTS may be more informative and 
reliable cellular model than traditional 2D monolayers to be used for predicting tracer uptake 
by xenografts and determining dose and schedule optimisation prior to pre-clinical in vivo 
experiments in PET oncology. This may be important in minimising the cost of the studies 
and the use of animals in translational approaches. Currently, pre-clinical tumour xenograft 
models are mostly generated by subcutaneous or intraperitoneal injection of human cancer 
cell lines into immune-compromised mice. These pre-clinical xenograft models are relatively 
easy to produce and they mimic tumour 3D micro-environment but they fail to mimic human 
microenvironment and key aspect of human malignancies such as metastasis. An alternative 
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model currently under development is xenografting of fresh human biopsy specimens onto 
immunocompromised mice (Aubard 2003, Oktem and Urman 2009) 
 
Together, the results of this study encourage further investigation into the potential clinical 
utility of AKT or DNA-PK inhibitors in combination with DNA-damage agents. Importantly, 
these studies also demonstrate the value and potential of using 3D models in a fully 
translational preclinical setting in order to both predict and optimise dose and scheduling 
plans prior to translation of preclinical data such as these to the clinical setting.  
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Fig. A.1 . Proteins showing different levels of expression in serous ovarian cancer 
tumours before and after treatment with GSK2141795 Biopsies from patients 
diagnosed with serous ovarian cancer were taken prior and following treatment with 
GSK2141795 for 4 weeks and differences in levels of protein expression between two 
samples were measured by RPPA analysis. The graph indicates proteins showing 
changes more than 1.3-fold in expression (n = 6). Data shows mean of samples for each 
protein ± SD.  
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Fig. A.2 . Proteins showing different levels of expression in endometrioid ovarian 
cancer tumours before and after treatment with GSK2141795 
 Biopsies from patients diagnosed with endometrioid ovarian cancer were taken prior 
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expression between two samples were measured by RPPA analysis. The graph 
indicates proteins showing changes more than 1.3-fold in expression (n = 2). Data shows 
mean of samples for each protein ± SD. 
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Fig. A.3 . Proteins showing different levels of expression in clear cell ovarian cancer tumours 
before and after treatment with GSK2141795.Biopsies from patients diagnosed with clear cell 
ovarian cancer were taken prior and following treatment with GSK2141795 for 4 weeks and 
differences in level of protein expression between two samples were measured by RPPA analysis. 
The graph indicates proteins showing A) up-regulations and B) down-regulations more than 1.3-fold 
in expression (n = 2). Data shows mean of samples for each protein ± SD.  
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Up-regulations 
Protein SEROUS Clear Cell Endometrioid Venn group* 
AKT_pS473 Yes Yes Yes 7 
AKT_pS473/norm Yes Yes Yes 7 
AKT_pT308_ Yes Yes Yes 7 
AKT_pT308/norm Yes Yes Yes 7 
Caveolin-1 Yes Yes Yes 7 
Caveolin-1 Yes Yes Yes 7 
HER2_pY1248 Yes Yes Yes 7 
HER2_pY1248/norm Yes Yes Yes 7 
p38_pT180_Y182 Yes Yes Yes 7 
EGFR Yes Yes No 4 
MAPK__pT202_204 Yes Yes No 4 
p27_pT198/norm Yes Yes No 4 
Rad50 Yes Yes No 4 
Tau Yes Yes No 4 
CHK2_pT68/norm Yes No Yes 6 
Era Yes No Yes 6 
p27_pT198 Yes No Yes 6 
 
Down-regulations 
Protein SEROUS Clear Cell Endometrioid Venn group* 
AKT Yes Yes No 4 
Claudin7_CLDN7 Yes No No 1 
E-cadherin Yes No No 1 
Src_pY416/norm Yes No No 1 
S6_pS235_236 No Yes Yes 5 
 
 
 
Table. A.1 Proteins which their expression altered in more than one tumour type in 
response to treatment with GSK2141795.  
*Venn group 7 = all three tumour type. Venn group 4 = serous and clear cell, Venn group 
5 = endometrioid and clear cell. Venn group 6 = serous and endometrioid 
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Up-regulations 
Serous Endometrioid clear cell 
Akt_pS473 Akt_pS473 Akt_pS473 
Akt_pT308 Akt_pS473/norm Akt_pT308 
MAPK_pT202_Y204- Akt_pT308 Bim 
p38_pT180_Y182 Akt_pT308/norm C-Raf_pS338 
- C-Raf_pS338 EGFR_pY992/norm 
- EGFR_pY1173/norm GSK3-alpha-beta_pS21_S9 
- EGFR_pY992/norm p38_pT180_Y182 
- p38_pT180_Y182/norm YB-1 
- YB-1 - 
 
 
 
 
 
 
 
Down-regulations 
Serous Endometrioid Clear cell 
- Cyclin_B1 4EBP1_pS65/norm 
- S6_pS235_236 4EBP1_pT37/norm 
- S6_pS240_244 b-Catenin 
- - Caspase_7_cleaved_Asp198 
- - Catenin_Beta 
- - S6_pS235_236 
- - VEGFR2 
Table. A.2 Proteins with common alternation in expression in both ovarian cancer 
clinical and pre-clinical samples from SKOV3 xenografts. .  
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B 
Figure A.4 Protein expression in SKOV3 monolayers treated with cisplatin in 
comparison with vehicle treated samples. SKOV3 monolayers were treated with 25 
µM cisplatin for a) 0.5 hour and b) 8 hours. Proteins were filtered using 1.3-fold cut off 
between vehicle and cisplatin.  
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B 
Figure A.5 Protein expression levels in PEO4 monolayers treated with cisplatin in 
comparison with vehicle treated samples. PEO4 monolayers were treated with 25 µM 
cisplatin for A) 0.5 hour and B) 8 hours. Proteins were filtered using 1.3-fold cut off 
between vehicle and cisplatin.  
 
 
Figure 6.9. Protein expression levels in PEO4 monolayers treated with cisplatin in 
comparison with vehicle treated samples. PEO4 monolayers were treated with 25 µM 
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Figure A.6 Comparison of A) Up-regulation and B) down-regulation of 147 proteins in 
SKOV3 in vitro and in vivo models. Protein expression was compared in SKOV3 
monolayers treated with cisplatin for 30 minutes and 8 hours and also 3 hours in SKOV3 
xenografts 
 
Figure 6.10. Comparison of A) Up-regulation and B) down-regulation of 147 proteins in 
SKOV3 in vitro and in vivo models. Protein expression was compared in SKOV3 
monolayers treated with cisplatin for 30 minutes and 8 hours and also 3 hours in SKOV3  
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Protein expression up-regulation in SKOV3 models in response to GSK2141795 
Protein SKOV3_cddp_0.5h SKOV3_cddp_8h SKOV3_vivo_cddp Venn 
group 
ER-alpha_pS118/norm Yes Yes Yes 7 
p70S6K_pT389/norm Yes No Yes 6 
AMPK_pT172/norm No Yes Yes 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table A.3 Proteins expression in SKOV3 xenografts in response to treatment with 
cisplatin compared with the same treatment in SKOV3 monolayers.  
 
 
Table 6.8. Proteins expression in SKOV3 xenografts in response to treatment with 
cisplatin compared with the same treatment in SKOV3 monolayers.  
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Figure A.7 Comparison of protein expression in SKOV3 and PEO4 monolayers in 
response to treatment with cisplatin. No protein was found to be upregulated A) or down-
regulated C) in both SKOV3 and PEO4 monolayers treated with cisplatin for 30 minutes. Two 
proteins were upregulated B) and no proteins was down-regulated D) in both SKOV3 and 
PEO4 cells treated with cisplatin for 8 hours.  
 
Figure 6. 11. Comparison of protein expression in SKOV3 and PEO4 monolayers in 
response to treatment with cisplatin. No protein was found to be upregulated A) or down-
A 
 
A 
B 
 
B 
D 
 
D 
C 
 
C 
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Table A.4 Proteins which showed increase in expression in both SKOV3 and PEO4 
monolayers treated with cisplatin.  
 
Protein SKOV3_cddp_8h PEO4_cddp_8h Venn group 
AMPK_pT172/norm Yes Yes 3 
Chk1_pS345/norm Yes Yes 3 
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Figure.A.8 Protein expression in SKOV3 monolayers treated with combination of 
cisplatin and GSK2141795 in comparison with vehicle treated samples. SKOV3 
monolayers were treated with combination of 5 µM GSK2141795 and 25 µM cisplatin for 
A) 0.5 hour and B) 8 hours. Proteins were filtered using 1.3-fold cut off between vehicle 
and combination groups.  
 
 
Figure.6.14. Protein expression in SKOV3 monolayers treated with combination of 
cisplatin and GSK2141795 in comparison with vehicle treated samples. SKOV3 
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Figure.A.9 Protein expression in PEO4 monolayers treated with combination of 
cisplatin and GSK2141795 in comparison with vehicle treated samples. PEO4 
monolayers were treated with combination of 5 µM GSK2141795 and 25 µM cisplatin for 
A) 0.5 hour and B) 8 hours. Proteins were filtered using 1.3-fold cut off between vehicle 
and combination groups.  
 
 
Figure.6.15. Protein expression in PEO4 monolayers treated with combination of 
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Figure A.10 Comparison of protein expression alternation in PEO4 
monolayers treated with cisplatin for 30 minutes or 8 hours. Two proteins were 
up-regulated A) and 2 proteins were down-regulated B) in both time-points.  
 
Figure 6.12. Comparison of protein expression alternation in PEO4 
monolayers treated with cisplatin for 30 minutes or 8 hours. Two proteins were 
up-regulated A) and 2 proteins were down-regulated B) in both time-points.  
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Protein PEO4_cddp_0.5h PEO4_cddp_8h Venn group 
ACC_pS79/norm Yes Yes 3 
AMPK_pT172/norm Yes Yes 3 
 
Protein PEO4_cddp_0.5h PEO4_cddp_8h Venn group 
Akt_pS473  Yes Yes 3 
Akt_pS473/norm Yes Yes 3 
 
 
 
 
 
 
 
 
 
 
Table A.5 Proteins which their expressions altered in response to cisplatin in PEO4 
monolayers in both 30 minutes and 8 hours.  
 
 
Table 6.10. Proteins which their expressions altered in response to cisplatin in PEO4 
monolayers in both 30 minutes and 8 hours.  
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Figure A.11 Comparison of A) Up-regulation and B) down-regulation of 147 proteins in 
SKOV3 in vitro and in vivo models. Protein expression was compared in SKOV3 xenografts 
treated with combination of GSK2141795 and SKOV3 monolayers treated with combination of 
cisplatin and GSK2141795 for 30 minutes and 8 hours.  
 
 
 
 
 
 
Figure 6.16. Comparison of A) Up-regulation and B) down-regulation of 147 proteins in 
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Protein 
SKOV3_cddp_gsk795_0.5h SKOV3_cddp_gsk795_8h SKOV3_vivo_cddp_795 
Akt_pS473 Yes Yes Yes 
Akt_pS473/norm Yes Yes Yes 
Akt_pT308 Yes Yes Yes 
Akt_pT308/norm Yes Yes Yes 
p38_pT180_Y182  Yes Yes No 
p38_pT180_Y182/norm Yes Yes No 
Caspase-
7_cleavedD198 
Yes No Yes 
Bax  Yes No No 
MAPK_pT202_Y204 Yes No No 
MEK1_pS217_S221  Yes No No 
MEK1_pS217_S221-
/norm 
Yes No No 
Notch3  Yes No No 
AMPK_pT172/norm No Yes Yes 
Beclin  No Yes Yes 
Bim  No Yes Yes 
HER3  No Yes Yes 
STAT5-alpha  No Yes Yes 
Table.A.6 Up-regulation of proteins expression in SKOV3 xenografts in response to 
combination treatment with cisplatin and GSK2141795 compared with the same 
treatment in SKOV3 monolayers.  
 
 
Table.6.13. Up-regulation of proteins expression in SKOV3 xenografts in response to 
combinati n treatment with cisplatin and GSK2141795 compared with the same 
treatment in SKOV3 monolayers.  
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Protein SKOV3_gsk795_0.5h SKOV3_cddp_gsk795_8h sSKOV3_vivo_cddp+795 
4E-BP1_pS65  Yes Yes Yes 
4E-BPYes_pS65/norm Yes Yes Yes 
S6_pS235_S236  Yes Yes Yes 
S6_pS240_S244  Yes Yes Yes 
GSK3_pS9  Yes Yes No 
GSK3-alpha-beta_pS21_S9  Yes Yes No 
mTOR_ pS2448  Yes Yes No 
mTOR_ pS2448/norm Yes Yes No 
p70S6K_pT389  Yes Yes No 
p70S6K_pT389/norm Yes Yes No 
PRAS40_pT246  Yes Yes No 
c-Myc  Yes No No 
JNK_ pT183-T185  Yes No No 
p53  Yes No No 
Cyclin_B1  No Yes Yes 
ER-alpha  No Yes Yes 
Rb_pS807_S811  No Yes Yes 
Tuberin  No Yes Yes 
 
 
 
 
 
 
 
Table.A.7 Down-regulation of proteins expression in SKOV3 xenografts in response to 
combination treatment with cisplatin and GSK2141795 compared with the same 
treatment in SKOV3 monolayers.  
 
 
Table.6.13. D w -regulation of proteins expression in SKOV3 xenografts in response to 
combination treatment with cisplatin and GSK2141795 compared with the same 
treatment in SKOV3 monolayers.  
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Figure A.12 Comparison of protein expression in SKOV3 and PEO4 monolayers in 
response to combination treatment with cisplatin and GSK2141795. One protein was 
found to be upregulated A) and 8 to be down-regulated C) in common in both SKOV3 and 
PEO4 monolayers treated with cisplatin and GSK2141795 for 30 minutes. Five proteins 
were upregulated B) and 12 proteins were down-regulated D) in both SKOV3 and PEO4 
cells treated with cisplatin and GSK2141795 for 8 hours.  
 
Figure 6. 17. Comparison of protein expression in SKOV3 and PEO4 monolayers in 
response to combination treatment with cisplatin and GSK2141795. One protein was 
found to be upregulated A) and 8 to be down-regulated C) in common in both SKOV3 and 
PEO4 monolayers treated with cisplatin and GSK2141795 for 30 minutes. Five proteins 
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Up-regulation in SKOV3 v PEO4 cells treated with GSK795 and cddp (8 hours) 
Protein SKOV3_cddp_gsk795_8h PEO4_cddp_gsk795_8h Venn group 
ACC1 Yes Yes 3 
AMPK_pT172/norm Yes Yes 3 
Chk1_pS345  Yes Yes 3 
COX-2 Yes Yes 3 
Fibronectin-R  Yes Yes 3 
 
Down-regulation in SKOV3 v PEO4 cells treated with GSK795 and cddp (8 hours) 
Protein SKOV3_cddp_gsk795_8h PEO4_cddp_gsk795_8h Venn group 
4E-BP1_pS65  Yes Yes 3 
ACC_pS79/norm Yes Yes 3 
C-Raf_pS338 Yes Yes 3 
GSK3_pS9 Yes Yes 3 
GSK3-alpha-beta_pS21_S9  Yes Yes 3 
mTOR_ pS2448  Yes Yes 3 
mTOR_ pS2448/norm Yes Yes 3 
p70S6K_pT389  Yes Yes 3 
p70S6K_pT389/norm Yes Yes 3 
PRAS40_pT246  Yes Yes 3 
S6_pS235_S236  Yes Yes 3 
S6_pS240_S244  Yes Yes 3 
 
Down-regulation in SKOV3 v PEO4 cells treated with GSK795 and cddp (30 minutes) 
Protein 
SKOV3_cddp_gsk795_0.5h PEO4_cddp_gsk795_0.5h Venn 
group 
4E-BP1_pS65/norm Yes Yes 3 
COX-2  Yes Yes 3 
GSK3_pS9  Yes Yes 3 
GSK3-alpha-beta_pS21_S9 Yes Yes 3 
mTOR_ pS2448  Yes Yes 3 
S6_pS235_S236 Yes Yes 3 
S6_pS240_S244  Yes Yes 3 
STAT5-alpha Yes Yes 3 
Up-regulation in SKOV3 v PEO4 cells treated with GSK795 and cddp (30 minutes) 
Protein SKOV3_cddp_gsk795_0.5h PEO4_cddp_gsk795_0.5h Venn 
group 
p38_pT180_Y182 Yes Yes 3 
Table. A.8 Alternations in protein expression in response to combination of cisplatin 
and GSK2141795 in SKOV3 monolayers compared with the response to the same 
treatment in PEO4 cells.  
 
 
 
 
Table. 6.15 Alternations in protein expression in response to combination of cisplatin 
and GSK2141795 in SKOV3 monolayers compared with the response to the same 
treatment in PEO4 cells.  
 
 
 
335 
 
 
 
 
 
 
 
 
 
15 2
PEO4 8 hours
7
123
PEO4 0.5 hour
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113
PEO4 0.5 hour
Figure A.13 Comparison of protein expression alternation in PEO4 monolayers 
treated with combination of cisplatin and GSK2141795 for 30 minutes or 8 hours. 
Two proteins were up-regulated A) and 7 proteins were down-regulated B) in common in 
both time-points  
 
Figure 6.18. Comparison of protein expression alternation in PEO4 monolayers 
treated with combination of cisplatin and GSK2141795 for 30 minutes or 8 hours. 
Two proteins were up-regulated A) and 7 proteins were down-regulated B) in common in 
both time-points.  
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Down-regulation in protein expression in PEO4 cells treated with GSK795 and cddp for 30 minutes v 8 hrs 
Protein PEO4_cddp_gsk795_0.5h PEO4_cddp_gsk795_8h Venn 
group 
C-Raf_pS338-R-C  Yes Yes 3 
C-Raf_pS338-R-C/norm Yes Yes 3 
GSK3_pS9-R-V  Yes Yes 3 
GSK3-alpha-beta_pS21_S9-R-V  Yes Yes 3 
mTOR_ pS2448-R-C  Yes Yes 3 
S6_pS235_S236-R-V  Yes Yes 3 
S6_pS240_S244-R-V  Yes Yes 3 
 
 
 
 
 
 
 
 
 
 
Up-regulation in protein expression in PEO4 cells treated with GSK795 and cddp for 30 minutes v 8 hrs  
Protein PEO4_cddp_gsk795_0.5h PEO4_cddp_gsk795_8h Venn 
group 
AMPK_pT172-R-V/norm Yes Yes 3 
Cyclin_B1-R-V Yes Yes 3 
Table A.7 Proteins which showed alternation in expression in response to 
combination of cisplatin and GSK2141795 in PEO4 monolayers in both 30 minutes 
and 8 hours  
 
 
Table 6.16. Proteins which showed alternation in expression in response to 
combination of cisplatin and GSK2141795 in PEO4 monolayers in both 30 minutes 
and 8 hours.  
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Figure A.13 Comparison of changes in protein expression level in response to 
cddp or GSK2141795 as single agents or in combination in SKOV3 monolayers 
treated for 30 minutes. SKOV3 monolayers were treated with cddp or GSK2141795 or 
combination of two drugs for 30 minutes. Up-regulations (A) or down-regulations (B) of 
protein expression in response to the three treatments were compared in Venn diagrams. 
 
Figure 6.20. Comparison of changes in protein expression level in response to 
cddp or GSK2141795 as single agents or in combination in SKOV3 monolayers 
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B 
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Up-regulation in protein expression level 
Protein SKOV3_cddp_0.5h SKOV3_gsk795_0.5h SKOV3_cddp_gsk795_0.5h Venn 
group 
4E-BP1_pS65/norm 0 Yes Yes 5 
c-Myc No Yes Yes 5 
GSK3_pS9 No Yes Yes 5 
GSK3-alpha-
beta_pS21 
No Yes Yes 5 
mTOR_ pS2448 No Yes Yes 5 
mTOR_ pS2448/norm No Yes Yes 5 
p53 No Yes Yes 5 
p70S6K_pT389 No Yes Yes 5 
p70S6K_pT389/norm No Yes Yes 5 
PRAS40_pT246 No Yes Yes 5 
S6_pS235_S236 No Yes Yes 5 
S6_pS240_S244 No Yes Yes 5 
4E-BP1_pS65 No Yes No 2 
JNK_ pT183-T185 No Yes No 2 
Caveolin-1 No No Yes 3 
COX-2 No No Yes 3 
NF2 No No Yes 3 
Paxillin No No Yes 3 
STAT5-alpha No No Yes 3 
     
Down-regulation in protein expression level 
Protein SKOV3_cddp_0.5h SKOV3_gsk795_0.5h SKOV3_cddp_gsk795_0.5h Venn 
group 
ER-alpha_pS118/norm Yes No No 1 
p70S6K_pT389/norm Yes No No 1 
S6_pS235_S236 Yes No No 1 
Akt_pS473 No Yes Yes 5 
Akt_pS473/norm No Yes Yes 5 
Akt_pT308  No Yes Yes 5 
Akt_pT308/norm No Yes Yes 5 
p38_pT180_Y182  No Yes Yes 5 
p38_pT180_Y182/norm No Yes Yes 5 
Beclin  No Yes No 2 
Bax No No Yes 3 
Caspase-7_cleavedD198  No No Yes 3 
MAPK_pT202_Y204 No No Yes 3 
MEK1_pS217_S221  No No Yes 3 
MEK1_pS217_S221/norm No No Yes 3 
Notch3-R-C  No No Yes 3 
Table. A.9 Comparison of up-regulations and down-regulations in protein expression levels in 
response to cddp and GSK2141795 as single agents or in combination in SKOV3 monolayers 
(30 minutes treatment) 
 
Table. 6.19. Comparison of up-regulations and down-regulations in protein expression levels in response 
to cddp and GSK2141795 as single agents or in combination in SKOV3 monolayers (30 minutes 
treatment) 
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Figure A.14 Comparison of changes in protein expression levels in response to cddp 
or GSK2141795 as single agents or in combination in SKOV3 monolayers treated for 
8 hours. SKOV3 monolayers were treated with cddp or GSK2141795 or combination of two 
drugs for 8 hours. Up-regulations (A) or down-regulations (B) of protein expression in 
response to the three treatments were compared in Venn diagrams. 
 
Figure 6.21. Comparison of changes in protein expression levels in response to cddp 
or GSK2141795 as single agents or in combination in SKOV3 monolayers treated for 
8 hours. SKOV3 monolayers were treated with cddp or GSK2141795 or combination of two 
drugs for 8 hours. Up-regulations (A) or down-regulations (B) of protein expression in 
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Protein SKOV3_cddp_8h SKOV3_gsk795_8h SKOV3_cddp_gsk795_8h Venn 
group 
AMPK_pT172/norm Yes Yes Yes 7 
Caveolin-1 Yes Yes No 4 
Chk1_pS345  Yes No Yes 6 
Chk1_pS345/norm Yes No Yes 6 
ER-alpha_pS118/norm Yes No Yes 6 
ACC1  No Yes Yes 5 
Akt_pS473  No Yes Yes 5 
Akt_pS473/norm No Yes Yes 5 
Akt_pT308  No Yes Yes 5 
Akt_pT308/norm No Yes Yes 5 
Bim No Yes Yes 5 
Fibronectin  No Yes Yes 5 
p38_pT180_Y182  No Yes Yes 5 
p38_pT180_Y182/norm No Yes Yes 5 
EGFR_pY1068/norm No Yes No 2 
EGFR_pY992/norm No Yes No 2 
N-Cadherin  No Yes No 2 
p53  No Yes No 2 
YB-1  No Yes No 2 
Beclin  No No Yes 3 
COX-2 No No Yes 3 
HER3  No No Yes 3 
STAT5-alpha  No No Yes 3 
 
 
 
 
 
 
Table. A.10 Comparison of up-regulations in protein expression levels in response to 
cddp and GSK2141795 as single agents or in combination at 8 hours in SKOV3 
monolayers  
 
Table. 6. 0. Comparison of up-regulations in protein expression level  in response to 
cddp and GSK2141795 as single agents or in combination at 8 hours in SKOV3 
monolayers  
341 
 
 
 
 
Protein SKOV3_cddp_8h SKOV3_gsk795_8h SKOV3_cddp_gsk795_8h 
Venn 
group 
YB-1_pS102/norm Yes Yes Yes 7 
ER-alpha  Yes No Yes 6 
PI3K-p110-alpha  Yes No No 1 
4E-BP1_pS65  No Yes Yes 5 
4E-BP1_pS65/norm No Yes Yes 5 
ACC_pS79/norm No Yes Yes 5 
C-Raf_pS338  No Yes Yes 5 
GSK3_pS9  No Yes Yes 5 
GSK3-alpha-beta_pS21_S9  No Yes Yes 5 
mTOR_ pS2448  No Yes Yes 5 
mTOR_ pS2448/norm No Yes Yes 5 
p70S6K_pT389 No Yes Yes 5 
p70S6K_pT389/norm No Yes Yes 5 
p90RSK_pT359_S363  No Yes Yes 5 
PRAS40_pT246 No Yes Yes 5 
Rb_pS807_S811  No Yes Yes 5 
S6_pS235_S236  No Yes Yes 5 
S6_pS240_S244 No Yes Yes 5 
Tuberin No Yes Yes 5 
YAP_pS127/norm No Yes Yes 5 
4EBP1_pT37-T46/norm No Yes No 2 
ACC_pS79 No Yes No 2 
Cyclin_B1 No No Yes 3 
GAB2 No No Yes 3 
HER3_pY1298/norm No No Yes 3 
YAP_pS127  No No Yes 3 
YB-1_pS102 No No Yes 3 
 
 
 
 
 
Table. A.11 Comparison of down-regulations in protein expression levels in response to 
cddp and GSK2141795 as single agents or in combination at 8 hours in SKOV3 monolayers  
 
Table. 6.21. Comparison of down-regulations in protein expression level  in response to 
cddp and GSK2141795 as single agents or in combination at 8 hours in SKOV3 monolayers  
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Figure A.15 Comparison of changes in protein expression level in response to cddp or 
GSK2141795 as single agents or in combination in PEO4 monolayers treated for 30 
minutes. PEO4 monolayers were treated with cddp or GSK2141795 or combination of two 
drugs for 30 minutes. Up-regulations (A) or down-regulations (B) of protein expression in 
response to the three treatments were compared in Venn diagrams. 
 
Figure 6.22. Comparison of changes in protein expression level in response to cddp or 
GSK2141795 as single agents or in combination in PEO4 monolayers treated for 30 
minutes. PEO4 monolayers were treated with cddp or GSK2141795 or combination of two 
A 
 
A 
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Protein PEO4_cddp_0.5h PEO4_gsk795_0.5h PEO4_cddp_gsk795_0.5h 
Venn 
group 
ACC1 Yes Yes Yes 7 
ER-alpha_pS118  Yes Yes Yes 7 
ER-alpha_pS118/norm Yes Yes Yes 7 
Fibronectin  Yes Yes Yes 7 
MSH6  Yes Yes Yes 7 
mTOR  Yes Yes Yes 7 
Akt_pS473  Yes No No 1 
Akt_pS473/norm Yes No No 1 
4E-BP1_pS65/norm No Yes Yes 5 
COX-2 No Yes Yes 5 
C-Raf_pS338 No Yes Yes 5 
C-Raf_pS338/norm No Yes Yes 5 
GSK3_pS9  No Yes Yes 5 
GSK3-alpha-beta_pS21_S9 No Yes Yes 5 
mTOR_ pS2448  No Yes Yes 5 
S6_pS235_S236 No Yes Yes 5 
S6_pS240_S244 No Yes Yes 5 
4E-BP1_pS65 No Yes No 2 
eEF2 No Yes No 2 
NF2 No Yes No 2 
ACC_pS79  No No Yes 3 
HER2_pY1248 No No Yes 3 
PKC-alpha_pS657 No No Yes 3 
Src_pY527  No No Yes 3 
STAT5-alpha No No Yes 3 
Tuberin  No No Yes 3 
 
 
 
 
 
Table. A.12 Comparison of up-regulations in protein expression levels in response to cddp 
and GSK2141795 as single agents or in combination at 30 minutes in PEO4 monolayers  
 
Table. 6.22. Comparison of up-regulations in protein expression levels in response to cddp 
and GSK2141795 as single agents or in combination at 30 minutes in PEO4 monolayers  
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Protein PEO4_cddp_0.5h PEO4_gsk795_0.5h PEO4_cddp_gsk795_0.5h 
Venn 
group 
ACC1 Yes Yes Yes 7 
ER-alpha_pS118  Yes Yes Yes 7 
ER-alpha_pS118/norm Yes Yes Yes 7 
Fibronectin  Yes Yes Yes 7 
MSH6  Yes Yes Yes 7 
mTOR Yes Yes Yes 7 
Akt_pS473  Yes No No 1 
Akt_pS473/norm Yes No No 1 
4E-BP1_pS65/norm No Yes Yes 5 
COX-2  No Yes Yes 5 
C-Raf_pS338 No Yes Yes 5 
C-Raf_pS338/norm No Yes Yes 5 
GSK3_pS9  No Yes Yes 5 
GSK3-alpha-beta_pS21_S9 No Yes Yes 5 
mTOR_ pS2448  No Yes Yes 5 
S6_pS235_S236  No Yes Yes 5 
S6_pS240_S244  No Yes Yes 5 
4E-BP1_pS65  No Yes No 2 
eEF2  No Yes No 2 
NF2  No Yes No 2 
ACC_pS79  No No Yes 3 
HER2_pY1248 No No Yes 3 
PKC-alpha_pS657  No No Yes 3 
Src_pY527 No No Yes 3 
STAT5-alpha  No No Yes 3 
Tuberin No No Yes 3 
 
 
 
 
Table. A.13 Comparison of down-regulations in protein expression levels in response to 
cddp and GSK2141795 as single agents or in combination at 30 minutes in PEO4 
monolayers  
Table. 6.23. Comparison of down-regulations in protein expression levels in response to 
cddp and GSK2141795 as single agents or in combination at 30 minutes in PEO4 
monolayers  
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Figure A.16 Comparison of changes in protein expression level in response to cddp or 
GSK2141795 as single agents or in combination in PEO4 monolayers treated for 8 hours. 
PEO4 monolayers were treated with cddp or GSK2141795 or combination of two drugs for 30 
minutes. Up-regulations (A) or down-regulations (B) of protein expression in response to the three 
treatments were compared in Venn diagrams. 
 
Figure 6.23. Comparison of changes in protein expression level in response to cddp or 
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B 
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Up-regulations 
Protein PEO4_cddp_8h PEO4_gsk795_8h PEO4_cddp_gsk795_8h 
Venn 
group 
AMPK_pT172/norm Yes No Yes 6 
ACC_pS79  Yes No No 1 
ACC_pS79/norm Yes No No 1 
Chk1_pS345/norm Yes No No 1 
ACC1  No Yes Yes 5 
Claudin-7  No Yes Yes 5 
COX-2  No Yes Yes 5 
Akt_pT308  No Yes No 2 
Akt_pT308/norm No Yes No 2 
VEGFR2 No Yes No 2 
Chk1_pS345  No No Yes 3 
Cyclin_B1  No No Yes 3 
Fibronectin  No No Yes 3 
MSH6  No No Yes 3 
mTOR No No Yes 3 
 
Down-regulations 
Protein PEO4_cddp_8h PEO4_gsk795_8h PEO4_cddp_gsk795_8h 
Venn 
group 
Akt_pS473  Yes Yes Yes 7 
Akt_pS473/norm Yes Yes Yes 7 
p70S6K_pT389  Yes Yes Yes 7 
C-Raf_pS338  No Yes Yes 5 
C-Raf_pS338/norm No Yes Yes 5 
GSK3_pS9  No Yes Yes 5 
GSK3-alpha-beta_pS21_S9  No Yes Yes 5 
mTOR_ pS2448  No Yes Yes 5 
mTOR_ pS2448/norm No Yes Yes 5 
p70S6K_pT389/norm No Yes Yes 5 
PRAS40_pT246  No Yes Yes 5 
S6_pS235_S236 No Yes Yes 5 
S6_pS240_S244  No Yes Yes 5 
4E-BP1_pS65  No No Yes 3 
ACC_pS79/norm No No Yes 3 
MAPK_pT202_Y204  No No Yes 3 
MEK1_pS217_S221  No No Yes 3 
MEK1_pS217_S221/norm No No Yes 3 
p38_pT180_Y182  No No Yes 3 
Shc_pY317 No No Yes 3 
 
Table. A.14 Comparison of up-regulations and down-regulations in protein expression 
levels in response to cddp and GSK2141795 as single agents or in combination for 8 hours 
in PEO4 monolayers  
 
Table. 6.24. Comparison of up-regulations and down-regulations in protein expression 
levels in response to cddp and GSK2141795 as single agents or in combination for 8 hours 
in PEO4 monolayers  
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Figure.A.17 Protein expression in SKOV3 monolayers treated with combination of 
cisplatin and GSK2141795 in comparison with vehicle treated samples. SKOV3 
monolayers were treated with combination of 5 µM GSK2141795 and 25 µM cisplatin for 
a) 0.5 hour and b) 8 hours. Proteins were filtered using 1.3-fold cut off between vehicle 
and combination groups.  
 
A 
B 
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Table A.15. Differences in protein expression between biopsies taken from responder 
and non-responder patients prior to the daily treatment with GSK2141795 
 
protein 
t-test for Equality of 
Means 
Mean 
Difference 
between 
Responders 
and Non-
responders 
Std. Error 
Difference 
between 
Responders and 
Non-responders 
p-value 
MAPK__pT202_204 -2.77 -0.29 0.11 0.02 
Xiap(C)_1 -2.76 -0.17 0.06 0.02 
PARP_cleaved 2.42 0.40 0.16 0.04 
PKC_pS657 -2.08 -0.19 0.09 0.06 
MAPK_pT202 -2.03 -0.42 0.21 0.07 
PKC_pS657 -1.99 -0.23 0.12 0.08 
4EBP1_pT70_/norm -1.97 -0.21 0.11 0.08 
Stat3_pS705 -1.96 -0.21 0.11 0.08 
p90RSK_pT359 -1.89 -0.13 0.07 0.09 
PR 1.85 2.39 1.29 0.09 
ACC1 1.75 0.57 0.33 0.11 
YAP 1.67 0.52 0.31 0.13 
CHK2_pT68 -1.62 -0.20 0.12 0.14 
IGFBP2 -1.61 -1.59 0.99 0.14 
Myc_2 -1.59 -0.27 0.17 0.14 
p27_1 1.59 0.41 0.26 0.14 
4EBP1_pT70_/norm -1.58 -0.16 0.10 0.15 
MSH2 1.55 0.50 0.32 0.15 
4EBP1 1.53 0.19 0.13 0.16 
Gata3 -1.50 -0.14 0.09 0.16 
LKB1 -1.50 -0.17 0.12 0.17 
Shc_pY317 -1.46 -0.17 0.12 0.17 
Rad50 -1.45 -0.15 0.10 0.18 
AKT -1.44 -0.27 0.19 0.18 
p70S6K_pT389_1 1.44 0.54 0.37 0.18 
CDC2 1.43 0.35 0.25 0.18 
349 
 
protein 
t-test for Equality of 
Means 
Mean 
Difference 
between 
Responders 
and Non-
responders 
Std. Error 
Difference 
between 
Responders and 
Non-responders 
p-value 
S6_pS240_244_2 1.36 0.45 0.33 0.20 
mTOR -1.33 -0.21 0.16 0.21 
BIM 1.32 0.54 0.41 0.22 
S6_pS235_236_1 1.30 0.52 0.40 0.22 
Rad50 -1.27 -0.21 0.17 0.23 
Myc_1 -1.24 -0.19 0.15 0.24 
p70S6K_pT389/norm_tp70S6K_1 1.23 0.59 0.48 0.25 
YAP_pS127_/norm_tYAP -1.22 -0.31 0.25 0.25 
Rb(4H1) -1.20 -0.10 0.08 0.26 
p38___MAPK 1.18 0.14 0.12 0.26 
4EBP1_pS65(V)_/norm -1.17 -0.18 0.16 0.27 
MEK1_pS217_221 -1.17 -0.09 0.08 0.27 
Notch3 1.16 0.15 0.13 0.27 
eIF4E 1.15 0.24 0.21 0.28 
INPP4B -1.15 -0.32 0.28 0.28 
AR -1.11 -0.24 0.21 0.29 
MSH6 1.10 0.39 0.35 0.30 
Tau© 1.07 0.20 0.19 0.31 
Caveolin-1 1.06 0.64 0.60 0.31 
ERK2 -1.05 -0.20 0.19 0.32 
Cadherin-P 1.04 2.84 2.73 0.32 
53BP1 -1.04 -0.22 0.21 0.32 
PTEN -1.03 -0.23 0.23 0.33 
PCNA(V) 1.02 1.72 1.68 0.33 
Cadherin-P 1.01 2.14 2.12 0.34 
NF-kB_p65_pS536 -1.01 -0.17 0.17 0.34 
Bcl-xL -0.99 -0.05 0.05 0.34 
Snail -0.99 -0.20 0.21 0.35 
EGFR -0.99 -0.15 0.15 0.35 
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protein 
t-test for Equality of 
Means 
Mean 
Difference 
between 
Responders 
and Non-
responders 
Std. Error 
Difference 
between 
Responders and 
Non-responders 
p-value 
Src_pY527_/norm_tSrc 0.99 0.16 0.16 0.35 
Src(V) -0.98 -0.40 0.41 0.35 
b-Catenin -0.98 -0.36 0.37 0.35 
Stathmin 0.96 0.14 0.15 0.36 
Beclin -0.94 -0.36 0.39 0.37 
p38_T180_182_/norm_tp38_MAPK -0.94 -0.33 0.35 0.37 
VEGFR2 -0.93 -0.24 0.26 0.37 
p27_pT157_/notm__p27 -0.93 -0.36 0.39 0.37 
MEK1_pS217_221_/norm_tMEK1 -0.91 -0.07 0.08 0.39 
S6_ 0.90 0.18 0.20 0.39 
YB1 0.90 0.12 0.13 0.39 
Tuberrin(TSC2) -0.89 -0.10 0.11 0.39 
XBP-1 -0.89 -0.26 0.30 0.39 
4EBP1_pT37 0.89 0.13 0.15 0.40 
 0.90 0.12 0.13 0.40 
FOX03a_ 0.86 0.13 0.15 0.41 
PI3K-p85 0.86 0.15 0.18 0.41 
Cyclin_B1_ 0.85 0.37 0.43 0.41 
Bcl-2 0.84 0.59 0.70 0.42 
eEF2K -0.84 -0.33 0.39 0.42 
cJun_pS73 -0.83 -0.07 0.08 0.43 
Bak 0.83 0.13 0.16 0.43 
Src_pY416_/norm_tSrc 0.82 0.27 0.33 0.43 
FOXO3a_pS318/norm_tFOXO3a -0.81 -0.12 0.14 0.44 
Collagen_VI 0.80 1.81 2.26 0.44 
EGFR_pY1173 -0.80 -0.08 0.10 0.44 
PKCa -0.79 -0.09 0.11 0.45 
Catenin_Beta -0.79 -0.25 0.31 0.45 
Chk1_pS345 -0.79 -0.10 0.13 0.45 
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protein 
t-test for Equality of 
Means 
Mean 
Difference 
between 
Responders 
and Non-
responders 
Std. Error 
Difference 
between 
Responders and 
Non-responders 
p-value 
p27_pT198_/norm__tp27 -0.78 -0.48 0.62 0.46 
PTCH -0.77 -0.15 0.20 0.46 
PARP_Cleaved -0.75 -0.12 0.16 0.47 
HER2_pY1248_/norm_tHER2 -0.75 -0.92 1.23 0.47 
BAX 0.74 0.08 0.11 0.48 
Cyclin_E1 0.74 0.31 0.42 0.48 
Rb_pS807_811_/norm_tRb 0.74 0.21 0.29 0.48 
p21 0.73 0.15 0.21 0.48 
PI3K-p85 0.73 0.15 0.21 0.48 
IGFR1b -0.73 -0.14 0.20 0.48 
Notch-1 -0.73 -0.58 0.80 0.48 
ERa_pS118_1_/norm_tERa -0.72 -0.34 0.47 0.49 
ERa_pS118 -0.72 -0.27 0.37 0.49 
Met© -0.71 -0.50 0.71 0.50 
Mre11(31H) -0.70 -0.29 0.41 0.50 
Pea15 0.69 0.19 0.27 0.50 
Cyclin_D1 -0.67 -0.09 0.14 0.52 
Pras40_pT246 0.66 0.05 0.07 0.52 
GSK3_pS21/norm_tGSK3beta -0.66 -0.25 0.38 0.52 
p70S6K_pT389_2 -0.65 -0.08 0.13 0.53 
c-Met_pY1235 -0.65 -0.17 0.27 0.53 
Rab25 0.64 0.25 0.39 0.54 
HER2_pY1248 -0.63 -0.73 1.16 0.55 
p27_2 0.61 0.14 0.22 0.55 
p27_pT157 -0.61 -0.24 0.39 0.56 
AKT_pS473 -0.61 -0.27 0.44 0.56 
Caspase_7_cleaved_Asp198 -0.61 -0.26 0.43 0.56 
Rab25 0.60 0.40 0.67 0.56 
p53(CS9282)_ 0.58 0.12 0.20 0.57 
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protein 
t-test for Equality of 
Means 
Mean 
Difference 
between 
Responders 
and Non-
responders 
Std. Error 
Difference 
between 
Responders and 
Non-responders 
p-value 
FOX03a_pS318_321_/norm_tFOXO3a -0.58 -0.09 0.15 0.58 
p70S6K_pT389_3 0.56 0.08 0.15 0.59 
p53_ -0.55 -0.34 0.62 0.59 
Src_pY416 0.55 0.14 0.26 0.60 
p27_pT198 -0.55 -0.31 0.58 0.60 
Pras40_pT246 0.54 0.04 0.08 0.60 
YB1_pS102(V)_ 0.54 0.08 0.16 0.60 
FOXO3a_pS318 -0.53 -0.04 0.08 0.61 
eEF2 -0.52 -0.34 0.66 0.62 
Taz 0.52 0.07 0.14 0.62 
MIG-6(V) -0.51 -0.10 0.20 0.62 
CHK2_pT68_/norm -0.50 -0.15 0.30 0.63 
S6_pS235_236_/norm_tS6_1 0.50 0.17 0.34 0.63 
Raf-B© -0.50 -0.09 0.17 0.63 
4EBP1_pT37(V)_norm -0.49 -0.08 0.16 0.64 
4EBP1_pS65 0.49 0.09 0.19 0.64 
Raf-C_pS338_2 -0.48 -0.06 0.12 0.64 
p38_T180_182 -0.48 -0.18 0.38 0.64 
Kit-_1 0.48 0.09 0.20 0.64 
Raf-C__pS338_1 -0.48 -0.07 0.14 0.64 
caspase-3_(active) -0.47 -0.05 0.10 0.65 
ACC_pS79 -0.46 -0.28 0.61 0.65 
NF2 -0.46 -0.09 0.19 0.66 
Smad4 -0.45 -0.24 0.52 0.66 
Smad3 -0.44 -0.03 0.07 0.67 
p70S6K_pT389_/norm_tp70S6K_2 -0.44 -0.09 0.19 0.67 
FAK 0.43 0.46 1.09 0.68 
Taz_pS89 -0.42 -0.03 0.08 0.68 
Taz_pS89_/norm_tTaz -0.42 -0.06 0.13 0.69 
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protein 
t-test for Equality of 
Means 
Mean 
Difference 
between 
Responders 
and Non-
responders 
Std. Error 
Difference 
between 
Responders and 
Non-responders 
p-value 
S6_pS240_244_/norm_tS6_2 0.41 0.10 0.25 0.69 
E-cadherin -0.38 -0.21 0.54 0.71 
AKT_pS473_/norm_tAKT -0.38 -0.19 0.49 0.71 
Raf-C_pS338_/norm_tRaf-C_2 0.38 0.12 0.33 0.71 
Bcl-X -0.37 -0.04 0.11 0.72 
Rb_pS807_811_ 0.35 0.12 0.34 0.73 
Raf-C -0.35 -0.04 0.12 0.73 
c-Jun 0.34 0.05 0.16 0.74 
PI3K_P110a 0.34 0.04 0.10 0.74 
XRCC1 0.34 0.02 0.07 0.74 
Raf-C__pS338_/norm_tRaf-C_1 0.33 0.08 0.25 0.75 
p90RSK_pT359_S363 0.33 0.04 0.12 0.75 
ERa_pS118 0.33 0.04 0.13 0.75 
ERCC1© 0.32 0.01 0.05 0.76 
GSK3_pS21 -0.31 -0.11 0.35 0.76 
p70S6K_pT389_/norm_tp70S6K_3 0.30 0.08 0.26 0.77 
PDK1_pS241 -0.29 -0.04 0.14 0.77 
p70S6K 0.27 0.04 0.15 0.79 
AKT_pT308/norm_tAKT 0.26 0.08 0.31 0.80 
Vasp 0.26 0.05 0.21 0.80 
EGFR_pY1173_/norm_tEGFR 0.23 0.02 0.08 0.82 
ATM_ -0.23 -0.13 0.54 0.82 
CD31(V) -0.23 -0.03 0.13 0.82 
Ku80 0.23 0.04 0.16 0.82 
GSK3-beta 0.23 0.03 0.12 0.82 
IRS-1 0.22 0.04 0.17 0.83 
Stat5 -0.21 -0.13 0.64 0.84 
Src_pY527 0.21 0.02 0.10 0.84 
Cox-2 0.19 0.03 0.18 0.85 
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protein 
t-test for Equality of 
Means 
Mean 
Difference 
between 
Responders 
and Non-
responders 
Std. Error 
Difference 
between 
Responders and 
Non-responders 
p-value 
CHK1 0.19 0.03 0.16 0.86 
HER2 0.18 0.05 0.25 0.86 
AIB-1 -0.17 -0.02 0.12 0.87 
p53_ 0.15 0.04 0.28 0.89 
Chk1_pS345_/norm -0.15 -0.03 0.19 0.89 
AKT_pT308 0.14 0.04 0.28 0.89 
FOX03a_pS318_321 -0.10 -0.01 0.11 0.92 
4EBP1_pT70_ 0.08 0.01 0.07 0.94 
YB1_pS102(V)_/norm_tYB1 0.08 0.02 0.23 0.94 
MEK1 -0.06 0.00 0.08 0.95 
DJ-1 -0.06 -0.01 0.11 0.95 
Transglutaminase -0.05 -0.02 0.42 0.96 
YAP_pS127 0.05 0.01 0.26 0.96 
Annexin 0.03 0.01 0.35 0.97 
Claudin7_CLDN7 -0.03 -0.01 0.44 0.98 
Pras40_pT246 0.03 0.00 0.16 0.98 
PI3K-p85 -0.03 -0.01 0.25 0.98 
Rad51 0.02 0.00 0.17 0.98 
Chk2(1C12) -0.02 0.00 0.18 0.99 
Paxillin 0.01 0.00 0.13 0.99 
 
